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PhD Thesis Zusammenfassung
1 Zusammenfassung
Epigenetische Regulatoren gelten als mögliche Angriffspunkte in der Krebstherapie, da
sie in vielen Tumoren fehlreguliert sind. Vor allem Protein Methyltransferasen sind gut
beschrieben und können durch niedermolekulare Hemmer addressiert werden. Das SET
und MYND Domain enthaltene Protein 2 (SMYD2) wurde in der Literatur mehrfach als
potenzielles Onkogen beschrieben und eine Überexpression dieses Proteins in Tumorproben
war prognostisch für eine schlechtere Überlebensrate und einen aggressiveren Tumor. Für
SMYD2 wurden verschiedene Substrate beschrieben u.a. Histon H3 und der Tumor Sup-
pressor p53, allerdings ist die Biologie dieses Enzymes noch kaum verstanden. Durch die
Entwicklung einer Testsubstanz zur spezifischen Hemmung des SMYD2 Enzymes könnte
ein möglicher therapeutischer Nutzen besser untersucht werden, sowie das allgemeine Ver-
ständnis dieser Lysin Methyltransferase vorangetrieben werden.
In der vorliegenden Arbeit sollte daher die Entwicklung eines zellulären mechanistischen
Tests zur Messung der enzymatischen Aktivität des SMYD2 Enzyms etabliert werden.
Hierfür wurde ein polyklonaler Antikörper, der gegen ein methyliertes p53 Peptid gerichtet
war, generiert. Überraschenderweise detektierte der Antikörper (SY46) nach Überexpres-
sion des SMYD2 Enzymes weitere unbekannte Methylierungen imWesternblot. Die zusätz-
lichen Signale erwiesen sich als spezifisch und wurden für die Etablierung eines mechanis-
tischen Tests genutzt. Mit Hilfe dieses Tests konnte ein spezifischer zellulär aktiver SMYD2
Hemmer identifiziert werden, der aufgrund seiner Selektivität und Potenz für das SMYD2
Enzym als Testsubstanz unter dem Namen BAY-598 der wissenschaftlichen Gemeinschaft
zur Verfügung gestellt wurde (für Details siehe Eggert et al.32).
Im weiteren Verlauf dieser Arbeit wurde eine Proteomstudie durchgeführt, um zelluläre
Lysinmethylierungen zu detektieren, mit dem Ziel neue SMYD2 Substrate zu identifizieren.
Dabei wurden hunderte von neuen Lysinmethylierungsstellen entdeckt. Durch Anwendung
verschiedener Selektionskriterien wurde das AHNAK Protein als SMYD2Methylierungssub-
strat identifiziert und validiert. Dabei zeigte sich, dass das AHNAK Protein bevorzugt
an sogenannten Central Repeated Units (CRUs) innerhalb von LKGPK Sequenzmotiven
multi-methyliert werde kann. Die AHNAKMethylierung konnte in verschiedenen Zelllinien
und im Muskelgewebe von Mäusen nachgewiesen werden, welches eine konservierte Funk-
tion dieser Modifikation vermuten lässt.
Im letzten Teil der Arbeit wurde die spezifische Testsubstanz BAY-598 genutzt, um exem-
plarisch verschiedene in der Literatur aufgekommene Hypothesen zur SMYD2 Funktion zu
testen. Dabei wurde in einem ersten Ansatz die Differenzierung von Maus C2C12 Myo-
blasten in muskelähnliche Myotuben unter permanenter SMYD2 Hemmung untersucht. In
einem zweiten Zellsystem wurde der RAS Transformationseffekt in NIH3T3 Maus Fibro-
blasten unter SMYD2 Hemmung oder Knockout getestet, da es in vivo Hinweise gab, dass
SMYD2 die RAS getriebene Adenocarcinomentstehung im Pankreas beeinflusst.
Die vorliegende Arbeit hat mit dazu beigetragen die potente und selektive SMYD2 Testsub-
stanz BAY-598 zu entwickeln. Außerdem wurde mit AHNAK ein neues SMYD2 Substrat
identifiziert und validiert. Diese Methylierung ist nicht nur in humanen Zellkulturen nach-
weisbar sondern auch im Muskelgewebe der Maus. Die Relevanz des SMYD2 Enzymes und
der AHNAK Methylierung erfordert weitere Forschungsarbeit, die durch die Bereitstellung
der spezifischen Testsubstanz BAY-598 deutlich verbessert werden sollte.
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2 Introduction
2.1 Cancer is an emerging burden to the society
Cancer is after heart disease the second most common cause of death in western countries.
Due to the aging population, it is estimated that the worldwide cancer incidence will in-
crease124. According to the WHO World Cancer Report 2014124, there were 14 million
new cases and 8.2 million cancer-related deaths worldwide in 2012. The number of new
cancer cases is expected to increase to 22 million within the next two decades. In the
United States, the lifetime risk of developing cancer on average is about 1 in 2 in men
and about 1 in 3 in women56. Although in the US the 5-year relative survival rate for all
cancers has improved from about 49% in the 1970’s to about 69% in the 2010’s basically
due to better diagnosis and improved treatment, there is still a high unmet medical need
for better treatment options of cancer patients.
Cancer is a generic term for a large group of malignant neoplasms, which can affect any
tissue of the body. The most common cases of cancer related death worldwide are malignan-
cies of lung (1.59 million deaths), liver (745 000 deaths), stomach (723 000 deaths), colorec-
tal (694 000 deaths), breast (521 000 deaths), and esophageal cancer (400 000 deaths)124.
One defining feature of cancer is the abnormal cell proliferation beyond their usual bound-
aries and the ability to invade surrounding tissue and spread to other parts of the body,
which is known as metastasizing. Metastases are the major cause of death from cancer.
With a better understanding of the molecular mechanisms that drive oncogenesis, it has
become apparent that tumors originating from the same organs can display very different
molecular profiles and underlying mutations134. This dramatically influences prognosis
and response to treatment and requires different therapeutic intervention. Targeted thera-
pies have emerged as a promising strategy to more specifically tackle cancer cells based on
molecular categorization and may avoid unintended side effects that arise from unspecific
chemotherapy9. For instance, specific inhibition of EGFR in tumors that display hyperac-
tivation of this tyrosine kinase receptor significantly improved the outcome in this patient
population. However, targeted therapy turned out to be more challenging as initially an-
ticipated due to a lack in understanding the complex underlying biology and pathobiology
and more research is needed to identify effective targets in non-responding patients.
For targeted therapy in cancer, potential vulnerabilities have been hypothesized and in 2000
Hanahan and Weinberg defined the so called “hallmarks of cancer” that are mandatory for
normal cells to acquire in order to develop a full-blown cancer48. These hallmarks were
defined as sustained proliferative signaling, evasion of growth suppressors, resistance to
cell death, induction of angiogenesis, replicative immortality, and activation of invasion
and metastasis. A decade later, the list of original hallmarks was extended by deregulation
of cellular energetics, genome instability and mutations, avoidance of immuno destruction,
and tumor promoting inflammation (Fig. 2.1)49.
– 2 –
PhD Thesis Introduction
Sustaining 
proliferative 
signaling 
Evading 
growth 
suppressors 
Avoiding 
immune 
destruction 
Enabling 
replicative 
immortality 
Tumor 
promoting 
inflammation 
Activating 
invasion & 
metastasis 
Inducing 
angiogenesis 
Genome 
instability & 
mutation 
Resisting 
cell 
death 
Deregulating 
cellular 
energetics 
Fig. 2.1: Hallmarks of cancer.
Cartoon representing the updated “hallmarks of cancer” as defined by Hanahan and Weinberg.
The cartoon was modified from the corresponding publication49.
Originally, it was thought that these hallmarks were solely acquired by genetic mutations.
However, more recent data suggest that many of the changes during transformation are
caused by epigenetic alterations, which act in concert with genetic mutations139. For in-
stance, in many tumors DNA methylation patterns, histone modifications and nucleosome
positioning differ dramatically between healthy and tumoral tissue, which causes important
changes in gene expression and behavior of the cells. Because epigenetic changes can occur
without changes in the underlying DNA sequence, it is believed that these changes are
reversible and may allow a correction of the abnormal cancer phenotype by specific inter-
ventions. Therefore, epigenetic modifiers have emerged as promising new targets. Indeed,
the first generation of DNA methyltransferase inhibitors is already on the market to treat
myelodysplastic syndromes101 and more epigenetic target classes are considered for cancer
therapy in preclinical and clinical research. Among the diverse classes, protein methyl-
transferases (PMTs) are well-defined enzymes with reasonable drugability and are often
misregulated in cancer and other diseases51. In fact, inhibitors for two protein methyl-
transferases, namely DOT1L and EZH2 have already entered clinical trials and more are
expected to come88.
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2.2 Protein methylation & Protein methyltransferases (PMTs)
Protein methylation was first discovered in 1959 in a bacterial flagellar protein5 and a
few years later, this posttranslational modification (PTM) was also found on mammalian
histones89. In general, protein methylation is enabled by the transfer of a methyl group
(–CH3) from the cofactor S-adenosyl-L-methionine (SAM; also known as AdoMet) to sev-
eral amino acid residues of target proteins with the byproduct S-adenosyl-L-homocysteine
(SAH)20. SAH can then be hydrolyzed to homocysteine and adenosine by S-adenosyl-
L-homocysteine hydrolase. In a second step, methionine synthases catalyze the transfer
of a methyl group from 5-methyltetrahydrofolate to homocysteine to produce methionine.
SAM is finally recycled from methionine and ATP by methionine adenosyltransferase37.
It is estimated that SAM is the second most widely used enzyme co-factor after ATP
indicating that methylation in general (of DNA, RNA, proteins, metabolits, etc.) plays
important roles within the cells. However, the metabolic price for methylation is high.
Whereas a kinase consumes 1 ATP equivalent for catalyzing phosphorylation, methylation
reactions using SAM as a methyl donor comes with a cost of 12 ATP equivalents, thus
active methylation is one of the most expensive reactions per carbon basis7. Having said
that, the biological relevance of individual methylation reactions might be put under con-
stant evolutionary pressure.
Enzymes responsible for protein methylation reactions can be classified into distinct protein
classes based on the target amino acid of the methylation reaction. In human, two classes
of PMTs have been identified and are referred to as protein arginine and protein lysine
methyltransferases (PRMTs and PKMTs), respectively12. PRMTs catalyze the transfer of
a methyl group from SAM to the guanidino nitrogen atoms of arginine residues, which can
result in arginine mono- or dimethylation, whereby dimethylation can occur either sym-
metrically (one methyl group per terminal nitrogen atom) or asymmetrically (two methyl
groups on a single terminal nitrogen atom)10. The other important class comprises the
protein lysine methyltransferases (PKMTs), which catalyze the methylation of the -amino
group of lysine residues. This can result in mono-, di-, or trimethylation (Fig. 2.2)75.
The addition of multiple methyl groups to lysine residues might be catalyzed by a single
PKMT or might be catalyzed subsequently by different enzymes. For instance, NSD family
members can mono- and dimethylate H3 K36, the latter one of which serves as the sub-
strate for SETD2-dependent trimethylation73;132. In contrast, EZH2 is able to generate
mono-, di-, and trimethylated lysines on H3 K27 albeit with different catalytic efficien-
cies121. Proteins can be methylated at different lysine residues by different PKMTs and
single lysine residues on certain proteins can be the target of unique PKMTs or may be
a target of many PKMTs. For instance, H3 K79 is a unique target of DOTL1 methyla-
tion92, whereas H3 K9 has been reported to be methylated by at least eight PKMTs136.
On the other hand, one PKMT can have many substrates26. Based on initial experiments
showing a half-life of histone methylation similar to the half-life of histones themselves, it
was suggested to be an irreversible posttranslational modification (PTM)8. However, due
to the discovery of lysine-specific demethylase 1 (LSD1; also known as KDM1A)116, as
well as the Jumonji C (JmjC)-domain-containing protein family130, both of which could
be shown to possess protein demethylase activity, it became apparent that protein lysine
methylation is dynamically regulated.
Initially, PMTs were most commonly referred to as histone methyltransferases (HMTs), be-
cause most discoveries and characterizations were done on histones. However, more recent
discoveries are indicating that histones constitute only a subset of all potential protein tar-
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gets within the cell54. With a few exceptions like DOTL135 and METTL21A117, which are
structurally closer to PRMTs, most PKMTs contain a SET domain, which is responsible
for the catalytic activity. The SET domain is approximately 130 amino acids in length and
was originally identified in the Su(var)3–9, Enhancer-of-zeste and Trithorax proteins, from
where the name was derived58;129. It is defined by specific amino acid motifs (ELxF/YDY
and RFINHxCxPN, where x is any amino acid) and a pseudoknot structure109. In addi-
tion, all SET domain containing PKMTs also possess I-SET (immunoglobulin-SET) and
post-SET domains, which both contribute to peptide and SAM substrate recognition109.
 
Lysine methylation 
SAM SAH SAM SAH SAM SAH 
Fig. 2.2: Lysine methylation.
Representation of the amino acid lysine and subsequent methylation of the -amino group
from non-methylated to tri-methylated. Methylation reactions are catalyzed by lysine methyl-
transferases (KMTs) using cofactor S-adenosyl-L-methionine (SAM) as methyl donor, which
is converted into S-adenosyl-L-homocystein (SAH). KMTs are either specific for methylation
reactions of specific methylation states or can catalyze all three methylation states. Methy-
lated lysines can be demethylated by lysine demethylases (KDM) such as LSD1104 indicating
a dynamic regulation within cells. Reaction scheme was adjusted from website of Gozani lab
(http://web.stanford.edu/group/gozani/cgi-bin/gozanilab/research)
2.3 PKMTs - the SMYD family
Currently, more than 50 SET domain containing PKMTs have been identified in the human
genome and based on sequence similarity of the functional domains these can be divided
into several families (Fig. 2.3)6. Among them, the SMYD gene family is defined by a
conserved core comprising a SET domain interrupted by a MYND zinc finger domain. The
mammalian genomes encode for five SMYD genes named SMYD1-5. Crystal structures
are available for human SMYD1-3. Their overall structure and domain arrangement is
very similar with an N-terminal SET and MYND domain followed by a C-terminal do-
main (CTD), which structurally resembles tetra-trico peptide repeats (TPR) and may be
involved in protein-protein interactions. Overall, they share sequence identity of approx-
imately 31% among each other, which is mainly due to the conserved SET and MYND
domains. SMYD4 has an additional TPR-like domain at the N-terminus in front of the
SET and MYND domain, whereas SMYD5 has no TPR-like domain. Whereas orthologs
of SMYD3, SMYD4 and SMYD5 can be found already in early metazoans, Calpena et
al. suggested that chordate-specific SMYD1 and vertebrate-specific SMYD2 evolved from
gene duplication events of an ancestral gene of SMYD315.
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Fig. 2.3: Phylogenetic tree of human SET domain containing PKMTs.
Phylogenetic tree of human SET domain containing PKMTs based on sequence homology of the
catalytic SET domain. The SMYD protein family is highlighted in red. The phylogenetic tree
was derived from the ChromoHub of the SGC homepage81.
SMYD1 
SET MYND TPR 490 
SMYD2 
SET MYND TPR 433 
SMYD3 
SET MYND TPR 428 
SMYD4 
SET MYND TPR2 TPR1 804 
SMYD5 
SET MYND G 418 
Fig. 2.4: Domain structure of human SMYD protein family.
The human SMYD family comprises five members named SMYD1-5. They are characterized by
a MYND domain, which interrupts the catalytic SET domain. SMYD1-3 have an additional C-
terminal TPR like domain, whereas SMYD4 comprises one N-terminal and a second C-terminal
TPR like domain. SMYD5 lacks TPR like domains and has a glutamine rich C-terminus. The
numbers at the end indicate the number of amino acids of the polypeptides. The cartoon from
the domain architecture was adjusted from Abu-Farha et al.2
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Generally, SMYD proteins have been assigned functional roles in cardiomyogenesis and
myofibrillogenesis31 as well as in oncogenesis45. The most significant function has been
demonstrated so far for SMYD1 also known as BOP, which is mainly expressed in car-
diac and skeletal muscle cells. Homozygous knockout (KO) of SMYD1 in mice resulted
in embryonic lethality by disrupting maturation of ventricular cardiomyocytes41. Similar
loss of function studies in zebrafish also indicated an important role for SMYD1 in myofib-
ril organization and muscle contraction127. Additional studies in zebrafish suggested that
SMYD1 is localized to the sarcomeric M-line, where it physically associates with myosin61.
In vitro methylation assays suggested methylation activity towards histones127. However,
localization of SMYD1 is mainly in the cytoplasm79.
SMYD3 is mostly cited in the context of cancer as a potential oncogene17;44;46 and very
little is known about its normal physiological function. It is more broadly expressed com-
pared to SMYD1, but similar to SMYD1 it has been linked to cardiac and skeletal muscle
function, as SMYD3 specific antisense morpholino-oligonucleotides in zebrafish resulted in
disturbed muscle development and inappropriate expression of heart-chamber markers and
myogenic regulatory factors39. However, in contrast to SMYD1, dependency of SMYD3
in zebrafish muscle development was not observed in mice, as SMYD3 knockout mice were
viable, fertile, and showed no obvious phenotype86. The same group who generated com-
plete SMYD3 knockout mice also generated pancreas specific knockouts and showed that
RAS induced tumor formation in pancreas was retarded in SMYD3-KO mice. They discov-
ered MAP3K2, a mitogen activated kinase family member, as a new substrate of SMYD3.
Methylation of MAP3K2 may prevent its dephosphorylation at neighboring residues, which
led to extended kinase activity downstream of RAS signaling. This might have promoted
tumor formation.
Very little is known about SMYD4 and SMYD5. A homolog of SMYD4 in fruit fly was
reported to be a muscle-specific transcriptional modulator involved in development128. A
second study in cellular breast cancer models suggested a potential tumor suppressor func-
tion for SMYD4 by suppressing the expression of platelet derived growth factor receptor
alpha (PDGFRα)53. SMYD5 was suggested to methylate H4 K20 based on biochemical
methylation assays on recombinant histones. This was associated with negative regulation
of inflammatory response genes123. A very recent report described SMYD5 as an impor-
tant player in hematopoiesis during zebrafish embryogenesis38. However, more work is
needed to better understand the functions of SMYD4 and SMYD5.
2.4 SET and MYND domain containing 2 - SMYD2
SET and MYND domain containing 2 (SMYD2), also known as KMT3C, HSKM-B,
or ZMYND14 is a SET domain containing protein lysine methyltransferase. The hu-
man SMYD2 gene is encoded on chromosome 1 at 1q32.3 and the mature transcript
(NM_020197.2) derives from 12 exons. The coding sequence (CDS) encodes for a protein
of 433 aa (NP_064582.2) with a predicted molecular weight of 49.5 kDa. No alternative
splicing variants or protein isoforms have been described so far.
SMYD2 is a multi-domain protein and consists primarily of two lobes, that are sepa-
rated by a deep groove (Fig. 2.5)36. The N-terminal lobe (residues 1-279) comprises the
catalytic SET domain, the MYND domain, the insertion SET-I domain, and the post-SET
domain. The catalytic SET domain within the N-terminal lobe is split into an N-terminal
S-sequence (residues 1–49) and a core SET domain (residues 183–246). In between lies the
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MYND domain (for Myeloid, Nervy, and DEAF-1, residues 50–98). Whereas the SET do-
main is responsible for the methyltransferase activity towards lysine residues28, the MYND
domain with its conserved zinc-finger motif can mediate protein-protein interactions by
binding to proline-rich sequences122. For instance, it was shown that SMYD2 binds to
proteins such as the cytoskeleton associated protein EBP41L3 via interaction of its MYND
domain with PxLxP motifs1. Though interrupted in its primary sequence, the catalytic
SET domain occupies a similar overall fold compared to other SET domain containing pro-
teins59. SET-I domain (residues 101–182) and the cysteine rich post-SET domain (residue
246–282) are thought to support SAM cofactor and peptide substrate binding21. Three
highly conserved sequence motifs can be found within the catalytic SET domain of SMYD2
and are essential for efficient SAM binding18. These are the GxG motif (residues 18–20
of the S-sequence), the NHxCxPN motif (residues 206–212 of the core SET domain), and
the GEExxxxY motif (residues 233–240 of the core SET domain). Disruption of these mo-
tifs have been shown to interrupt efficient SAM binding and therefore methyltransferase
activity1;137. The C-terminal lobe (residues 280-433) comprises one domain, referred to as
C-terminal domain (CTD) or tetratrico peptide repeat (TRP) like domain120, which is less
well characterized. The CTD spans around 150 aa among most SMYD-family members.
It is composed of seven antiparallel α-helices with an overall structural fold similar to
tetratricopeptide repeats (TPRs). Therefore, the CTD has been suggested to be involved
in protein-protein interactions59.
Fig. 2.5: Human SMYD2 protein structure.
Domain representation of SMYD2 (top). The domains are indicated by color and numbers
indicate amino acid residues that define the boundaries of the domains. Bottom, shows a ribbon
diagram of SMYD2 structure. Individual domains are colored according to the above domain
scheme. The co-factor SAH is shown as a brown stick model, a p53 substrate peptide is shown
as a yellow stick-and-ball model, zinc ions are shown as magenta spheres. The figure was taken
from Wang et al.133.
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2.4.1 SMYD2 in normal physiology
Several groups have tried to uncover the function of SMYD2 in normal physiology. In
2006 Brown et al. were the first, who published a functional characterization of SMYD213.
In that report, the enzyme had been described to methylate H3 K36 based on in vitro
methyltransferse assays using recombinant histones and methylation specific antibodies.
Furthermore, the authors suggested an inhibitory activity of SMYD2 towards transcrip-
tion, based on results from a luciferase gene reporter assay using SMYD2-GAL4 fusion
protein and an SV40 promotor with GAL4 binding sites. The inhibitory activity was ex-
plained by observed interactions of ectopic SMYD2-GAL4 with ectopic histone deacetylase
HDAC1 and endogenous Sin3A upon immunoprecipitation, the last two, which have been
shown to form transcriptional repressor complexes66. By northern blot analyses they de-
tected high transcript levels of SMYD2 in various mice tissues, especially in the brain, the
heart and the developing embryo. Kawamura et al. confirmed high expression of SMYD2
in cardiac and skeletal muscle in Xenopus laevis 65. This was further confirmed by Diehl
et al. on RNA level and protein level in tissues from mice and rat. This group not only
showed a high expression of SMYD2 in the postnatal heart, but they were also the first who
published data from a genetic knockout of SMYD2 in mice27. They generated conditional
knockout (cKO) mice harboring a cardiomyocyte-specific deletion of SMYD2. Unexpect-
edly, in contrast to its high expression in the neonatal heart and its regulation during heart
development, SMYD2-KO mice were functional and morphological indistinguishable from
control mice, suggesting no non-redundant contribution to the development and mainte-
nance of normal heart physiology. Importantly, global H3 K4 and K36 methylation was
not affected in SMYD2-KO cells, challenging the relevance of initial findings of SMYD2
activity towards these histone marks. Donlin et al. discovered SMYD2-dependent lysine
methylation of HSP90 at residue K616 (K615 in human) in several cell lines including mus-
cle cells, which enabled complex formation between SMYD2, HSP90 and the sarcomeric
protein titin30. Specifically, methylation of HSP90 was shown to be necessary to enable
complex formation of SMYD2 and HSP90 with the N2A domain of titin at the I-band
of the sarcomeres. A subsequent study by Voelkel et al. confirmed SMYD2-mediated
complex formation of methylated HSP90 and the N2A domain of titin131. Interestingly,
in contrast to mammals, downregulation of SMYD2 in zebrafish was reported to disrupt
the stability of the sarcomeric titin springs, which resulted in severely impaired mobility,
malformation of the tails, reduced heart rates, and fractional shortening131. This sug-
gested a compensatory mechanism for SMYD2 in rodents. SMYD2 expression has also
been shown to be induced during human embryonic stem cell (ESC) differentiation113.
Connecting findings from both cancer research and cardiac muscle physiology, Sajjad et
al. investigated the p53-dependent apoptotic induction in cardiomyocytes upon hypoxia
in the context of SMYD2 activity106(p53 was described as a SMYD2 substrate as dis-
cussed later). They found that SMYD2 is downregulated upon apoptotic triggers both on
the transcriptional and post-translational level. They further suggested that SMYD2 had
an inhibitory effect on apoptosis induction by the observation that SMYD2-null cardiomy-
ocytes revealed a stronger apoptotic response upon CoCl2-induced hypoxia as an apoptotic
trigger. However, the strong expression of SMYD2 during development and in cardiac and
skeletal muscle remains a mystery in view of the lack of phenotype in SMYD2 knock-
out mice (besides cardic-specific SMYD2-KO mice, another group has generated complete
knockouts with no observed phenotype103). Abu-Farha and colleagues combined proteomic
and genomic approaches to identify the SMYD2 interactome and its impact on gene reg-
ulation1. Potential protein interaction partners where identified by mass spectrometry
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after immunoprecipitation of ectopic FLAG-tagged SMYD2 using the human embryonic
kidney derived 239T cell line. The authors identified 21 potential SMYD2 interacting
proteins. Further validation experiments by co-immunoprecipitation of ectopic SMYD2
variants and potential interactors revealed interactions of SMYD2 with HSP90 indepen-
dent of its SET and MYND domains, with p53 dependent on functional SET domain and
of EPB41L3 dependent on the MYND domain. The interaction of EPB41L3, a membrane
and cytoskeletal associated protein was presumed to depend on a PxLxP motif within the
protein. Furthermore, they showed that the interaction of HSP90 with SMYD2 enabled
SMYD2 to mono-methylate H3 K4 in biochemical methylation assays. They also observed
mainly upregulation of genes upon ectopic SMYD2 overexpression in 293T cells. They
hypothesized that upregulation was due to the ability of SMYD2 to methylate H3 K4 on
the corresponding promotor regions.
2.4.2 SMYD2 function in cancer
Huang et al. were the first who published the ability of SMYD2 to methylate the tumor
suppressor p53 and thereby inhibiting p53 transactivation activity55. Specifically, the au-
thors were able to demonstrate, both in biochemical and in cellular assays, that K370 of
p53 is a specific target lysine for monomethylation by SMYD2. They further showed that
modulation of SMYD2 abundance by either knockdown or overexpression, respectively in-
creased or decreased the p53-dependent induction of canonical p53 target genes p21 and
mdm2. In addition, knockdown of SMYD2 also resulted in a pronounced p53 mediated
apoptosis induction in the U2OS osteosarcoma cell line model (p53 WT) upon treatment of
the DNA damage-inducing agent Adriamycin. Using a double chromatin immunoprecipita-
tion approach (ChIP 1 against total p53, ChIP 2 against methylated p53) the authors then
provided evidence for a mechanistic model, by which p53 K370 mono-methylation reduces
the ability of p53 to bind chromatin and thereby impairing transcriptional induction of
p53 target genes. Importantly, these findings indicated a potential oncogenic activity for
SMYD2. Subsequently, several crystal structures were published of SMYD2 in conjunction
with p53 derived peptides, which supported p53 regulation by SMYD2 methylation36;133.
In 2009, Komatsu et al. published that SMYD2 lies in a frequently amplified chromosomal
region within 1q32–q41 in esophageal squamous cell carcinoma (ESCC) patients and that
overexpression of SMYD2 in ESCC correlated with a poor prognosis of these patients70.
What is more, this correlation was considered to be not only valuable as prognostic marker
but also a causal driver of oncogenesis, as knockdown of SMYD2 expression inhibited and
ectopic overexpression of SMYD2 promoted the proliferation of ESCC cell lines. How-
ever, SMYD2 overexpression was independent of the p53 mutation status and prompted
towards additional roles of SMYD2 besides p53 regulation. Similar results were later found
in gastric cancer69, in bladder carcinomas19, in acute lymphoblastic leukemia (ALL)107
and in human papillomavirus (HPV)–unrelated head and neck squamous cell carcinomas
(HNSCC)95. All these reports pointed towards a critical role of SMYD2 in tumorigenesis
and a potential target for cancer therapy. Mechanistically, SMYD2 methylation activity
has been linked to several substrates besides p53 and histone H3. For instance, it has been
reported that retinoblastoma protein (RB), a tumor suppressor and a major regulator of
cell cycle progression at the G1/S phase, can be methylated by SMYD2 at residue K860105.
The authors also detected an increase in RB methylation upon DNA damage caused by
Etoposide treatment. In this study, it was furthermore indicated that monomethylation of
RB at K860 may serve as a binding motif for the L3MBTL1 transcriptional repressor via
its MBT domain. This hypothesis was based on co-immunoprecipitation experiments of
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ectopic RB and ectopic L3MBTL1 in the presence or absence of ectopic SMYD2. Overall,
these data suggested a repressive function of RB methylation towards RB target genes
and an antiproliferative effect of SMYD2 activity. This is in contrast to another study,
where Cho et al. discovered SMYD2-dependent RB methylation at K810, which promoted
cell cycle progression by increasing neighboring RB phosphorylation at S807/81119. Addi-
tional studies discovered the nuclear hormone receptor estrogen receptor alpha (ERα) to
be a direct target for protein methylation at residue K266 by SMYD2141. Methylation at
K266 reduced the ability of ERα to bind to its target genes. However, stimulation with
estradiol diminished ERα methylation and subsequent target gene activation. Later on, a
crystal structure was published of SMYD2 with a peptide ligand derived from ERα con-
taining the methylated target lysine K26660. Hamamoto et al. showed that FLAG-tagged
SMYD2 can immunoprecipitate HSP90AB1 and is able to monomethylate HSP90AB1 at
residues K531 and K574, which increased its dimerization ability and supported cancer
cell growth. Interaction of SMYD2 with HSP90 was shown to be dependent on the SET
domain of SMYD2 and the C-terminal region of HSP9047. This is in contrast to Abu-Farha
et al. who indicated an interaction of SMYD2 with HSP90 independent of the SET and
MYND domain. Piao et al. reported on findings showing that SMYD2 is able to methylate
Poly(ADP-ribose) polymerase-1 (PARP1) at residue K52898. PARP1 is highly abundant in
the nucleus and involved in DNA repair, chromatin modification, transcriptional regulation
and genomic stability62;94. Methylation of PARP1 increased its poly-(ADPribosyl)ation
(PAR) activity in biochemical assays. Furthermore, knockdown of SMYD2 decreased PAR
activity in cells after DNA damage and oxidative stress as measured in immuno-fluorescence
analyses by a PAR-specific antibody. Nakakido et al. reported that SMYD2 methylates
PTEN at residue K313 in vitro and in vivo91. The authors suggested a model by which
methylation of PTEN at K331 supports PTEN phosphorylation at S380 and thereby in-
activating PTEN tumor suppressor function and activation of the PI3K – AKT signaling
pathway. In contrast, knockdown of SMYD2 reduced AKT activity, as measured by AKT
phosphorylation on residue T308, and resulted in growth inhibition of breast cancer cell
lines. Taken together, multiple regulatory functions have been assigned to SMYD2 towards
prominent oncogenes or tumor suppressor genes. In addition, it is frequently overexpressed
in many tumor types and is associated with a worse outcome. Therefore, SMYD2 may rep-
resent a promising anti-cancer target. The fact that SMYD2 knockout mice are viable and
show no phenotype may predict good tolerability of healthy tissue upon SMYD2 inhibition
and therefore may allow a targeted therapy specific to cancer cells. This is the reason, why
pharmaceutical companies started drug discovery projects for the development of potent
small molecule SMYD2 inhibitors.
2.5 Drug discovery and development
For the development of targeted therapies highly selective and potent small molecules or
biologics are needed. This requires a comprehensive drug discovery and development pro-
cess, which is cost and time consuming, often with a time frame from “first hit” to market
launch of over ten years and costs exceeding on average $ 1 billion29. The prerequisite to
engage in a drug discovery program are defined first by an unmet clinical need and second
by a scientific hypothesis, often originating from basic science, which suggests a potential
benefit for patients when targeting a certain protein or pathway in the underlying disease.
The preclinical stages of drug discovery start with initial target identification (either from
phenotypical screenings or from literature mining) and to some extent target validation.
However, the latter one is only partially feasible due to technical limitations and time.
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Subsequently, assays need to be developed that are suitable for high-throughput screening
(HTS) in order to discover suitable chemical structures as starting points for further opti-
mization towards the defined target. The HTS will identify initial hits from a compound
or biological library. Upon confirmation of initial hits, certain leads with most promising
properties will be selected for further lead optimization (LO). Parallel to the LO phase,
which is driven in the case of small molecule inhibitors mainly by medicinal chemistry,
more comprehensive in vitro and in vivo pharmacological characterization is performed to
test for cellular activity of the generated compounds. For that purpose, cellular mecha-
nistic assays are highly desired that adequately monitor the specific activity of a target.
At the end of the LO phase, best candidates are chosen for comprehensive toxicology and
pharmacokinetic/pharmacodynamic testing in animal models before the "first in man" tri-
als can be initiated in phase 1 clinical studies. This marks the transition from preclinical
to clinical development.
The clinical development normally consists of phase 1-3 clinical studies after which approval
from healthcare authorities may be given, if effectiveness and safety of the investigational
new drug can be demonstrated at a proper risk/benefit ratio3. However, there is a big
attrition on the way to market launch and advanced drug candidates can fail for two main
reasons: Either they are not effective or they are not safe. Lack of efficacy and safety can
be due to the under- or overestimated consequences of inhibiting or activating a certain
target of interest or due to unintended off-target effects. Although many of the effects
are difficult to predict, especially when transferring from preclinical models to human, a
better understanding of the biology of individual targets can significantly mitigate late
stage failure.
High quality small molecule probes can make a contribution to generate a more efficient
drug discovery and development process, because they will allow a broad scientific com-
munity to work with these tools and advance our understanding of proposed targets and
may even identify new unexpected applications or indications for certain targets. Small
molecule probes are especially valuable as they are easy to handle (e.g. treating cells with
a compound is much easier accomplished than transfecting them with siRNAs or creating
knockouts), possess completely different dynamics compared to genetic tools like RNAi
mediated knockdown, and often better mimic the pharmacological properties of drugs in
the clinic. In addition, phenotypes can greatly vary between the depletion of a protein
by knockout/knockdown or the inhibition of a specific activity of that protein (e.g. en-
zymatic activity, protein-protein interaction, protein-DNA interaction), which otherwise
may compromise interpretation of target characterization. Therefore, high quality potent
and selective drug-like probes that are suitable for in vitro and in vivo research are highly
desired by both academic research and pharmaceutical industry to enhance the scientific
progress and enable faster delivery of better drugs to patients.
2.6 Previous research activities as starting point for the current thesis
Due to a high need for better anti-cancer therapies and the hints coming from research
that SMYD2 might be involved in oncogenesis, this enzyme was suggested as a therapeu-
tic target. However, the biology of SMYD2 remains elusive and there is still an ongoing
debate about its relevant substrates and molecular mode of action during tumorigenesis
and further exploration is needed to solidify potential therapeutic benefits for patients.
Therefore, it was envisioned to develop a specific in vivo probe for SMYD2 to allow more
research on the impact of pharmacological inhibition of SMYD2 in diverse model systems.
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2.7 Aim of this thesis
To continue in the development of a SMYD2 probe after screening, similar to the above
described process for drug discovery and development, it was my first task to support the
establishment of a SMYD2 specific cellular mechanistic assay that is able to monitor the
enzymatic activity and the effects of small molecule inhibition.
Secondly, I intended to discover novel substrates of SMYD2 that might enable a better
understanding of that enzyme in the cellular context.
Finally, I aimed at testing the biological relevance of SMYD2 activity in selected cellular
models by genetic depletion of SMYD2 and by inhibiting SMYD2 activity with BAY-598,
a potent and selective SMYD2 probe that was developed in the course of this project. The
latter one should be seen as a starting point towards additional research about SMYD2
protein and the suitability of using probes to address specific scientific questions.
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3 Materials & Methods
3.1 Mammalian cell culture
All cell lines were purchased from the American Type Culture Collection (ATCC) or the
German Collection of Microorganisms and Cell Cultures (DSMZ) and were handled with
aseptic techniques according to general recommendations. Cells were kept in 25 - 300 cm2
cell culture flasks with filter caps (TPP Techno Plastic Products AG) and incubated in
a humidified incubator at 37°C and 5% (v/v) CO2. MDA-MB231 cells were maintained
in RPMI 1640 medium with stable glutamine (Merck Millipore, #FG1215) supplemented
with 10% (v/v) heat inactivated fetal calf serum (hiFCS) (Biochrom, #S0615). KYSE150
cells were cultured in DMEM/Ham’s F12 medium with stable glutamine (Merck Millipore,
#FG4815) supplemented with 10% (v/v) hiFCS. HEK293, NIH3T3 and C2C12 cells were
cultured in DMEM high glucose with stable glutamine, without sodium pyruvate (Thermo
Fisher Scientific, #10566). For HEK293 and NIH3T3 medium was supplemented with
10% (v/v) hiFCS. For C2C12 medium was supplemented with 20% (v/v) hiFCS and 2.5
mg/L insulin (Sigma Aldrich, #I9278). FCS was heat inactivated for 30 min at 56°C in
a water bath and sterile filtered. For continuous cell culture, cells were split 2-3 times
a week to be subconfluent at the next round of splitting. C2C12 cells were split every
second day. To split cells, old media was aspirated and cell layers were carefully washed
once with sterile PBS (Merck Millipore, #L1825) and then covered with a thin layer
of trypsin/EDTA solution (Thermo Fisher Scientific, #R001100) at RT. After 2-4 min
cells were thoroughly resuspend in fresh medium and a fraction was transferred into a
new flask. Cell numbers were determined with a Countess II Automated Cell Counter
(Thermo Fisher Scientific, #AMQAX1000) according to the manufacturer’s instructions.
A549, A498, KYSE70, KPL-4, T47D, MCF7, EFM-19, ZR-75-1 cell lines for western blot
analyses were kindly provided as snap-frozen cell pellets from colleagues and were handled
according to ATCC recommendations.
3.2 Proliferation assay by Xcelligence
Proliferation of cell lines was measured using Xcelligence DP device (OMNI Life Sci-
ence) according to the manufacturer’s instructions. After seeding of 2000 cells/96-well in
quadroduplicate, cells were permanently grown for 6 days. Eight hours after cell seeding,
proliferation signals measured by conductivity were normalized to one for each individual
well. Conductivity is represented as cell index, which is a compilation of cell division, cell
growth, and cell adherence and served as surrogate for cell proliferation.
3.3 Differentiation of C2C12 cells
For differentiation of C2C12 myoblasts, cells grown to confluence and growth medium was
changed to differentiation medium (DMEM with 2% (v/v) heat inactivated horse serum
(HS) (Thermo Fisher Scientific, #26050088)). During the differentiation phase 90% of old
medium was replaced by fresh medium every day.
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3.4 Antibody generation
Customized methylation specific antibody SY46 was generated and purified by an external
provider. For immunization of rabbit, a peptide corresponding to amino acids 361-380
from human p53 protein (NP_000537.3) with a mono-methyl lysine at the corresponding
amino acid K370 (NH2-GSRAHSSHLK(me1)SKKGQSTSRH-COOH) was cross-linked at
its N-terminus to Keyhole limpet hemocyanin (KLH) carrier protein. Antibodies were
purified from sera of immunized rabbits via cross-affinity purification using a methylated
and a non-methylated version of the peptide (see Fig. 4.13).
3.5 ELISA
Enzyme-linked immunosorbent assay (ELISA) for validation of SY46 methylation speci-
ficity was performed by the same provider as antibody generation using a sandwich ELISA.
Briefly, 96-well plates were spotted with methylated or non-methylated peptide and blocked
with BSA. Aliquots of different purification steps were incubated in a ten-fold dilution
series with the peptides and unbound antibodies were washed off. Primary antibodies spe-
cific to the peptides were detected by secondary goat anti-rabbit antibodies cross-linked
to horseradish peroxidase (HRP). Signals were measured at 492 nM after substrate addi-
tion.
3.6 IC50 determination
IC50 is the concentration of a compound at which a biological process is inhibited half
maximal. For IC50 determination cells were treated with a half-logarithmic dilution series
of the corresponding compound. For calculation of the IC50 measurement, values were nor-
malized by setting the value at the highest compound concentration to 0% and the value
at the lowest compound concentration to 100%. Normalized values were plotted against
the log10-transformed compound concentrations and a regression curve was determined
with GraphPad Prism 6 software using a four parameter non-linear dose-response model
and least squares fit.
Equation: log(inhibitor) vs. response - Variable slope:
Y = Bottom+ (Top−Bottom)/(1 + 10((LogIC50−X)∗HillSlope))
X: log of dose or concentration
Y: response, decreasing as X increases
Top and Bottom: Plateaus in the same unit as Y
logIC50: same log units as X
Hill slope: Slopefactor or Hill slope, unitless.
3.7 Proteom study
For detection of global lysine methylation in cells approximately 2x108 MDA-MB231 cells
stably overexpressing SMYD2-WT were harvested by 2-3 min detachment in Trypsin/EDTA
solution and resuspension in cell culture media as described in 3.1. Cells were centrifuged
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for 5 min at 300x g and the cell pellet was washed twice in PBS. The dry cell pellet was
snap-frozen and sent to an external provider. There, cell lysate preparation and enrichment
of methylated peptides was done as described in42. For immuno-affinity enrichment either
the customized SY46 methylation antibody or a pan-mono/di-methyl lysine antibody (Cell
Signaling Technology, #14809) were used. Peptides were detected by LC-MS/MS. A list
of all detected peptides containing methylated lysines was provided.
3.8 In silico analyzes
Copy number alterations (CNA) CNA for SMYD2 in human cancer patient samples
were retrieved from cBioPortal database (www.cbioportal.org/).
Sequence motifs Sequence motifs were generated with WebLogo 3 software (http://
weblogo.threeplusone.com/create.cgi) using the standard hydrophobicity color schema
for amino acids.
Sequence alignments Sequence alignments were performed with Jalview (http://www.
jalview.org/).
3.9 RNA microarray expression analyzes
For study of global gene expression of stable SMYD2 knockdown cells, cells were seeded
into six-well culture plates in quadroduplicates and grown for 48 h until subconfluence.
RNA was extracted using RNeasy Plus mini Kit (Qiagen, #74134) as described in 3.15.
For each replicate, 250 ng of total RNA was amplified using the GeneChip WT PLUS
Reagent Kit (Affymetrix, #902281) according to the protocol described in User Manual
Target Preparation for GeneChip Whole Transcript (WT) Expression Arrays (P/N 703174
Rev. 2). An Affymetrix Human Gene 2.1 ST 96-array plate was hybridized with 3 g of
fragmented and labeled single stranded cDNA, washed, stained, and scanned according
to the protocol described in the User Manual GeneTitan Instrument User Guide for Ex-
pression Arrays Plates (P/N 702933 Rev.1) and Affymetrix geneChip Command Console
User’s Guide (P/N 702569 Rev.9) using the Affymetrix geneTitan instrument. Principal
component and correlation analyses were used to confirm data reproducibility. Differen-
tially expressed probe sets were determined by carrying out paired t test comparisons of
knockdown versus control cells. Significant probe sets with a FDR (Benjamini–Hochberg)
< 0.1 were filtered by fold-change > 2.0 using Expressionist-GeneData software.
3.10 In vitro methylation
One µg of recombinant SMYD2 enzyme was incubated with 1 µg of protein substrate
overnight at RT in 20 µL methylation buffer (50 mM Tris-HCl pH 9.0, 0.01% (w/v) BSA,
0.0022% (v/v) pluronic, 1 mM DTT, 100 µM SAM). Reactions were stopped by addition
of 20 µL sample buffer and denaturation for 10 min at 95°C. Recombinant SMYD2 enzyme
and recombinant p53 was kindly provided inhouse by Dr. Joerg Weiske and was generated
as previously described32. Recombinant AHNAK-CRUs were expressed and purified as
described in 3.33.
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3.11 NIH3T3 focus formation assay
For focus formation assays, 1x105 NIH3T3 cells were seeded into 6-well plates and trans-
duced with retrovirus (for H-RAS-G12V) and/or lentivirus (for SMYD2-WT, SMYD2-
H207A or GFP) as described in 3.32. If needed, 24 h later cells were additionally treated
with small molecule inhibitors. Media with/without fresh compound was replaced every
second day. Focus formation was analyzed 10-20 days after transduction. For that, cells
were washed one in PBS buffer and stained with methylene blue solution (Sigma-Aldrich,
#77515) for 5 min. Cells were carefully washed twice with PBS and images were scanned for
documentation. Retroviral H-RAS-G12V was kindly provided inhouse from Dr. Michael
Steckel and was prepared from pRev(MSG)CMV-hRasG12V-Neo plasmid by the Natural
and Medical Sciences Institute of the University of Tuebingen.
3.12 GATEWAY cloning
To efficiently transfer DNA sequences of interest into different plasmid vectors Gateway
cloning was utilized64. Synthetic DNA fragments flanked by appropriate attB-sites were
ordered from GeneArt (Thermo Fisher Scientific). The fragments were first cloned into
a donor vector via BP reaction to generate an entry clone. Inserts were further trans-
ferred from an entry clone into the desired destination vectors via LR reaction to generate
the corresponding expression clones. A list of vectors and their application is shown in
Tab. 3.2. BP and LR reactions were performed according to manufacturer’s instructions
using BP clonase II (Thermo Fisher Scientific, #11789) and LR clonase II (Thermo Fisher
Scientific, #117110) enzyme kits, respectively.
Tab. 3.2: List of GATEWAY compatible plasmids
Name Company Cat. # Description
pDONR221 Thermo Fisher Scientific 12536017 donor vector
for entry clones
pDEST15 Thermo Fisher Scientific 11802014 IPTG inducible
expression vector
for E. coli
pLenti6.3/V5Dest_verA Thermo Fisher Scientific V53306 mammalian expression
vector for
lentivirus production
3.13 Transformation of chemically competent E.coli
An aliquot of 50 µL of chemically competent E. coli was thawed on ice and up to 5 µL
of sample or around 100 ng of plasmid DNA was added and incubated on ice for 30 min
with occasional flicking. Cells were heat shocked for 45 s at 42°C in a thermo block,
chilled on ice for 1 min and resuspended with 200 µL S.O.C. medium (Thermo Fisher
Scientific, #15544034). Cells were shaken for 1 h, 180 rpm, 37°C. Depending on transfor-
mation efficiency, 20-100 µL was plated on LB agar containing the appropriate antibiotic.
Colonies were picked after 24 h for further processing. For lenti-vectors the Stbl3 strain
(Thermo Fisher Scientific, #C737303) was used. For protein expression the BL21 strain
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(Thermo Fisher Scientific, #C600003) was used. Otherwise the DH10B derived Top10
strain (Thermo Fisher Scientific, #C404010) was used. LB medium was made of 1%
(w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, pH 7. LB agar was made of
LB medium and 1.5% (w/v) bactoagar.
3.14 Plasmid DNA preparation
For small scale a single colony of transformed E. coli was inoculated in 4 mL LB-medium
containing the appropriate selection marker (100 µg/mL ampicillin or 50 µg/mL kanamycin;
Sigma Aldrich). Cultures were incubated overnight at 37°C, 180 rpm. Plasmid preparation
was done with the QIAprep Spin miniprep Kit (Qiagen, #27104) according to the manu-
facturer’s instructions. For transfection of mammalian cell cultures the EndoFree Plasmid
Maxi Kit (Qiagen, #12362) was used according to the manufacturer’s instructions.
3.15 RNA preparation
RNA from mammalian cell cultures was prepared with the RNeasy Plus mini Kit (Qiagen,
#74134) according to the manufacturer’s instructions. Typically, cells within a 6-well plate
were lysed in 300 µL RLT Plus buffer. Sticky lysates were centrifuged for 1 min at 16,000x g
through a QIAshredder spin column (Qiagen, #79656).
3.16 Preparation of cDNA
For preparation of cDNA from RNA the SuperScript III First-Strand Synthesis SuperMix
(Thermo Fisher Scientific, #11752250) was used according to the manufacturer’s instruc-
tions. Briefly, prior to cDNA synthesis RNA concentration from different samples was
adjusted and 1-10 µg of total RNA was used for one 20 µL reaction. Samples were sub-
sequently diluted with RNase-free water to 34 ng/µL of initial RNA and stored at -20°C
until usage.
3.17 Quantitative real-time PCR with Taqmen probes
For RNA expression analyzes prepared cDNA was quantitatively measured by real-time
PCR using a 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific, #4329001).
Ten µL reactions were prepared in MicroAmp Optical 384-Well Reaction Plates (Thermo
Fisher Scientific, #4309849) using the TaqMan Fast Advanced Master Mix (Thermo Fisher
Scientific, #4444557) according to the manufacturer’s instructions and predesigned Taq-
men probes (for individual probes see Tab. 3.3). Typically, 3 µL of pre-diluted cDNA
(corresponding to 100 ng of input RNA) was used per reaction. Individual samples were an-
alyzed in triplicates. Plates were sealed with MicroAmp Optical Adhesive Films (Thermo
Fisher Scientific, #4311971). The thermal cycling profile was as follows: a single initial
step of 2 min at 50°C and 20 s at 95°C, followed by 40 repeating cycles of 1 s at 95°C and
20 s at 60°C. Relative expression values were quantified by the ∆∆Ct or ∆’Ct methods as
described by Livak et al.83.
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Tab. 3.3: List of Taqmen probes from Thermo Fisher Scientific
Gene Symbol Species Assay ID Reporter dye
SMYD2 Human Hs00220210_m1 FAM
GAPDH Human Hs03929097_g1 FAM
ACTB Human Hs99999903_m1 FAM
Actb Mouse Mm00607939_s1 FAM
Ahnak Mouse Mm00613028_m1 FAM
Ahnak2 Mouse Mm03015444_m1 FAM
Dmd Mouse Mm01216951_m1 FAM
Gapdh Mouse Mm99999915_g1 FAM
Mef2c Mouse Mm01340842_m1 FAM
Myod1 Mouse Mm00440387_m1 FAM
Myog Mouse Mm00446194_m1 FAM
Rpl41 Mouse Mm02524711_g1 FAM
Rps24 Mouse Mm01623058_s1 FAM
Smyd1 Mouse Mm00477663_m1 FAM
Smyd2 Mouse Mm00660598_m1 FAM
Smyd3 Mouse Mm00510201_m1 FAM
Smyd4 Mouse Mm00662052_m1 FAM
Smyd5 Mouse Mm00523415_m1 FAM
3.18 Photometric quantification of nucleic acids
For quantification of nucleic acids (DNA/RNA) the extinction at 260 nM was measured
with a NanoDrop 2000 (Thermo Fisher Scientific, #ND-2000) according to the manufac-
turer’s instructions.
3.19 Preparation of protein lysates from mammalian cell culture
Typically, cell culture media was aspirated and cells were washed once in chilled PBS
buffer. Cells were then detached from culture plates by a cell scraper resuspended in PBS
buffer and transferred to a reaction tube. Cells were collected by centrifugation for 5 min at
300x g and resuspended by pipetting in approximately 5 volumes of lysis buffer containing
1x Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, #78440)
and 1 U/µL Benzonase endonuclease (Merck Millipore, #101656). RIPA buffer (Thermo
Fisher Scientific, #89900) was used for whole cell lysates and IP buffer (Thermo Fisher
Scientific, #87787) was used for immuno-precipitation. Lysates were homogenized with a
Bioruptor Sonication device (Diagnode, #UCD-200) for 5 min at high settings according
to the manufacturer’s instructions. Homogenized lysates were incubated on ice for 30 min
and insoluble cell debris was spun down for 10 min at 16,000x g. The supernatant was
used for further proceedings.
3.20 Preparation of tissue samples from mice
Mice (strain C57BL/6N, female, 7 weeks old) were euthanized according to regulatory
requirements and different organs were surgically removed, shortly rinsed in PBS buffer,
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snap frozen in liquid nitrogen and stored at -80°C until further processing.
3.21 Preparation of protein lysates from mice tissue
Tissue samples were crushed in liquid nitrogen with a mortar and pestle and resuspended
in tissue lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
0.1% (w/v) SDS, 1% (w/v) Triton-X100, 10% (v/v) glycerol, 1 mM DTT, 2x Halt Protease
and Phosphatase inhibitor cocktail, 2 U/µL Benzonase). Tissue lysates were homogenized
first by sonication as described in 3.19 and second after 20 min of incubation on ice by cen-
trifugation for 10 min at 16,000x g through a QIAshredder spin column (Qiagen, #79656).
Insoluble debris formed a fragile pellet at the bottom of the QIAshredder tube and the
supernatant with soluble protein was transferred to a new reaction tube.
3.22 Determination of protein concentrations
To determine the protein concentration of cell/tissue lysates, an aliquot of the sample
of 1-10 µL was added to 200 µL BCA reagent (freshly prepared working solution from
50 volumes reagent A and 1 volume reagent B, Thermo Fisher Scientific, #23225) in 96-
well plates (TPP, #92696) and incubated for 30 min at 37°C. A defined BSA dilution series
(Thermo Fisher Scientific, #23208) was used to create a standard curve. After 30 min the
extinction at 562 nM was measured using a Sunrise plate reader (Tecan, #16039400).
Values were blanked against BCA reagent with lysis buffer instead of protein samples and
absolute protein concentrations were calculated from the BSA standard curve.
3.23 Immuno-precipitation
Protein lysates were obtained as described in 3.19. An aliquot of 500 µL with 2 mg/mL
total protein was used per IP in a 1.5 mL reaction tube. For mice tissue, original protein
lysates were diluted in IP buffer to 2 mg/mL total protein. Two µg of primary antibody
were given to the lysates and incubated on an overhead rotator overnight at 4°C. Isotype
IgGs were used as negative controls. For precipitation of the immuno-complexes 50 µL of
equilibrated Protein G dynabeads (Thermo Fisher Scientific, #10003D) were added and
incubated with rotation for 1-2 h at 4°C. Dynabeads were recovered with a magnetic rack
(Thermo Fisher Scientific, #12321D) and washed 3 times for 10 min with 1 mL of IP
lysis buffer. Immuno-precipitated proteins were recovered by incubation of dynabeads for
10 min at 95°C in 50 µL 2x sample buffer (prepared with 1/2 vol. 4x LDS sample buffer
(Thermo Fisher Scientific, #NP0007), 1/5 vol. of 10x NuPAGE Reducing Agent (Thermo
Fisher Scientific, #NP0004) in aqua bidest). Samples were directly applied to protein gel
electrophoresis.
3.24 Denaturing protein gel electrophoresis
Sixty five µL of concentration adjusted protein lysates were denatured with 25 µL 4x Nu-
PAGE LDS Sample Buffer (Thermo Fisher Scientific, #NP0007) and 10 µL 10x NuPAGE
Sample Reducing Agent (Thermo Fisher Scientific, #NP0004) for 10 min at 95°C. Sam-
ples were chilled for 1 min on ice and equal volumes were loaded onto a pre-cast 4-12%
Bis/Tris NuPAGE Protein Midigel (Thermo Fisher Scientific, #WG1402A). Empty lanes
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were loaded with 1x sample buffer. The gel was run on a XCell4 SureLoc Midi-Cell Elec-
trophoresis System (Thermo Fisher Scientific, #WR0100) with 1x NuPAGE MOPS SDS
Running Buffer (Thermo Fisher Scientific, #NP0001) at 80-150 V according to the manu-
facturer’s instructions. A Precision Plus Protein Dual Color Standard (Biorad, #1610374)
was used as size marker.
3.25 Coomassie staining of protein gels
To visualize protein bands after gel electrophoresis gels were stained with Coomassie In-
stantBlue (Expedeon, #ISB1L) according to the manufacturer’s instructions.
3.26 Western transfer and immunodetection
Western transfer After separation of proteins by gel electrophoresis, proteins were
transferred to nitrocellulose membranes (Thermo Fisher Scientific, #LC2009) by western
blotting using a Trans-Blot Electrophoretic Transfer Cell (Biorad, #1703853) according
to the manufacturer’s instructions. The transfer was performed in 1x NuPAGE Transfer
Buffer (Thermo Fisher Scientific, #NP0006) w/o methanol for 2 h at 40 V or overnight
at 15 V in an ice cooled water bath. After electrophoresis proteins transferred to the
membrane were visualized by ATX Ponceau S (Sigma Aldrich, #09276-6X1EA-F) staining
for 5 min to monitor transfer efficiency.
Immuno-detection Membranes were blocked for 1 h at RT in blocking buffer (1x PBS
buffer (Thermo Fisher Scientific, #AM9625), 5% (w/v) non-fat dry milk (Sigma Aldrich,
#M4709), 0.1% (v/v) Tween-20 (Sigma-Aldrich, #P2287)). After blocking, membranes
were incubated overnight at 4°C with primary antibodies diluted in blocking buffer (for
details on antibodies see Tab. 3.4). The primary antibody solution was removed and
membranes were washed three times for at least 10 min in washing buffer (1x PBS, 0.1%
(v/v) Tween-20). Membranes were then incubated for 2 h at RT with secondary antibodies
diluted in blocking buffer. Blots were again washed three times for at 10 min in washing
buffer before detection of the antibody signals were performed. Fluorescence labeled and
HRP-conjugated secondary antibodies were detected with the appropriate channels using
an Odyssey Fc imaging device (LI-COR) according to manufacturer’s instructions. Fluo-
rescent signals were quantified with the corresponding software package, if needed. HRP
signals were obtained with the SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Fisher Scientific, #34094).
3.27 In-cell-western (ICW)
Cells were seeded and treated within 100 µL cell culture media in 96-well cell culture plates
(TPP, #92096) depending on the individual experiment. At the experimental endpoint,
the medium was completely aspirated without detaching the cells and cells were fixed
for 20 min in 50 µL ICW-fixation buffer (freshly prepared by diluting 37% formaldehyde
solution (Sigma Aldrich, #33220) 1:10 in 1xPBS buffer). After two washes with 100 µL
PBS, cells were incubated for 15 min in permeabilization buffer (0.25% (v/v) Triton X-100
(Sigma Aldrich, #93443) in PBS buffer). After one wash with PBS, cells were incubated
for 1 h at RT in 100 µL ICW-blocking buffer (5% (w/v) nonfat dry milk (Sigma Aldrich,
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Tab. 3.4: List of primary antibodies for WB
Target MW Type/ Company Cat.# Dilution
(kDa) Host
β-Actin 42 mMs Abcam ab8224 1:1000
β-Tubulin 50 pRb Santa Cruz Biotech. sc-9104 1:1000
AHNAK 629 mMs Santa Cruz Biotech. sc-390743 1:500
(C-terminus)
AHNAK 629 mMs Antikörper-online ABIN263928 1:1000
(N-terminus)
c-myc tag - mMs Santa Cruz Biotech. sc-40 1:2000
GAPDH 35 mMs Santa Cruz Biotech. sc-32233 1:2000
H3 17 mMs Abcam ab10799 1:2000
H3 K36me1 17 pRb Abcam ab9048 1:1000
H3 K36me2 17 mRb Cell Signaling Tech. 2901 1:1000
H3 K36me3 17 pRb Abcam ab9050 1:1000
H3K4me1 17 pRb Abcam ab8895 1:1000
H3K4me3 17 pRb Abcam ab8580 1:1000
HSP90 90 mMs BD Pharmingen 610418 1:5000
IgG-isotyp - pMs Santa Cruz Biotech. sc-2025 -
IgG-isotyp - pRb Santa Cruz Biotech. sc-2027 -
Kme1 (SY46) - pRb - customized 1:250
MyoD 34 pRb Santa Cruz Biotech. sc-304 1:1000
myogenin 25 mMs Santa Cruz Biotech. sc-12732 1:1000
myosin 223 mMs Developmental Studies MF 20-c 1:1000
(MHC) Hybridoma Bank
p53 53 mMs BD Pharmingen 554294 1:1000
p-ERK1/2 44, 42 mRb Cell Signaling Tech. 4370 1:1000
SMYD1 56 mMs Santa Cruz Biotech. sc-514805 1:1000
SMYD2 50 pRb Abcam ab108217 1:1000
SMYD2 50 mMs Santa Cruz Biotech. sc-393827 1:500
SMYD3 49 pRb Santa Cruz Biotech. sc-67210 1:1000
SMYD5 47 pRb Thermo Fisher Scientific PA5-29153 1:1000
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Tab. 3.5: List of secondary goat antibodies
Target Fluorophore Company Cat.# Dilution Application
Mouse Alexa Fluor 680 Thermo Fisher Sc. A-21058 1:2000 WB, ICW
Rabbit Alexa Fluor 680 Thermo Fisher Sc. A-21109 1:2000 WB, ICW
Mouse IRDye 800CW LI-COR 926-32210 1:2000 WB, ICW
Rabbit IRDye 800CW LI-COR 926-32211 1:2000 WB, ICW
Rabbit Alexa Fluor 488 Thermo Fisher Sc. A-11008 1:1000 IF
Rabbit Alexa Fluor 555 Thermo Fisher Sc. A-21428 1:1000 IF
Rabbit Alexa Fluor 647 Thermo Fisher Sc. A-21245 1:1000 IF
Mouse Alexa Fluor 488 Thermo Fisher Sc. A-11001 1:1000 IF
Mouse Alexa Fluor 555 Thermo Fisher Sc. A-21422 1:1000 IF
Mouse Alexa Fluor 647 Thermo Fisher Sc. A-21235 1:1000 IF
Rabbit HRP-conjugated Santa Cruz Biotech. sc-2004 1:1000 WB
Mouse HRP-conjugated Santa Cruz Biotech. sc-2005 1:1000 WB
#M4709) in PBS buffer). After blocking, cells were exposed overnight at 4°C to 50 µL
primary methylation antibody (SY46, 1:200 in ICW-blocking buffer). One row of cells on
each plate was not exposed to primary antibody and served as background control. The
wells were washed three times for 10 min with 100 µL PBS buffer before secondary IR800-
conjugated antibody (LI-COR, #92632211) and DNA-intercalating dye DRAQ5 (Thermo
Fisher Scientific, #62251) were incubated for 3 h at RT (both 1:1000 in ICW-blocking
buffer). After five washes with PBS, the fluorescence in each well was measured on an
Odyssey CLx scanner (LI-COR) at 800 nM (SY46 methylation signal) and 700 nM (DRAQ5
signal) according to the manufacturer’s instructions. Fluorescence intensity was quantified
and normalized to background (wells with no primary antibody) and DRAQ5 signals.
3.28 Confocal fluorescence microscopy
Cells were seeded and treated within 200 µL cell culture media in an 8-well Millicell EZ
chamber slide cell (Merck Millipore, #PEZGS0816) depending on the individual experi-
ment. At the experimental endpoint, the medium was completely aspirated without de-
taching the cells and cells were fixed at RT for 10 min in 100 µL fixation buffer (freshly
prepared by diluting 37% formaldehyde solution (Sigma Aldrich, #33220) 1:10 in 1x PBS
buffer). After two washes with PBS, cells were incubated at RT for 1 h in LSM-blocking
buffer (5% (v/v) goat-serum (Thermo Fisher Scientific, #16210064) and 0.5% Triton X-
100 (Sigma Aldrich, #93443) in Odyssey blocking buffer (LI-COR, #P/N 927-40000)).
After blocking, cells were exposed overnight at 4°C to primary antibodies diluted in LSM-
blocking buffer (for details on antibodies see Tab. 3.6). Isotype control IgGs were used
as negative controls. The wells were washed three times for 10 min with LSM blocking
buffer before Alexa Flour-conjugated secondary antibodies (for details see Tab. 3.5) were
incubated for 2 h at RT in LSM blocking buffer. After one wash, nuclei were stained for
10 min with DNA-intercalating dyes either DAPI (Thermo Fisher Scientific, #62251) or
Hoechst 33342 (Thermo Fisher Scientific, #62249) diluted at 1 µg/mL in PBS. If desired,
filamentous actin was stained with phalloidin A555 (Thermo Fisher Scientific, #A34055).
A stock solution of 200 U/mL in methanol was diluted 1:30 in PBS and cells were incubated
for 30 min at RT. After three additional washes for 5 min with PBS the well chamber was
removed from the glass slide and samples were sealed with self-hardening VECTASHIELD
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mounting medium (VECTRO Laboratories, #H-1400) and a coverslip according to the
manufacturer’s instructions. Images were acquired using an Zeiss LSM700 confocal mi-
croscope and a 63X, 1.3 N.A. oil-immersion objective according to the manufacturer’s
instructions.
Tab. 3.6: List of primary antibodies for IF/ICW
Target Host Company Cat.# Dilution
AHNAK (N-terminus) mMs Antikörper-online ABIN263928 1:200
c-myc tag mMs Santa Cruz Biotech. sc-40 1:500
IgG-isotyp control mouse pMs Santa Cruz Biotech. sc-2025 1:200
IgG-isotyp control rabbit pRb Santa Cruz Biotech. sc-2027 1:200
Kme1 (SY46) pRb - customized 1:200
SMYD2 mMs Santa Cruz Biotech. sc-393827 1:200
3.29 Transient gene knockdown by siRNA transfection
For transient gene knockdown in cell culture, cells were seeded one day before transfection
to reach a confluency on the day of transfection of around 80%. Transfection of siRNAs was
done with the Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific,
#13778-150) according to the manufacturer’s instructions. For the generation of the trans-
fection mix serum-reduced Opti-MEM medium (Thermo Fisher Scientific, #31985062) was
used. For a 6-well typically 75 pmol of individual siRNAs was transfected at a lipid/siRNA
ratio of 2:1. Cells were analyzed 3 days after transfection. For details on individual siRNAs
see Tab. 3.7.
Tab. 3.7: List of siRNAs
Target Species Company Cat.#
AHNAK Human Sigma Aldrich EHU058201
SMYD2 Human Sigma Aldrich EHU049591
Renilla Luciferase (neg. control) Renilla Sigma Aldrich EHURLUC
3.30 Plasmid transfection in mammalian cells
Cell were seeded one day before transfection to reach a confluency on the day of transfec-
tion of around 80%. Transfection of plasmids was achived with the Lipofectamine LTX
PLUS Reagent (Thermo Fisher Scientific, #15338-100) according to the manufacturer’s in-
structions. For the generation of the transfection mix serum-reduced Opti-MEM medium
(Thermo Fisher Scientific, #31985062) was used. For a 6-well typically 2 µg of plasmid
DNA was transfected at a lipid:DNA ratio of 3:1. For details on individual plasmids see
Tab. 3.2.
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3.31 Lentivirus production
All work was performed in an S2 laboratory. For lentivirus production 1.510 HEK293FT
cells (Thermo Fisher Scientific, #R70007) were seeded in a 75 cm2 cell culture flask (Corn-
ing, #3290) in DMEM high glucose medium (PAA, #E15-843) containing 10% FCS. The
day after, cells were transfected with 2.4 µg of lenti-vector and 7 µg of ViraPower Lentiviral
Packaging plasmid mix (Thermo Fisher Scientific, #K497500) using Lipofecatmine 2000
reagent (Thermo Fisher Scientific, #11668019) according to the manufacturer’s instruc-
tions. The medium was exchanged after 24 h and cells were incubated for further 24 h
This time, medium with virus particles was collected in a 50 mL reaction tube and stored
at 4°C. Cells were incubated with fresh media for additional 24 h. Medium from both days
was pooled and centrifuged for 10 min at 500x g at 4°C to remove cells. The virus particles
containing supernatant was sterile filtered (pore size 0.45 µm) and ultra-centrifuged at
50,000x g for 2.5 h The virus pellet was resuspended in 400 µL medium and aliquots of
100 µL were stored at -80°C until transduction. Virus titer was determined by HIV-1 P24
ELISA (Perkin Elmer, #NEK050) according to the manufacturer’s instructions. A list of
shRNA clones for lentivirus production is shown in Tab. 3.8.
Tab. 3.8: List of shRNA clones for lentivirus production
Name Target gene Developer TRC clone ID
sh#1 human SMYD2 Broad Institute TRCN0000276083
sh#2 human SMYD2 Broad Institute TRCN0000276082
sh#3 human SMYD2 Broad Institute TRCN0000276154
sh#4 human SMYD2 Broad Institute TRCN0000276085
sh#5 human SMYD2 Broad Institute TRCN0000276155
control - Broad Institute SHC201
3.32 Lentivirus transduction
Cells that were seeded in their appropriate cell culture medium in 12-well plates 24 h prior
transduction to reach a confluency of 80-90% at the day of transduction. For transduction,
the media was discarded and 250 µL fresh media containing pre-diluted lenti-viral particles
was applied to the cells. Normally, cells were transduced at a MOI of 10. For calculations
of MOI it was assumed that 1 in 10 particles is infective. For instance, 10 M viral particles
(determined by p24 ELISA) were used to transduce 100,000 cells. Cells were incubated
with the viral media for 6 h. The medium was then discarded and cells were trypsinized and
transferred to 25 cm2 cell culture flasks and incubated in fresh media for 2-3 days. After this
recovery period, positive transduced cells were selected for at least 10 days with appropriate
selection media. During the selection medium was further supplemented with 1x penicillin-
streptomycin (Thermo Fisher Scientific, #15140122) to prevent contamination.
3.33 Recombinant protein expression in E. coli of GST-tagged proteins
and purification
In order to produce sufficient amounts of recombinant proteins, the targets of interest were
cloned in an expression plasmid (for details on plasmids see Tab. 3.2) to generate an
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N-terminal GST-fusion protein using GATEWAY cloning as described in 3.12. Approxi-
mately 100 ng of expression plasmid was transformed into One Shot BL21(DE3) chemically
competent E. coli (Thermo Fisher Scientific, #C600003) as described in 3.13.
3.33.1 Small scale protein expression for optimization
Protein expression In order to identify well expressing clones and to determine opti-
mized culture conditions for upscale protein expression, several colonies were picked the day
after transformation, inoculated in a 2 mL LB-medium containing 200 µg/mL ampicillin
(Sigma-Aldrich, A5354) in a 14 mL Falcon tube (Corning, prod. #352059) and incubated
in a round shaker at 180 rpm, 37°C. After 5 h 50 µL of the pre-culture was transferred into
2 mL of freshly prepared 1x M9 medium in a 24-deep well plate (Qiagen, #19583), sealed
with breathseal foil (Greiner Bio-One, #676051) and incubated over night at 180 rpm,
37°C. An aliquot of the pre-culture was prepared as glycerol stock by 1:1 dilution in 100%
glycerol and stored at -80°C. The next day, protein expression was induced by adding
500 µL 5x circle growth medium (MP Biomedicals, #3000-146) incl. 200 µg/mL ampicillin
and IPTG (Sigma-Aldrich, #11284) to obtain a final concentration of either 0, 0.1, 0.5, or
1.0 mM IPTG. This results in occupation of four wells/plate for each clone. Plates were
prepared in duplicate and incubated for 20 h, 180 rpm and either 17°C or 27°C.
Cell disruption and sample preparation After 20 h of induction of protein expres-
sion, cells were harvested by centrifugation (Eppendorf, 5810R) within the 24-deep well
plates for 15 min, 17°C, 4000 rpm. Supernatants were discarded and dry cell pellets were
stored at -80°C until further processing. For cell lysis pellets were thawed on ice and resus-
pended in 500 µL lysis buffer (100 mM KPO, 300 mM NaCl, 10% (v/v) glycerol, 1x com-
plete protease inhibitor cocktail (Roche, prod. #11697498001), 5 mM DTT, pH 7.5). Cell
supspensions were then disrupted by sonication with a Covaris device (Covaris E210) ac-
cording to the manufacturer’s recommendations. After sonication lysates were diluted by
additional 500 µL of lysis buffer and completely transferred to a 2 mL 96 deep well plate
(Greiner Bio-One, ref. #786201). Cell debris was removed by centrifugation for 30 min,
4000 rpm, 4°C. Seven hundred fifty µL of supernatant was transferred to a 96-well turbo
filter plate (Qiagen, #120025), which was put on a 96 deep well plate and again centrifuged
for 2 min, 500x g, 4°C. The flow through was considered the soluble protein fraction.
GST-purification For GST-purification 100 µL of glutathione sepharose 4B (GE Health-
care, #17075601) was added to a 96-well receiver plate (Machery / Nagel, #89807) and
centrifuged for 2 min, 500x g, 4°C. Flowthrough was discarded and beads were equilibrated
by 500 µL washing buffer (identical to lysis buffer, w/o protease inh.) and centrifugation
twice. Beads were then incubated with 600 µL soluble lysate, plates were sealed and shaken
overhead for 30 min, 4°C. Plates were then centrifuged for 10 min, 100x g, 4°C. Beads were
washed twice with 500 µL washing buffer and centrifuged 2 min, 500x g, 4°C. Bead bound
proteins were recovered by overhead shaking for 30 min in 100 µL elution buffer (washing
buffer containing 15 mM freshly prepared glutathione (Sigma-Aldrich, #G4251) at 4°C
and centrifugation for 4 min, 100x g, 4°C. Final eluates were snap frozen in liquid nitrogen
and stored at -80°C until further downstream analyses.
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3.33.2 Midi scale protein expression for downstream analyses
protein expression For midi-scale protein expression the reagents and bacteria cultures
were scaled up from small-scale proportionally to reach a final culture volume of 400 mL.
Glycerol stocks of positive screened clones were used as starting material. Optimized IPTG
concentration and temperature were chosen based on small scale results.
Cell disruption and GST-purification Cell pellets were resuspended in 5 mL lysis
buffer and transferred to TC20 ultra centrifuge tubes (Biosciences, #520012). Cells were
disrupted by sonication as before and lysate volume was adjusted to 10 mL with lysis
buffer and ultracentrifuged for 45 min, 25,000x g, 4°C. The supernatant applied to 500 µL
equilibrated glutathione sepharose 4B beads.
GST-purification GST-purification was basically done as in small-scale. Five hun-
dred µL of glutathione sepharose 4B transferred to a poly-prep chromatography column
(Biorad, #7311550) was used per 400 mL cell culture. Equilibration was done with 2x
6 mL wash buffer and centrifugation for 3 min, 150x g, 4°C. For protein binding, the
supernatant after ultracentrifugation was incubated with equilibrated beads by overhead
shaking of 30 min at 4°C. Flowthrough was discarded and beads were washed twice with
6 mL washing buffer. GST-fusion proteins were eluted by overhead shaking for 30 min in
750 µL elution buffer for 30 min at 4°C following centrifugation for 5 min, 300x g, 4°C.
Elution step was repeated three times and eluates were pooled subsequently.
Removal of free glutathione Free glutathione in eluates was removed by size exclusion
chromatography using a zeba spin desalting column (Thermo Fisher Scientific, #89892).
The column was equilibrated with 2 mL washing buffer and centrifugation for 2 min,
1000x g, 4°C. The step was repeated four times before 2 mL of the eluate was applied and
centrifuged as before. The final flow through was recovered and aliquots were snap frozen
in liquid nitrogen and stored at -80°C.
3.34 Biochemical methylation assay for western blot analyses
In vitro methylation of recombinant proteins for western blot analyses was performed over
night at RT in methylation buffer (50 mM Tris/HCl pH 9.0, 1 mM DTT, 0.01% (w/v)
BSA, and 0.0022% (v/v) Pluronic) plus 1 µM freshly prepared S-adenosyl-L-methionine
(SAM) and 1 µg of recombinant SMYD2 enzyme as well as 1 µg of recombinant substrate
protein. Reactions were stopped by addition of sample buffer, denatured for 10 min at
95°C, subjected to SDS-PAGE and analyzed by Coomassie stain and western blot. Protein
methylation was detected by western blot using SY46 methylation specific antibody.
3.35 Biochemical SPA methylation assay using oligo-peptide substrates
and 3H-SAM
In vitro methyltransferase activity of SMYD2 towards oligopeptides was analyzed using a
scintillation proximity assay (SPA), which measured methylation by the enzyme of syn-
thetic, biotinylated peptides. For p53 a peptide derived from the C-terminal regulatory
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domain comprising the K370 target lysine (K*) was derived
(Biotin-Ahx-GSRAHSSHLK*SKKGQSTSRH-amide (Biosyntan)). For AHNAK, a pep-
tide was derived from CRU domains comprising the suspected LK*GPK* target motif
(PDVDLHLKGPKVKGD-Ahx-Biotin). A recombinant human SMYD2 full-length en-
zyme was kindly provided by Dr. Joerg Weiske and Dr. Amaury Ernesto Fernandez-
Montalvan32. Assays were conducted in 384-well microtiter plates in methylation buffer
(50 mM Tris/HCl pH 9.0, 1 mM DTT, 0.01% (w/v) BSA, and 0.0022% (v/v) Pluronic), and
a final volume of 5 µL. The SMYD2 concentration in the assay was 3 nM, while tritiated
S-adenosyl-L-methionine (3H-SAM, Perkin Elmer, #NET155H) and the peptide substrate
were present at 60 nM and 1 µM, respectively (apparent Km of both substrates). Enzyme
kinetics were followed over 2 h by quenching the reactions as described above at time points
0, 5, 10, 15, 30, 60, 90, and 120 min. Compounds were tested in 11-point, 3.5-fold dilution
series ranging from 0.1 nM to 20 µM. Reactions were run for 30 min and quenched by
adding Streptavidin PS SPA imaging beads (PerkinElmer) to a concentration of 3.12 µg/L
and 25 µM “cold” SAM (Sigma, #A-2408). The amount of product was evaluated using a
Viewlux (PerkinElmer) CCD plate imaging device [emission filter 613/55].
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4 Results
4.1 Establishment of a cellular mechanistic assay
4.1.1 SMYD2 shows frequent gene amplification
Apart from cancer indications with described relevance for SMYD2 like esophageal squa-
mous cell carcinoma (ESCC), I was interested if SMYD2 showed mutations or copy number
alterations (CNA) in other cancer indications. For that purpose, SMYD2 was queried at
the cBioPortal web service for cancer genomics (http://www.cbioportal.org/) using data
from 147 cancer studies. Using a cut-off of at least 2% of samples per study with SMYD2
alterations, 34 studies remained. Overall, the main alteration found for SMYD2 was gene
amplification, which may indicate a potential oncogenic activity in contrast to loss of func-
tion alterations, which rather indicate tumor suppressor activity. Interestingly, 6 out of 9
breast cancer studies showed amplification of SMYD2 above the cut-off. Especially a large
study of advanced breast cancer (METABRIC, Nature 201223) detected SMYD2 amplifi-
cation in nearly 25% of the samples, indicating potential significance of SMYD2 in that
indication (Fig. 4.7).
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Fig. 4.7: Analysis of SMYD2 alterations in cancer using data from 147 cancer studies avail-
able at cBioPortal (http://www.cbioportal.org). Out of 147 studies available comprising
different cancer indications 34 studies revealed SMYD2 gene alterations in at least 2% of the
samples. From all alterations, gene amplification of SMYD2 was dominant, suggesting a poten-
tial oncogenic activity. Amplification of SMYD2 was observed in several indications, especially
in invasive breast carcinoma (6 out of 9 breast cancer studies available >2% of samples).
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4.1.2 SMYD2 is expressed in different cancer cell lines
For the development of a mechanistic assay that is able to measure SMYD2 activity, cancer
cell lines with reasonable SMYD2 activity had to be identified. In the case of PKMTs in
general, so far the best predictor for methylation activity is protein abundance. Therefore,
several cell lines available inhouse were tested for SMYD2 expression by western blot, with
a focus on breast cancer cell lines due to above received results from cBioPortal (Fig. 4.7).
Specifically, analyzed cancer cell lines were derived from lung (A498, A549), cervix (HeLa),
esophagus (KYSE70, KYSE150), and breast (KPL-4, MDA-MB231, T47D, MCF-7, EFM-
19, ZR-75-1). SMYD2 protein was readily detected in HeLa and KYSE150 cells and in all
breast cancer cell lines tested Fig. 4.8. High expression of SMYD2 in KYSE150 was in
line with reported gene amplification in that cell line70. High expression of SMYD2 in all
breast cancer cell lines in addition to frequent gene amplification in samples of breast cancer
patients further pointed towards biological relevance of SMYD2 in that indication. For
further analyses I selected KYSE150, MDA-MB231, and HeLa cell lines, because of their
high expression of SMYD2 and their convenience in cell culture. Furthermore, the MDA-
MB231 breast cancer cell line was reported to be sensitive to SMYD2 knockdown91.
HSP90 
SMYD2 
50 kDa 
Fig. 4.8: SMYD2 is expressed in different cancer cell lines. Based on previous reports and data
from cBioPortal several cancer cell lines derived from lung (A498, A549), cervix (HeLa), esopha-
gus (KYSE70, KYSE150), and breast (KPL-4, MDA-MB231, T47D, MCF-7, EFM-19, ZR-75-1)
were tested for SMYD2 protein expression by western blot. For SDS-PAGE, 30 µg total protein
was loaded. Snap frozen cell pellets from all tested cell lines were kindly provided by colleagues.
4.1.3 SMYD2 does not influence global levels of histone methylation
SMYD2 was initially described to methylate histone H3 at lysine K3613 and at lysine
K41. Therefore, I wondered, if a knockdown of SMYD2 will lead to changes in global
histone methylation at lysine K4 and K36. For this purpose, MDA-MB231 breast cancer
cells, which showed strong expression of SMYD2 protein in previous experiments, were
transfected with a SMYD2 specific siRNA and histone methylation of H3K4me1, H3K4me3,
H3K36me1, H3K36me2 and H3K36me3 were tested by western blot (Fig. 4.9). However,
despite significant down-regulation of SMYD2, global methylation of tested histone marks
was not affected. Therefore, I concluded that histone methylation of H3 K4 and K36 was
not suitable for further assay development, at least under the tested conditions.
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Fig. 4.9: Histone methylation is unaffected by SMYD2 knockdown.
MDA-MB231 cells were transfected with control siRNA or SMYD2-specific siRNA and proteins
lysates were analyzed 3 days after transfection to evaluate SMYD2 knockdown and global histone
methylation.
4.1.4 SMYD2 depletion does not change global gene transcription
Several reports have indicated that SMYD2 is involved in the regulation of transcrip-
tion activity1;19;27;105. Identifying target genes whose transcriptional activity is regulated
by SMYD2 would allow to establish a mechanistic assay. Therefore, I established sta-
ble SMYD2 knockdown cells from the MDA-MB231 breast cancer cell line model. Five
different polyclonal cell lines were generated by lentiviral transduction of five indepen-
dent shRNAs targeting different regions within the open reading frame of SMYD2. After
lentivirus transduction, cells were kept in selection medium for ten days to generate sta-
ble polyclonal knockdown cell lines. Quantitative real time PCR data confirmed efficient
knockdown of SMYD2 on transcript level of all five cell lines ranging from 70% (sh#4) to
95% (sh#2) knockdown efficiency compared to empty vector control cells (Fig. 4.10A).
This translated also in strongly reduced protein levels of SMYD2 in the knockdown cell
lines (Fig. 4.10B). However, in contrast to a previous report91, proliferation of individ-
ual established knockdown cell lines was not significantly affected compared to the empty
vector control cell line (Fig. 4.11).
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Fig. 4.10: Transduction of lentivirus shRNAs effectively reduced SMYD2 RNA and protein
level.
MDA-MB231 cells were transduced with different lentiviral shRNA vectors against SMYD2 or
empty vector control virus and tested for SMYD2 knockdown by qRT-PCR (A) and western
blot (B) 10 days after puromycin selection.
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Fig. 4.11: Proliferation of MDA-MB231 cells after knockdown of SMYD2 is not affected.
Proliferation was measured in MDA-MB231 cells stably transduced with SMYD2 specific
shRNAs or empty vector control using Xcelligence device. After seeding 2000 cells/96-well
in quadroduplicate, cells were permanently grown for 6 days. Eight hours after cell seeding
proliferation signals were normalized to one for each individual well. Quantified data are repre-
sented as cell index, which is a combined measure of cell division, cell growth, and cell adhesion
to the culture dish and served as surrogate for cell proliferation.
The four most efficient knockdown cell lines (sh#1, 3, 4, 5) as well as the empty vector
control cell line were used to measure their global gene expression in an expression pro-
filing experiment. Statistical testing with a principal component analysis indicated that
individual replicates of the different cell lines clustered together, which confirmed high
consistency of the prepared samples. However, cell lines derived from individual shRNA
constructs did not separate in a consistent way from the control cell line indicating that
the overall changes in gene expression were dominated by off-target effects independent
from SMYD2 knockdown (Fig. 4.12A). As all shRNA constructs showed efficient knock-
down of SMYD2, potential target genes regulated by SMYD2 should be affected in all
knockdown cell lines. Therefore, gene expression in the different knockdown cell lines were
compared to empty vector control cells. Differentially expressed genes were defined as hav-
ing at least a two-fold change in gene expression with a false discovery rate of 10% (q BH
<0.1). Using these criteria, the cell line derived from shRNA1 (sh#1) revealed nine differ-
entially expressed genes. In contrast, the cell line derived from shRNA3 (sh#3) showed 152
differentially expressed genes, whereas cell lines derived from shRNA4 and 5 (sh#4 and
sh#5) revealed 18 and 56 differentially expressed genes, respectively. When comparing the
overlap of the different gene sets, SMYD2 was the only gene that was commonly regulated
by all shRNAs (Fig. 4.12B). This indicated that the observed effects of the individual
shRNAs on gene expression are most likely not connected to the SMYD2 knockdown and
are rather off-target effects of the individual shRNAs used. Based on these data I con-
cluded that SMYD2 is not a regulator of gene transcription in MDA-MB231 cells at least
under the tested conditions and the chosen significance criteria and that mechanistic assay
development based on changes in gene expression downstream of SMYD2 activity in not
feasible.
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Fig. 4.12: SMYD2 knockdown has no significant impact on transcriptional regulation
Stable MDA-MB231 SMYD2 knockdown cells were established by lentiviral transduction of
five independent shRNA constructs as well as an empty vector control cell line. RNA samples
of four replicates were prepared for a human Affymetrix GeneChip array. Data were analyzed
using GeneData Expressionist software. Principal component analysis was used to visualize
overall differences in gene expression (A). Venn diagram compares differentially expressed genes
relative to empty vector between of all five shRNA cell lines (B). Differentially expressed genes
were defined as ≥ 2-fold change in gene expression (FDR q-value (BH) < 0.1).
4.1.5 Generation of a p53 specific methylation antibody
In addition to histone methylation and regulation of gene expression, the tumor suppressor
p53 had been described as a target for mono-methylation by SMYD2 at lysine K37055.
To follow up on this report, rabbit polyclonal antibodies were raised against p53K370me1
and cross-purified by an external provider (Fig. 4.13, for details see 3.4). Aliquots from
different steps of the purification process were further tested by the external provider for
methylation specificity by ELISA in a ten-fold dilution series (Fig. 4.14). As expected,
eluate 1 showed an increase in reactivity towards the methylated p53 peptide compared to
serum, whereas flowthrough 1 (FT1) revealed no reactivity (Fig. 4.14A). Eluate 1 was
further purified against non-methylated peptides to reveal FT2 that was specific only for
methylated p53 (Fig. 4.13 column 2). This was demonstrated by ELISA, where FT2,
in contrast to eluate 2, detected methylated p53 peptide but not the non-methylated form
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(Fig. 4.14B,C). For subsequent experiments antibodies derived from FT2 were used and
are referred to as SY46 antibody (methylation specific antibody).
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Fig. 4.13: Schematic representation of purification of a p53-methylation specific antibody
In order to detect p53 methylation, a polyclonal rabbit antibody was raised against a methy-
lated p53 peptide. Serum from an immunized rabbit was purified via cross-affinity purification.
Antibody generation and purification was done by an external provider.
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Fig. 4.14: ELISA analyses of different fractions of antibody purification confirms methylation
specificity
Antibody fractions after cross-affinity purification were tested on ELISA for specificity towards
methylated p53 peptide. Input serum was compared against flowthrough 1 (FT1) and eluate 1
(A). FT2 was compared with eluate 2 (B). FT2 and eluate 2 were tested for reactivity towards
non-methyl-p53 peptid (C).
4.1.6 SY46 detects SMYD2 dependent methylation
To test, if SY46 can also detect methylation on full-length p53, recombinant p53 was
incubated in a biochemical methylation reaction either in the presence or absence of re-
combinant SMYD2 and analyzed by western blot using SY46 antibody. Only p53 protein
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incubated with SMYD2 was detected by SY46 (Fig. 4.15), suggesting methylation specific
detection of p53 by SY46.
total p53 
SY46 
recomb. p53 
recomb. SMYD2 
+ + 
- + 
Fig. 4.15: Methylation antibody SY46 detects SMYD2-dependent methylation on full-length
p53.
Recombinant full-length p53 was in vitro methylated by SMYD2 overnight and methylation
was detected on western blot by SY46 methylation antibody.
To evaluate if p53 methylation also occurs in cells and if this can be detected with SY46
antibody I used the KYSE150 cell line model that has been previously described to overex-
press SMYD2 due to gene amplification and also shows stabilized levels of p5370. Cells were
treated with AZ505, a described SMYD2 tool compound36, to evaluate, if p53 methylation
can also be modulated by SMYD2 inhibition. Indeed, on western blot SY46 detected a
protein band at the MW of p53 and the signal was reduced upon increasing concentrations
of AZ505 (Fig. 4.16). This indicated that SMYD2 methylates p53 in cells. However, de-
tection of endogenous p53 methylation was not strong enough for a quantitative medium
throughput assay.
total p53 
DMSO 2.5 10 
SY46 
AZ505 (µM) 
Fig. 4.16: SMYD2-dependent p53 methylation can be detected in cells.
KYSE-150 cells were treated with 2.5 or 10 µM of SMYD2 tool compound inhibitor AZ505 for
48 h and endogenous p53 methylation signal was analyzed on western blot with SY46 antibody.
Therefore, I intended to ectopically overexpress SMYD2 in order to increase the pool of
methylated p53 relative to the total pool of p53. Surprisingly, ectopic overexpression of
SMYD2 did not increase measurable p53 methylation, but revealed strong methylation
signals (detected by SY46) on western above the size of the 100 kDa protein marker (Fig.
4.17 asterisk). The signal appeared to be either a result of methylation of several sub-
strates or arising from degradation products of one large protein. The antibody SY46 also
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reacted with a protein band at the expected size of histone H3 but this signal was not in-
creased upon SMYD2 overexpression, indicating unspecific cross-reactivity of the antibody
towards histone methylation (Fig. 4.17 arrow).
SMYD2-WT Parental 
WB: Kme1 (SY46) 
HSP90 
SMYD2 
250 
150 
100 
75 
50 
37 
25 
20 
15 
10 
* 
Fig. 4.17: Ectopic SMYD2 overexpression leads to massive increase in substrate methylation.
KYSE150 cells were transfected with an SMYD2 overexpression plasmid and protein lysates
were analyzed 48 h after transfection by western blot. SY46 antibody was used to detect
methylated substrates. Numbers on the left indicate molecular weight of protein markers.
To check, if the strong signal detected by SY46 on western blot upon SMYD2 overexpres-
sion is specific and can be modulated by SMYD2 inhibition, KYSE150 cells transfected
with a SMYD2 expression plasmid were treated with 10 µM AZ505 for up to 3 days and
examined by western blot. The SY46 derived signal on western blot was decreased in sam-
ples of longer treatment (Fig. 4.18 asterisk). This indicated that SY46 in fact detects
SMYD2-dependent protein methylation. In contrast, cross-reactivity towards a histone
band was not affected by treatment (Fig. 4.18 arrow). In conclusion, SY46 detects pro-
tein methylation that is strongly induced upon ectopic SMYD2 overexpression and depends
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on SMYD2 enzymatic activity.
AZ505 
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WB: Kme1 (SY46) 
* 
Fig. 4.18: Substrate methylation upon ectopic SMYD2 overexpression can be prevented by
SMYD2 catalytic inhibition.
KYSE150 cells were transfected with SMYD2 overexpression plasmid and treated with 10 µM
AZ505 for up to three days. Methylation was analyzed on western blot by SY46 antibody.
Numbers on the left indicate molecular weight of protein markers.
To have additional assay options, I was wondering, if the strong methylation signal can also
be detected in fixed cells via immuno-fluorescence staining. Therefore, KYSE150 cells were
transfected with a SMYD2 expression plasmid, fixed 48 h after transfection and stained for
ectopic SMYD2 expression (c-myc tag) and substrate methylation (SY46 antibody). As
transfection efficiency was not 100%, SMYD2 positive and negative cells could be directly
compared. Interestingly, ectopic SMYD2 was mainly localized to the cytoplasm, which
probably could explain unaffected histone methylation in cells. Furthermore, SMYD2 pos-
itive cells also showed a strong cytoplasmic staining derived from SY46 antibody (Fig.
4.19 arrowheads), which tended to become enriched at the cell periphery in more con-
fluent cells (Fig. 4.19 center). SY46 also stained nuclei in all cells, which is in line with
the cross-reactivity of the antibody towards methylated histones. Interestingly, ectopic
SMYD2 and its methylation substrate(s) co-localized to the spindle fibers in mitotic cells
(Fig. 4.19 yellow arrow). This may point towards a role of SMYD2 during mitosis as a
cytoskeletal component. Taken together, signals from SMYD2 dependent protein methyla-
tion could be detected by SY46 antibody by western blot and via immuno-fluorescence.
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tivity. Subsequently, this assay was used to determine cellular IC50 for SMYD2 inhibition
of many chemical compounds (see Eggert et al.32). Among those, a compound similar to
compound 2, but with an additional chlorine atom at the phenol residue, revealed strong
cellular potency with an IC50 of 50 nM. Additional pharmacokinetic and pharmacody-
namic testing in mice confirmed in vivo suitability of that compound and was therefore
selected as preferred SMYD2 inhibitor probe referred to as BAY-598 (Fig. 4.21 and
Eggert et al.32).
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Fig. 4.20: SMYD2 substrate methylation can be quantified by In-Cell-Western detection.
KYSE150 cells were transfected with SMYD2 overexpression plasmid and treated with a di-
lution series of novel SMYD2 inhibitor candidates for 72 h. AZ505 was used as benchmark.
Substrate methylation was detected in an In-Cell-Western with SY46 antibody. DRAQ5 DNA
staining was used for normalization. Methylation signals were quantified to compare different
compounds.
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Structure Name 
SMYD2 
biochem. IC50 
(SPA) 
SMYD2 
cellular IC50 
(ICW) 
AZ505 800 nM 3 µM 
Compound 1 400 nM 450 nM 
Compound 2 8 µM 18 µM 
BAY-598 30 nM 60 nM 
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Fig. 4.21: Summary of different SMYD2 small molecule inhibitors.
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4.2 Discovery and validation of a novel SMYD2 substrate
Based on observations during the mechanistic assay development for SMYD2 it became
clear that this enzyme possesses so far unexplored substrates. The identification of such
substrates would probably allow for a deeper understanding of the biological function(s)
of SMYD2.
4.2.1 SMYD2 dependent methylation is specific and occurs in several cell line
models
To determine, if the observed methylation signal with SY46 antibody upon SMYD2 over-
expression was a unique feature of the esophageal cancer cell line KYSE150 or a more
general effect, additional cell lines derived from different tissues were tested. Therefore, I
established several syngeneic polyclonal cell lines by stable lentivirus transduction of MDA-
MB231 and HeLa. These cell lines ectopically overexpressed either wild type SMYD2
(SMYD2-WT) or SMYD2 mutated at amino acid residue 207 from histidine to alanine
(SMYD2-H207A). This residue sits within the SAM binding domain and is supposed to
render SMYD2 enzymatically inactive. In addition, cell lines were established, which over-
expressed the close homolog SMYD3 either as wild type (SMYD3-WT) or as mutant form
(SMYD3-N205A, similar to SMYD2 mutant). These two cell lines served as additional
controls for the specificity of SMYD2 methyltransferase activity compared to other methyl-
transferase activities. Furthermore, GFP overexpressing cells served as additional control.
Western blot analysis revealed successful overexpression of the corresponding proteins af-
ter two weeks of blasticidin selection (Fig. 4.22). The wild type proteins of the enzymes
appeared to be stronger expressed as the corresponding mutants, probably, because the
mutations were within the SAM binding pocket. This was supposed to prevent efficient
SAM binding, which might have compromised protein stability. Importantly, similar to the
KYSE150 cell line model, strong methylation signals were detected with the SY46 antibody
at high molecular weights in the SMYD2-WT overexpressing clones of MDA-MB231 and
HeLa (Fig. 4.22). No signals were detected in cell lines expressing the mutant SMYD2
protein, GFP, or the related SMYD3 enzymes. This demonstrated that the observed pro-
tein methylation is specific to SMYD2 enzyme activity and is not unique to the KYSE150
cell line and might have a functional role in different cell types.
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250 
SY46 
(Kme1) 
SMYD2 
SMYD3 
HSP90 
HeLa MDA-MB231 
Fig. 4.22: SMYD2-dependent methylation appears in different cell lines.
Syngeneic MDA-MB231 and HeLa cell clones stably overexpressing the indicated proteins were
analyzed by western blot. SY46 methylation is specific to SMYD2 and depends on SMYD2
enzymatic activity. An enzymatically dead point mutant H207A reveals no methylation signal.
GFP and SMYD3 constructs served as additional control.
4.2.2 Proteomic approach detects many novel lysine methylation sites in
SMYD2 overexpressing cells
The above results indicated that SY46 may be suitable to specifically capture methy-
lated SMYD2 substrates. Previous studies have shown that it is possible to discover novel
methylation sites on proteins from cell extracts in a more unbiased way by mass spectrom-
etry42. Therefore, I aimed at following a similar proteomic approach. In principle, cells are
lysed in denaturing urea buffer and proteins are proteolytically digested with trypsin into
smaller peptides. Methylated peptides are then immuno-precipitated with methyl-specific
antibodies and detected by LC-MS/MS. A schematic overview of the procedure is outlined
in Fig. 4.23. For immunoprecipitation SY46 antibody and a commercial pan-Kme1/2
specific antibody were used. For the analysis the MDA-MB231 cell line stably overexpress-
ing ectopic SMYD2-WT was chosen, because of the strong observed methylation signal(s).
Snap-frozen cell pellets and SY46 antibody were sent to an external company, which per-
formed sample preparations and MS analyses and a list of all detected methylated peptides
was returned.
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which were methylated by other enzymes.
#Kme1 sites 
pan 
Kme1 SY46 
70 118 577 
#Proteins 
pan 
Kme1 SY46 
48 73 430 
Hydrophilic: RKDENQ 
Neutral: SGHTAP 
Hydrophobic: YVMCLFIW 
p53_K370 
Overlap 
SY46 only 
pan Kme1 only 
A 
B 
Fig. 4.24: Proteome study reveals novel sites of lysine methylation.
Venn diagrams showing all mono-methylated peptides and corresponding proteins detected
either with SY46 antibody or a commercial pan-Kme1 antibody (A). Sequence motifs generated
from all detected peptides of the corresponding fraction with the methylated target lysine in
the center +/- three neighboring amino acids were compared (B). For comparison, the p53
sequence around lysine 370 is also shown. Different colors represent different hydrophobicity
properties of the amino acids according to the WebLogo3 classification22.
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4.2.3 Generation of a candidate list of SMYD2 substrates
Before generating a candidate list of novel SMYD2 substrates, I first checked, if the list of
methylated peptides contained already described SMYD2 target sites. Surprisingly, from
all so far reported substrates only HSP90 at lysine 607/615 (depending on the isoform) was
among the list (Fig. 4.25). This might be due to the abundancies of the individual sub-
strates in the MDA-MB231 cell line model. However, the fact that HSP90 methylation was
detected, indicated the feasibility of the approach for detecting SMYD2 methylation sites.
In order to narrow down the list of potential SMYD2 substrates, I decided to concentrate
only on proteins that had been detected by both antibodies, because K607/615 methy-
lation of HSP90 was also in that fraction and the sequence logo of the overlap revealed
the strongest enrichment for certain amino acids around the target lysine. In addition,
the detection of a methylated peptide in two independent measurements gave a higher
confidence that this methylation site can be reproducibly detected. Furthermore, I only
concentrated on proteins with a theoretical molecular weight higher than 150 kDa, because
of the SMYD2-dependent methylation signal observed on western blots (see previous sec-
tions). Using these selection criteria 11 proteins remained (Tab. 4.9). When comparing
the number of unique methylation sites corresponding to these proteins two proteins were
outstanding. Whereas most proteins contained one or two methylation sites, AHNAK and
AHNAK2 proteins contained 31 and 10 methylation sites, respectively, that were detected
by both antibodies. The high number of methylation sites could explain the strong methy-
lation signals observed on western blots. Therefore, I selected these two proteins as the
most promising candidates. However, in subsequent validation experiments I concentrated
only on AHNAK protein because AHNAK2 was barely described in the literature and
commercial antibodies were only available for AHNAK. In addition, microarray expression
data from MDA-MB231 cells suggested that AHNAK expression was much higher in this
cell line (Fig. 4.26).
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Fig. 4.26: AHNAK and AHNAK2 expression in MDA-MB231.
Comparison of AHNAK and AHNAK2 gene expression in MDA-MB231 from previous gene
expression study. The absolute fluorescence signals from microarray suggest much stronger
expression of AHNAK in the MDA-MB231 cell line. Error bars indicate standard deviation.
4.2.4 AHNAK is the main methylation substrate detected by SY46
To validate AHNAK as a potential substrate of SMYD2 methylation, I first checked if
the methylation signal derived from SY46 corresponded with the localization of AHNAK
protein. To this end, MDA-MB231 cells stably overexpressing SMYD2-WT were analyzed
by immuno-fluorescence microscopy and co-stained with SY46 (rabbit antibody) and AH-
NAK (mouse antibody). AHNAK and the SY46 derived methylation signal showed a clear
co-localization mainly in the cytosol Fig. 4.27. This indicated that the main methylation
signal might be derived from AHNAK protein.
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AHNAK Kme1 F-actin 
DAPI Merge 
Fig. 4.27: AHNAK co-localizes with SY46 methylation signal.
Immuno-fluorescence staining of stable SMYD2-WT overexpressing MDA-MB231 cells stained
for AHNAK, Kme1 (SY46), F-actin (phalloidin) and nuclei (DAPI). Scale bar indicates 20 µm.
To further pursue this question, MDA-MB231 cells overexpressing either SMYD2-WT
or the inactive mutant SMYD2-H207A were also analyzed by western blot and detected
with SY46 antibody for methylation and for AHNAK. AHNAK protein was detected in
both samples at similar levels at the top of the western blot. Strikingly, the methylation
signal detected by SY46 overlapped with AHNAK signal in the SMYD2-WT overexpressing
sample (Fig. 4.28A). This reinforced the above observation from immune-flourescence
stainings that co-localization of AHNAK and SY46 derived methylation might be due to
AHNAK methylation itself. To finally prove this hypothesis, siRNA mediated knockdown
of AHNAK not only diminished AHNAK protein level but also reduced the methylation
signal to the same extend (Fig. 4.28B). This clearly demonstrated that AHNAK is the
main methylation substrate in MDA-MB231 cells that was detected by SY46 antibody.
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Kme1 (SY46) 
AHNAK 
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GAPDH 
merge 
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SMYD2WT 
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Fig. 4.28: AHNAK is a novel substrate of SMYD2.
Western blot analysis of MDA-MB231 cells stably overexpressing either SMYD2-WT or an
enzymatically dead point-mutant SMYD2-H207A. The methylation signal derived from SY46
antibody perfectly overlaps with AHNAK signal (A) and upon AHNAK knockdown the methy-
lation signal decreased to the same extend as AHNAK protein level (B).
4.2.5 Immunoprecipitation of AHNAK enriches also for methylation
In order to check, if enrichment of AHNAK can also enrich for methylation and if SMYD2
and other proteins like HSP90 may form stable complexes with AHNAK dependent on the
methylation status, AHNAK protein was immunoprecipitated in MDA-MB231 cells stably
overexpressing SMYD2-WT after treatment for 3 days with 1 µM BAY-598 or DMSO (Fig.
4.29A). Eluates of AHNAK pulldown showed a clear enrichment of AHNAK protein inde-
pendent of the treatment. AHNAK methylation was also enriched in the untreated group,
but as expected was abolished by BAY-598 treatment. The similar amounts of AHNAK in
input and after enrichment for AHNAK in both treated and untreated samples suggested
that AHNAK protein stability is not affected by its methylation status. Similarly to AH-
NAK precipitation, precipitation with SY46 antibody enriched for the methylation signal
and for AHNAK in the untreated sample but not in the BAY-598 treated sample (Fig.
4.29B). In both experiments no co-purification of SMYD2 or HSP90 was observed in the
eluates, indicating only short interactions between SMYD2 and AHNAK during methy-
lation and either weak or no complex formation of AHNAK with HSP90. Interestingly,
pull-down with SY46 was also able to specifically capture p53 in the untreated group but
not HSP90. This is in contrast to the above proteome study, where methylated peptides
were detected from HSP90 but not from p53. An explanation could be that SY46 is not
able to capture methylated native full-length HSP90 in contrast to unstructured peptides.
The weak signal of p53 methylation after IP may be the reason why it was not detected
during the mass spectrometry measurement. It also indicated that only a small fraction
of the total p53 pool may actually be methylated even though SMYD2 was ectopically
overexpressed.
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Fig. 4.29: Methylated AHNAK can be immuno-precipitated.
Western blot analysis of stable SMYD2-WT overexpressing MDA-MB231 cells after immuno-
precipitation with the indicated antibodies. Cells were treated for 72 h with 1 µM BAY-598 or
DMSO.
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4.2.6 IC50 of BAY-598 based on AHNAK methylation
As cellular IC50 of BAY-598 was determined by the above mentioned in-cell-western assay
of engineered KYSE150 cells (see 3.27), I was wondering how well this assay correlated with
the methylation of AHNAK protein in MDA-MB231 cells. Therefore, MDA-MB213 cells
stably overexpressing SMYD2-WT were treated with increasing amounts of BAY-598 for
72 h. AHNAK methylation was determined on western blot (Fig. 4.30). Quantification
of the methylation signal relative to total AHNAK protein revealed a dose-response curve
with an IC50 of BAY-598 of around 50 nM. This is very similar to the cellular IC50
determined by ICW in KYSE150 cells and showed that the cellular IC50 for SMYD2
substrate methylation of BAY-598 is comparable between cell lines.
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Fig. 4.30: Cellular IC50 of BAY-598 for AHNAK methylation is similar to ICW assay.
IC50 determination of BAY-598 based on western blot analysis of AHNAK methylation (SY46).
Stable SMYD2-WT overexpressing MDA-MB231 cells were treated with a half-logarithmic
dilution series of BAY-598 for 72 h before analysis. For IC50 calculation methylation signals
were normalized to AHNAK.
4.2.7 Domain structure of AHNAK and mapping of methylation sites
Human AHNAK protein has been described as a giant scaffold protein of around 623 kDa .
The protein was described to be comprised mainly of three parts. First, the N-terminal
domain of 498 amino acids, which contains a PDZ domain known as a protein-protein
interaction domain. Second, it has a middle part, which consists of ˜38 repeating units
referred to as central repeated units (CRUs). These are either ˜128 aa (long) or ˜68 aa
(short) in length and are very similar to each other in their amino acid sequence. Finally,
there is a 1002 aa long C-terminal, which may contain nuclear localization signals. To figure
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out which regions of AHNAK might be methylated by SMYD2, all detected methylation
sites of AHNAK from the above proteome study were mapped to the full-length protein
sequence. This revealed a tendency of preferred lysine residues within the CRUs and parts
of the C-terminus (Fig. 4.31. A sequence motif derived from all methylated peptides of
AHNAK showed a clear enrichment for a [LF]KGPK motif (Fig. 4.32), where mainly the
first but also the second lysine residue were found to be methylated. This suggested that
this motif is a preferred recognition motif for SMYD2 methylation activity.
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Fig. 4.31: AHNAK domain structure and detected methylation sites.
Top: AHNAK domain structure is illustrated with red dashes indicating methylated lysines
detected by mass spectrometry in MDA-MB231 cells ectopically overexpressing SMYD2. The
central repeated units (CRUs) have been numbered from 1-38. P means pseudo-repeat (less
conserved compared to others), which is less well conserved. PDZ is a protein-protein inter-
action domain. Recombinant CRUs that have been used for in vitro methylation assays are
aligned to the corresponding regions. Bottom: Sequence alignment of the CRUs with short
CRUs on top and regular CRUs at bottom. Sequence alignment was adjusted from Kingsley et
al.67. All lysine residues are marked in yellow. All methylated lysines detected in the proteom
study are marked in red.
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Fig. 4.32: AHNAK methylation sites reveal enriched sequence motif.
A sequence motif derived from all methylated sites detected on AHNAK protein shows enriched
amino acids surrounding the target lysine.
4.2.8 Biochemical SPA methylation assay of SMYD2 using peptides derived
from AHNAK
To check, if SMYD2 can directly methylated peptides that contain the enriched motif,
an SPA assay, as previously established for p53-peptide to screen for SMYD2 inhibitors,
was used. A synthetic peptide derived from AHNAK and containing a lysine, which was
detected to be methylated in the proteomics study and containing the LKGPK motif, was
synthesized. As control, a p53-peptide was also tested. Unexpectedly, AHNAK peptide
completely failed to get methylated in contrast to p53 peptide, which showed increasing
methylation over time Fig. 4.33. This suggested that either SMYD2 is not able to di-
rectly methylate AHNAK peptides without additional cellular components or that peptides
were not able to recapitulate structural properties of AHNAK polypeptide, which may be
required for the methylation reaction.
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Fig. 4.33: SMYD2 is not able to methylate AHNAK peptides.
The ability of SMYD2 to methylate peptides derived from AHNAK or p53 was tested in
a biochemical SPA assay as described in 3.35. Reactions were quenched at indicated time
intervals and photon emission was quantified. Peptides derived from AHNAK revealed no
signal, whereas p53 peptides were clearly methylated over time.
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4.2.9 Design of recombinant AHNAK-CRU fragments for biochemical
methylation assays of structured substrate polypeptides
To further investigate, if structured AHNAK polypeptides may serve as a better substrate
for SMYD2 in vitro, ideally full-length recombinant AHNAK protein might have been pu-
rified and tested in a biochemical methylation assay. However, the large size of this protein
made it unsuitable to express the full-length protein by conventional cloning. Therefore,
only smaller parts of this protein were cloned into E. coli expression vectors and expressed
as GST-fusion proteins. Former reports from literature indicated that it might be possible
to express only subunits of the protein and this seemed indeed to be the standard proce-
dure for AHNAK. Therefore, I designed three different constructs that represented different
regions of the middle CRU part. All fusion constructs, when aligned to the full-length pro-
tein, contained methylation sites that had been detected in the proteome study. These
constructs were named 1CRU, 3sCRU (s for short), and 3lCRU (l for long), respectively
based on the size and the number of repeating elements (Fig. 4.31).
4.2.10 Optimization of AHNAK-CRU expression in E. coli
To obtain sufficient amounts of recombinant GST-fused AHNAK-CRU protein, different
expression conditions in E. coli were first tested at small scale. Protein expression was
comparable at different conditions but revealed best yields at 0.5 mM IPTG induction and
17°C expression temperature for all three constructs (Fig. 4.34). Therefore, this condition
was chosen for further protein expression.
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Fig. 4.34: Small scale purification of AHNAK-CRUs for optimization of expression condi-
tions.
Different AHNAK-CRU constructs were transformed in E. coli for recombinant protein ex-
pression and cultured under different temperature and IPTG concentrations to reveal optimal
expression conditions. All samples were purified via their GST-tags and final eluates were
analyzed on a Coomassie-gel. The apparent molecular weight of the prominent protein bands
are very similar to the theoretical MWs of 44 kDa, 51 kDa, and 71 kDa for 1CRU, 3sCRU, and
3lCRU, respectively. Numbers on the right indicate molecular weight of the protein markers.
4.2.11 Midi-scale purification of AHNAK-CRUs
For larger amounts of recombinant protein, protein expression was up-scaled to 400 mL
E. coli cultures and incubated under optimized conditions. Protein purification was per-
formed via GST-affinity purification (for details see 3.33). Final eluates revealed clean
protein bands corresponding to the calculated MWs of 44 kDa, 51 kDa, and 71 kDa for
1CRU, 3sCRU and 3lCRU, respectively (Fig. 4.35).
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Fig. 4.35: Midi scale purification of AHNAK-CRUs show clear enrichment in the eluate.
Different AHNAK-CRU constructs were transformed in E. coli for recombinant protein expres-
sion and cultured for 16 h at 17°C, 0.5 mM IPTG. Crude cell lysates were used for the GST
purification as described in materials and methods section. Aliquots of each purification step
were taken for SDS-PAGE and Coomassie stain. All samples were purified via their GST-tags
and final eluates were analyzed on a Coomassie-gel. M – marker, CE – crude extract, S –
soluble fraction, FT – flowthrough, W – wash step, E – eluate. Numbers on the left indicate
molecular weight of the protein markers.
4.2.12 In vitro methylation of AHNAK-CRUs
To determine, if AHNAK-CRUs can be directly methylated by SMYD2, recombinant GST-
fused AHNAK-CRUs (1CRU, 3sCRU, 3lCRU) were incubated +/- SMYD2 enzyme in
methylation buffer overnight. Aliquots of the reactions were subjected to SDS-PAGE and
analyzed by Coomassie staining and western blot using SY46 methylation specific antibody
(Fig. 4.36). In fact, SY46 antibody detected clear methylation signals in the samples that
contained both AHNAK-CRU substrate and SMYD2 enzyme. In the absence of substrate,
weak auto-methylation was observed on SMYD2. These data demonstrate that SMYD2
– 61 –
PhD Thesis Results
can directly methylate AHNAK fragments in vitro and that probably more structured
AHNAK derived polypeptides are required for efficient methylation. AHNAK-CRUs after
in vitro methylation were also cut off from Coomassie gels and analyzed by LC-MS/MS
inhouse to detect individual methylation sites. Indeed, several peptides were identified
containing a methylated lysines within the LKGPK motif. A representative fragment
spectra is shown in Fig. 4.37.
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Fig. 4.36: SMYD2 in vitro methylates AHNAK-CRUs.
Coomassie stain (above) and western blot (below) analysis of a biochemical SMYD2 methyla-
tion assay using recombinant AHNAK-CRU constructs. The reaction was incubated in methy-
lation buffer overnight at room temperature. Methylation was detected with SY46 antibody.
SMYD2 enzyme is marked by asteriks. Hashtag indicate automethylation of SMYD2. Red
frames indicate AHNAK-CRU constructs. Numbers on the left indicate molecular weight of
the protein markers.
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Fig. 4.37: SMYD2 in vitro methylates AHNAK-CRUs at LKGPK motifs.
Exemplary MS/MS spectrum of peptide from AHNAK-3sCRU after in vitro methylation with
SMYD2. Monomethylation was detected at lysine within the LKGPK motif. For detection,
protein bands from the gel shown in Fig. 4.36 were cut off and processed for mass spectrometry
analysis. Additional fragment spectra are shown in the supplement.
4.2.13 AHNAK methylation occurs in vivo
After demonstrating AHNAK methylation in vitro and in cell lines, I was curious, if AH-
NAK methylation occurs also in vivo. To test this hypothesis, protein lysates from several
mice organs were subjected to immunoprecipitation by SY46 antibody and eluates were
analyzed on western blot with AHNAK antibody. Indeed, AHNAK methylation was de-
tected in skeletal muscle tissue and to a weaker extend in cardiac muscle (Fig. 4.38A).
This correlated very well with the abundance of SMYD2 protein, which was highest in
skeletal muscle followed by heart tissue (Fig. 4.38B). This observation is consistent with
previous reports showing that SMYD2 is highly expressed in these tissues13. These data
demonstrate that AHNAK methylation occurs in vivo and may possess a relevant physi-
ological function. The observation that AHNAK methylation was detected in human cell
lines and in mice also suggests a conserved function for this posttranslational modification
in different mammalian species.
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Fig. 4.38: AHNAK is methylated in vivo.
Protein lysates from different mice organs were analyzed for AHNAK methylation and SMYD2
expression. AHNAK methylation was detected by immunoprecipitation with SY46 antibody
and detection on western blot with AHNAK antibody.
– 64 –
PhD Thesis Results
4.3 Functional characterization of SMYD2 inhibition with the inhibitor
BAY-598
After having discovered a novel substrate for SMYD2, and having a potent small molecule
probe in hand to specifically inhibit SMYD2 methyltransferase activity, I was interested
to test the biological relevance of SMYD2 in selected cellular model systems.
4.3.1 Differentiation of C2C12 myoblasts is not affected by SMYD2
inhibition
Based on my previous findings, which showed that AHNAK methylation occurs in skeletal
muscle and that SMYD2 expression is highest in this tissue, I intended to gain a deeper
understanding of SMYD2 and AHNAK methylation in muscle biology. For that purpose,
I chose the murine myoblast cell line C2C12. Murine C2C12 cells represent an easy to
culture cell line model to study muscle cell differentiation and regeneration. The cell line
was first established in 1977 by D. Yaffe and O. Saxel to study the functions of homoge-
nous populations of myoblasts138. Under subconfluent culture conditions and high levels
of fetal calf serum (FCS) these cells will continue to divide as undifferentiated myoblasts.
A general differentiation protocol has been established by which cells are grown to con-
fluence and FCS-rich media is changed to serum-low media. This induces fusion of the
mycoblasts into myotube like structures – a phenomenon resembeling normal muscle de-
velopment/regeneration. This process takes several days and involves massive changes in
gene expression and phenotype115. Therefore, I tested, how SMYD2 might be expresed
during that process, and if inhibition of SMYD2 activity by the selective small molecule in-
hibitor BAY-598 would have an effect during the differentiation process. C2C12 myoblasts
were cultured in growth medium (high serum) for three days in the presence of either 1 µM
of BAY-598 or DMSO to allow for a sufficient de-methylation phase before starting the
actual experiment (start of experiment at day -2, start of differentiation at day 0). Upon
differentiation, the treatment groups were kept permanently under BAY-598 (1 µM) and
DMSO treatment, respectively. The differentiation process was monitored for 8 days using
a light microscope (Fig. 4.39) after which myotubes showed spontaneous contractions
and started to peel off the cell culture surface (data not shown). During the differen-
tiation process, fusion of individual myoblasts and the progressive increase in myotubes
was readily observed. Treatment with BAY-598 did not affect overall cell morphology or
myotube formation (Fig. 4.39, compare DMSO vs BAY-598). Therefore, I reasoned that
inhibition of SMYD2 methylation does not disturb vital functions of C2C12 cells during
differentiation.
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Fig. 4.39: C2C12 differentiation into myotubes is not affected by BAY-598.
C2C12 myoblasts were treated with 1 µM BAY-598 three days prior to initiation of the exper-
iment (experimental start at -2d) to allow a comparison of C2C12 cells harboring completely
de-methylated SMYD2 substrates with C2C12 cells of normal SMYD2 substrate methylation
state. Cells were kept permanently under BAY-598 treatment to assess the effect of SMYD2
inhibition at all phases of differentiation. Cells were grown in 10 cm dishes and micrographs
were taken at different time points as indicated. Scale bar indicates 500 µM.
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To characterize gene expression changes of individual genes after SMYD2 inhibition, RNA
samples were taken at different time points of C2C12 differentiation and analyzed by qRT-
PCR. The expression values of a single gene at different time-points of DMSO and BAY-598
teatment were all normalized to the expression value of that gene from DMSO treatment at
time point zero (for details see 3.17). This allowed for the visualization of changes in gene
expression over time and between treatment groups. As differentiation processes in general
lead to massive changes in global gene expression patterns, relative gene expression data
were not calculated with the conventional ∆∆Ct-method, because this method requires
inert "house-keeping" genes that are unaffected in its expression rate by the experimental
conditions. However, genes like ACTB (encoding for beta-actin), GAPDH (metabolic
enzyme), RPL41 (encoding for the 60S ribosomal protein L41) or RPS24 (encoding for
the 40S ribosomal protein S24), which are generally considered as house-keepers, showed
relatively strong changes in gene expression and were therefore unsuitable as reference
genes for the ∆∆Ct method (Fig. 4.40).
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Fig. 4.40: Evaluation of house-keeping genes during C2C12 differentiation.
C2C12 myoblasts were treated with 1 µM BAY-598 three days prior to initiation of the exper-
iment (experimental start at -2d) to allow a comparison of C2C12 cells harboring completely
de-methylated SMYD2 substrates with C2C12 cells of normal methylation state. Cells were
kept permanently under BAY-598 treatment to assess the effect of SMYD2 inhibition at all
phases of differentiation. Cells were grown in 10 cm dishes and RNA samples were prepared for
qRT-PCR analyzes. Gene expression data are presented as log2-fold changes relative to time
point zero of DMSO treatment.
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Therefore, I decided to deploy the ∆’Ct method83, which normalizes the Ct values to
the total input of RNA/cDNA template. This method seemed appropriate as it showed
expected changes in gene expression of several biomarker genes of muscle differentiation.
For instance, genes like DMD (encodes for dystrophin, a vital component of the cytoskele-
ton in muscle fibers;40), MEF2C (a known transcription factor of the MEF2-family in-
volved differentiation and myogenesis34), and MYOG (a vertebrate specific transcription
factor known for its role in muscle differentiation and regeneration102) served as positive
biomarkers of myotube differentiation and showed a striking induction upon initiation of
differentiation of ˜8-fold (MEF2C) and up to ˜1000-fold (DMD, MYOG) (Fig. 4.41). In
contrast, the transcription factor MYOD was not significantly regulated upon induction
and showed even a slight down-regulation (Fig. 4.41). This might be explained by the
fact, that MYOD is one of the earliest markers of myogenic commitment and only silent in
quiescent satellite cells but not in proliferating myoblasts102. In all cases, treatment with
BAY-598 had no significant influence on these biomarkers, which is in agreement with the
undisturbed morphological changes observed above on micrographs (Fig. 4.39).
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Fig. 4.41: C2C12 biomarker genes indicated proper myotube differentiation.
C2C12 myoblasts were treated with 1 µM BAY-598 three days prior to initiation of the ex-
periment (experiment start at -2d) to allow a comparison of C2C12 cells harboring completely
demethylated SMYD2 substrates with C2C12 cells of normal methylation state. Cells were
kept permanently under BAY-598 treatment to assess the effect of SMYD2 inhibition at all
phases of differentiation. Cells were grown in 10 cm dishes and RNA samples were prepared for
qRT-PCR analyzes. Gene expression data are presented as log2-fold changes relative to time
point zero of DMSO treatment. n.d. = not detected.
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In order to evaluate, if other SMYD-family members may compensate for SMYD2 inhi-
bition, I compared the expression of all SMYD family members during the differentiation
process. Interestingly, different patterns of regulation were observed between SMYD genes
(Fig. 4.42). SMYD2, SMYD4, and SMYD5 were expressed at constant levels during
the myoblast phase (-2d – 0d), but started to continuously decrease in their expression
during the differentiation process, which reached a maximum of down-regulation of about
4-8 fold after 6 days of differentiation compared to day zero. The pattern of gene expres-
sion changes among these three genes may indicate a common transcriptional regulation
and a higher relevance of these genes in undifferentiated myoblasts. SMYD3 expression
was more fluctuating and did not show a clear positive or negative correlation with the
differentiation status. In contrast, SMYD1 behaved in the opposite direction compared
to SMYD2, SMYD4, and SMYD5 and showed a strong up-regulation after induction of
differentiation, which reached a plateau of around 64-fold increase in transcript level af-
ter four days of differentiation compared to day zero. This is in alignment to reports,
showing that SMYD1 is highly expressed in striated muscle tissue and is important for
myofilament organization41;90. In any case, treatment with BAY-598 did not show a sig-
nificant impact on transcript levels of either SMYD2 nor the other SMYD-family members,
suggesting that SMYD2 inhibition is not compensated by transcriptional up-regulation of
other family members.
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Fig. 4.42: Other SMYD-family members seem not to compensate for SMYD2 inhibition.
C2C12 myoblasts were treated with 1 µM BAY-598 three days prior to initiation of the exper-
iment (experimental start at -2d) to allow a comparison of C2C12 cells harboring completely
de-methylated SMYD2 substrates with C2C12 cells of normal methylation state. Cells were
kept permanently under BAY-598 treatment to assess the effect of SMYD2 inhibition at all
phases of differentiation. Cells were grown in 10 cm dishes and RNA samples were prepared for
qRT-PCR analyzes. Gene expression data are presented as log2-fold changes relative to time
point zero of DMSO treatment.
Finally, I was interested in the gene regulation of the validated SMYD2 substrate AHNAK
and its paralog AHNAK2, which, due to its conservation of the lysine target sites, also rep-
resents a likely SMYD2 substrate. Interestingly, both genes were reversely regulated (Fig.
4.43). AHNAK expression was induced over ten-fold during differentiation compared to
the undifferentiated myoblast state (days -2 and -1) whereas AHNAK2 expression was de-
creased up to around ten-fold during differentiation. Of note, absolute Ct values suggested,
that both genes were expressed at similar degrees (median Ct of AHNAK changed from
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26.4 at -2d to 23.2 at 8d, whereas median Ct from AHNAK2 changed from 23.4 at -2d
to 26.4 at 8d). Comparing this pattern to the SMYD2 expression pattern would suggest
that in this model system probably AHNAK2 is more likely to be a relevant substrate
for SMYD2. However, SMYD2 inhibition by BAY-598 treatment also revealed no changes
in gene expression of its potential substrates AHNAK and AHNAK2. Taken together,
these data indicate that SMYD2 inhibition does not induce a feedback loop, which would
change the transcriptional activity of itself, its family members, or its substrates AHNAK
and AHNAK2, et least under the tested conditions.
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Fig. 4.43: Gene expression patterns suggest Ahnak2 as dominant substrate SMYD2 in
C2C12.
C2C12 myoblasts were treated with 1 µM BAY-598 three days prior to initiation of the exper-
iment (experimental start at -2d) to allow a comparison of C2C12 cells harboring completely
de-methylated SMYD2 substrates with C2C12 cells of normal methylation state. Cells were
kept permanently under BAY-598 treatment to assess the effect of SMYD2 inhibition at all
phases of differentiation. Cells were grown in 10 cm dishes and RNA samples were prepared for
qRT-PCR analyzes. Gene expression data are presented as log2-fold changes relative to time
point zero of DMSO treatment.
To check, if SMYD2 inhibition may have an impact on the above mentioned genes at the
protein level, I performed western blot analyzes of the corresponding protein samples (Fig.
4.44). In general, western blot data revealed good correlations between transcript levels
and protein levels for SMYD1, SMYD2, and SMYD3. However, after two days of differen-
tiation initiation, stabilization of SMYD2 protein was observed in the BAY-598 treatment
group compared to DMSO treatment. This may indicate a compensatory regulation of
SMYD2 activity to rescue the substrate demethylation. However, it is also possible that
binding of the compound itself to the enzymatic pocket led to a stabilization of the protein,
a phenomenon, which has also been observed from other inhibitors.
SMYD5 antibody signal slightly increased during differentiation contrary to RNA tran-
script levels, which decreased. This may indicate additional levels of regulation beyond
transcriptional level. Furthermore, the half-life of SMYD5 potentially might be very long,
so that even after decreasing transcript levels the protein accumulates. For SMYD4 no
antibody was available. At protein level myogenin and myosin heavy chain (MYHC) served
as biomarker controls for differentiated myotubes and showed a clear induction after 1 day
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and 4 days of differentiation, respectively. Similar to transcript results, MYOD protein
level was present at similar amount at all stages of differentiation.
Unfortunately, I was not able to detect AHNAK protein levels in a consistent way for all
samples, as the protein tended to enrich in the non-dissolved cell debris of the protein
lysates with increasing differentiation and the attempt to dissolve cell debris resulted in
unequal degradation of the protein between samples, which made it unfeasible to compare
protein levels of different samples (data not shown). Therefore, also AHNAK methylation
could not be adequately determined. As a summary of this differentiation experiment I
concluded that SMYD2 expression is higher in more undifferentiated myoblasts and ac-
cording to transcript levels that AHNAK2 may present a more likely substrate in this
system. However, SMYD2 inhibition did not seem to influence myotube differentiation.
This finding supports an earlier study, where SMYD2 knockout mice showed no develop-
mental defect and were undiscernible from its wildtype littermates at least under normal
conditions103.
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Fig. 4.44: SMYD2 protein expression decreases in differentiating C2C12.
C2C12 myoblasts were treated with 1 µM BAY-598 three days prior to initiation of the exper-
iment (experimental start at -2d) to allow a comparison of C2C12 cells harboring completely
de-methylated SMYD2 substrates with C2C12 cells of normal methylation state. Cells were
kept permanently under BAY-598 treatment to assess the effect of SMYD2 inhibition at all
phases of differentiation. Cells were grown in 10 cm dishes and protein samples were analyzed
by western blot.
4.3.2 SMYD2 activity does not impact H-RAS transformation of NIH3T3
cells
In a recent report Reynoird and colleagues presented results showing that adenocarcinoma
formation in the pancreas induced by oncogenic RAS transformation led to a strong upreg-
ulation of SMYD2 protein expression, which is normally not detectable in healthy pancreas.
Furthermore, RAS transformation was significantly compromised by conditional knockout
of SMYD2 in the pancreatic cells103. They further provided mechanistic evidence that
SMYD2 methylates a MAP kinase involved in the RAS-ERK1/2 pathway and thereby
promoting ERK1/2 phosphorylation and oncogenesis.
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Based on this study, I was curious to test whether the observed effects can be recapitu-
lated in a simple NIH3T3 cell line model. NIH3T3 mouse fibroblasts have been a useful
system to study the transformation potential of many known oncogenes, including all RAS
variants.
SMYD2 compound inhibition during focus formation I employed a classical NIH3T3
focus formation assay by introducing oncogenic H-Ras-G12V99 via retrovirus transduction
(mutation from glycine to valine at amino acid residue 12 keeps RAS permanently activated
by preventing GTP hydrolysis to GDP, which normally reverts RAS activation). Trans-
duced cells were permanently treated with DMSO as control, 1 µM of the SMYD2 inhibitor
BAY-598 or 100 nM of Refametinib (biochemical IC50 for MEK1 = 19 nM, for MEK2 = 47
nM), a dual MEK1/2 inhibitor, which is able to block the RAS/RAF/MEK/ERK pathway
of oncogenic RAS signaling110. Transduced cells were also compared to the non-transduced
untreated parental cells. The focus formation assay was evaluated ten days after trans-
duction. Acidification of the cell culture media and changes in cell morphology clearly
indicated effects of oncogenic Ras activity in all transduced cells compared to the parental
cells (Fig. 4.45, light microscope). Parental cells showed dense monolayers, whereas Ras
transduced cells were radial shaped with intercellular space between adjacent cells and
appeared to be more shiny under a phase contrast light microscope. However, whereas the
MEK1/2 inhibitor Refametinib was able to prevent focus formation, clear focus formation
was observed in both DMSO and BAY-598 treated cells. This suggested that SMYD2
enzymatic inhibition was not able to prevent focus formation.
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Fig. 4.45: BAY-598 does not prevent focus formation in oncogenic RAS transduced NIH3T3
cells.
NIH3T3 mouse fibroblasts were seeded in triplicates in 6-well plates and transduced with
retrovirus encoding an oncogenic H-RAS (G12V) variant. Cells were cultured either in the
presents of DMSO control, 1 µMBAY-598 or 100 nM of the dual MEK1/2 inhibitor Refametinib
for up to ten days. Foci were visualized either by light microscopy (left) or methylene blue
staining. Scale bar indicates 500 µM.
Genetic SMYD2 knockout during focus formation As effects from enzymatic in-
hibition using small molecule inhibitors can significantly differ from genetic ablation of
the whole protein especially when active in protein complexes, I established NIH3T3-
CrispR/Cas9 SMYD2 knockout (SMYD2-KO) cells. Immuno-fluorescence analyzes re-
vealed a successful knockout and a solely cytosolic localization of endogenous SMYD2 in
the parental cells (Fig. 4.46).
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Fig. 4.46: SMYD2 localizes solely to the cytoplasm in NIH3T3 fibroblasts
NIH3T3 mouse fibroblasts either parental or a CrispR/Cas9 SMYD2 gene knockout were an-
alyzed by immuno-fluorescence for SMYD2 localization. DAPI was used to stain nuclei and
F-actin was visualized by Alexaflour 555-phalloidin. Scale bar indicates 50 µm.
Having this SMYD2-KO cell line generated, a focus formation assay in combination with
RAS-G12V transformation as above was repeated. SMYD2-KO cells were also comple-
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mented with ectopic SMYD2-WT or GFP as a control. However, RAS transformation
revealed focus formation and morphological changes to the same extent in parental cells
versus SMYD2-KO cells. In addition, ectopic SMYD2 overexpression did not increase
focus formation nor was it able to induce focus formation after 20 days by itself, when
transduced without RAS-G12V.
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Fig. 4.47: SMYD2 is not an oncogenic enhancer of RAS-G12V transformation in NIH3T3
fibroblasts
NIH3T3 mouse fibroblasts with endogenous levels of SMYD2 or a CrispR/Cas9 SMYD2-KO cell
line or SMYD2-KO cells complemented with ectopic SMYD2-WT or GFP were seeded in trip-
licates in 6-well plates and transduced with retrovirus encoding an oncogenic H-RAS (G12V)
variant. Foci were visualized either by light microscopy (left) or methylene blue staining ten
days (RAS-transformed) or 20 days (non-RAS transformed) after initiation of the experiment.
Scale bar indicates 500 µm.
4.3.3 ERK1/2 phosphorylation is not affected by SMYD2
To also evaluate, if RAS transformation leads to upregulation of SMYD2 expression as
reported by Reynoird et al., and if SMYD2 knockout compromises ERK1/2 phosphoryla-
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tion, I evaluated protein samples of the above mentioned NIH3T3 cell lines. Indeed, RAS
transformation led to an increase in ERK1/2 phosphorylation compared to parental non-
transformed cells, but SMYD2 knockout had no influence in the degree of phosphorylation
neither in the RAS transformed cells nor in the non-transformed cells (Fig. 4.48A). Fur-
thermore, RAS transformed cells showed no upregulation of SMYD2 compared to parental
cells. However, immunoprecipitation using SY46 methylation specific antibody revealed
endogenous AHNAK methylation in NIH3T3, which was absent in SMYD2-KO cells (Fig.
4.48A). In addition, when complementing SMYD2-KO cells either in the background of
RAS transformation or in non-transformed cells, SY46 methylation at the size of AHNAK
protein was readily observed in whole cell lysates. However, ERK1/2 phosphorylation was
not changed upon ectopic SMYD2 overexpression (Fig. 4.48B). These data indicated
that, in contrast to the pancreatic cancer in vivo model from Reynoids et al., SMYD2 pro-
tein abundance in NIH3T3 did not influence ERK1/2 phosphorylation nor did it influence
the transformation potential of these cells by oncogenic H-RAS.
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5 Discussion
5.1 SMYD2 and histone methylation
Many of the initially characterized mammalian protein methyltransferases were shown
to methylate histones. This was the reason, why this protein class was first described
as histone methyltransferases (HMTs) rather than protein methyltransferases (PMTs).
Prominent representatives of the SET domain containing protein lysine methyltransferases
(PKMTs) with known histone methyltransferase activity are EZH2 (H3 K27 methylation)16
and members of the MLL family like MLL3/MLL4 (H3 K4 methylation)52. However, more
recent data have also suggested that many of the PKMTs of the human genome are also
able to methylate non-histone proteins54. Similar to other PKMTs, SMYD2 was initially
reported to be a histone methyltransferase of H3 K4 and K36. However, these data were
solely based on biochemical methylation assays using recombinant histones or reconstituted
nucleosomes1;13. In the present study, global changes of these marks were not detected in
cells after siRNA mediated downregulation of SMYD2 protein (Fig. 4.9) or after inhibi-
tion of SMYD2 enzyme activity using BAY-598 (data not shown). These observations are
in line with analyses of global levels of all methylation states of H3 K4 and K36 in heart tis-
sue from cardiomyocyte specific SMYD2 knockout mice27, where the authors also did not
observe significant changes in global histone methylation compared to control mice. Fur-
thermore, another study in KYSE150 cells (SMYD2 amplified) did not detect significant
differences in a whole panel of histone modifications using quantitative mass spectrometry
after inhibition of SMYD2 activity with a small molecule inhibitor93. Although one can-
not rule out the possibility that some of these marks may be affected locally on individual
histones, so far cellular data are missing that would demonstrate a methylation activity
of SMYD2 on histones. A technical obstacle to answer the question if SMYD2 may alter
focal histone methylation is how to distinguish direct from indirect effects. For example,
experimental interventions by either knockdown, knockout or small molecule inhibition to
reduce SMYD2 activity may lead to changes in focal histone methylation under certain
conditions. However, these changes could occur due to changes in gene expression patterns
as a response of SMYD2 inhibition or directly due to interfering with SMYD2 activity on
these histones. To better clarify this, chromatin immunoprecipitation experiments would
be needed to map SMYD2 occupancy on the chromatin and align this with the occurrence
of individual histone marks. Preferably, the ability to capture chromatin by immunopre-
cipitation of SMYD2 should be compared to knockout samples or after SMYD2 inhibition
to demonstrate that obtained peaks are SMYD2 specific.
5.2 SMYD2 subcellular localization
Connected to the open question about in vivo histone methylation activity, controver-
sial reports on the subcellular localization of SMYD2 exist. Whereas some reports ob-
served nuclear localization, which would support potential histone methyltransferase ac-
tivity, other work rather points to a cytoplasmic localization. In the present study, a clear
cytoplasmic localization of endogenous SMYD2 was observed in NIH3T3 mouse fibrob-
lasts in immunofluorescence images (Fig. 4.46). The signal was completely absent in
NIH3T3 SMYD2 knockout cells, indicating the specificity of the antibody. Clear cytoplas-
mic localization of endogenous SMYD2 was also observed in KYSE150 cells (Fig. S7.52),
and in HeLa and MDA-MB231 cells on western blot after subcellular fractionation (Fig.
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S7.53) as well as predominantly cytoplasmic localization of ectopic SMYD2 in KYSE150
cells in immunofluorescence images (Fig. 4.19). Donlin et al. tested the localization of
several GFP fused PMTs and reported predominantly cytoplasmic localization of ectopic
SMYD2-GFP fusion proteins in HEK293 cells30. After quantification of GFP signals from
immunofluorescence images, they measured over 80% of the signal in the cytoplasm. In
comparison, Set6-GFP fusion protein, another methyltransferase was mainly localized to
the nucleus and less than 10% of the signal derived from the cytoplasm, indicating the
feasibility of this approach to determine subcellular distribution of PMTs. Also Voelkel
et al. showed a clear cytoplasmic staining with a striated pattern of endogenous SMYD2
in cultured neonatal rat cardiomyocytes and a localization of SMYD2 in human myofib-
rills on either sides of the Z-disk in the I-band region131. In contrast, Diehl et al showed
mainly nuclear localization of SMYD2 in cryosections of postnatal cardiomyocytes, which
was completely absent in tissue from SMYD2-KO mice27, demonstrating the specificity
of detected signals. Also Cho et al. showed mainly nuclear SMYD2 localization in SBC5
cells, a lung adenocarcinoma cell line19. It is unclear so far, how to explain such different
observations. The differences might be explained by different cell types tested or different
conditions and might suggest a potential shuffling of SMYD2 between the nucleus and the
cytoplasm. However, clear evidence is missing that would support an active shuffling be-
tween these compartments. Donlin et al. also noted, using in silico prediction algorithms
that they did not identify nuclear localization signals (NLS) in the SMYD2 sequence but
potential nuclear export signals (NES)30. Localization between different compartments
could also be accomplished by the formation of different protein complexes, which dis-
tribute differentially in the cell. Clearly, more work is needed to clarify this question and
although potential protein protein interaction partners for SMYD2 have been reported, it
is unclear in what kind of complexes SMYD2 is functional.
5.3 SMYD2 in transcriptional regulation
Protein methyltransferases have been shown to regulate gene transcription. For instance,
the methyltransferase EZH2 as part of the polycomb repressive complex 2 (PRC2) mediates
H3 K27 mono-, di-, and trimethylation at gene promotors, which is commonly associated
with gene silencing. In contrast, H3 K4 trimethylation, deposited by MLL containing
COMPASS complexes87 at gene promotors, is normally associated with gene activation,
showing that histone methylation can promote both transcriptional repression or activation
depending on the specific residue. More recent data have also pointed towards transcrip-
tional regulation by lysine methylation beyond histone methylation by influencing tran-
scription factor activity45 or more indirect even by modulating cellular signaling pathways,
as is the case for SMYD386. Taken together, in one or the other way, protein methylation
is often involved in transcriptional regulation. With that respect, also SMYD2 has been
reported in the literature to regulate transcription, although in opposite ways and with
different modes of action. For example, Brown et al. observed inhibition of gene expression
in a reporter gene assay upon ectopic SMYD2 overexpression13. This was unexpected as
in the same study SMYD2 was also observed to in vitro methylate H3 K36, a histone mark
normally associated with transcriptional elongation132. The authors explained their obser-
vation by a potential association of SMYD2 with the repressive histone deacetylase complex
Sin3A, but data on endogenous systems were missing. Huang et al. described an inhibition
of p53 target gene transcription by SMYD2 after DNA damage. This was explained by p53
methylation at K370, which prevented p53 from efficiently binding to chromatin55. In con-
trast, overexpression of SMYD2 in HEK293 cells resulted predominantly in upregulation
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of genes1. In this study, the authors detected ectopic SMYD2 occupancy in the promotor
regions of some of the upregulated genes and speculated, based on biochemical methylation
data, that SMYD2 mediated H3 K4 methylation and subsequent gene activation1. This is
in contradiction to the predominant cytoplasmic localization of SMYD2 in HEK293 cells30,
but may suggest that a subpool of SMYD2, at least under ectopic overexpression, acts as
nuclear H3 K4 methyltransferase and regulates gene activation.
In view of these observations and in the context of the two above discussed questions
about SMYD2 histone methyltransferase activity and subcellular localization, I was in-
terested, if and how SMYD2 might regulate gene transcription. To investigate on that
question, 5 polyclonal cell lines from the MDA-MB231 breast cancer cell line model were
generated, which stably expressed 5 different short hairpin oligonucleotids that efficiently
mediated SMYD2 knockdown. The aim was to compare global gene expression in those
cell lines with an empty vector control cell line to identify potential target genes regulated
by SMYD2. However, despite reasonable expression of SMYD2 in the parental cell line,
efficient knockdown did not reveal significant phenotypic changes. This was reflected by
only moderate changes in global gene expression. More importantly, comparison of the
individual SMYD2 knockdown cell lines revealed no commonly regulated genes besides
SMYD2 itself, suggesting that changes in gene expression were rather associated with off-
target effects of individual shRNAs. It has been appreciated that intervention by RNAi
mediated knockdown can lead to off-target effects that can compromise the interpreta-
tion of observed phenotypes or gene expression changes. Indeed, subsequently during the
project, in a similar experiment, parental MDA-MB231 cells were treated for 3 days with
1 µM BAY-598 (20x over cellular IC50 of substrate methylation) or DMSO and global
gene expression analysis revealed no changes in gene expression at all (data not shown).
These findings are similar to gene expression data from cardiomyocytes of SMYD2 knock-
out versus control mice, where only minimal changes were observed27. Taken together,
the observations in the current study that SMYD2 was mainly localized in the cytoplasm,
global histone methylation was unaffected, as was proliferation of knockdown cell lines,
and no significant changes in gene expression were observed, suggest that SMYD2 is not
a direct transcriptional regulator on chromatin at least under the tested conditions. This
is in contrast to some of the previous reports and might be explained by different cell
systems and different conditions tested. Perhaps, SMYD2 might have direct or indirect
effects on transcription upon specific stress conditions or stimuli either by relocalization to
the nucleus or by modulating signaling pathways that become activated by the stimuli.
5.4 SMYD2 dependent substrate methylation
Soon after the first characterization of SMYD2 as a histone methyltransferase, it was
demonstrated that SMYD2 possesses additional methylation activity towards the tumor
suppressor p53 - a finding that was also detected in cells55. This mono-methylation of
p53 at lysine residue K370 was suggested to inhibit the transactivation activity of p53
and thereby inhibiting p53 tumor suppressor activity. To potentially use this methyla-
tion activity of SMYD2 for the development of a cellular mechanistic assay, a customized
antibody (SY46) was generated to detect p53 monomethylation at lysine residue K370.
Indeed, cross-purified SY46 antibody was able to specifically detect methylated p53 and
this mark could also be decreased in cells upon SMYD2 inhibition. However, obtained
signals from endogenous proteins were too weak for the development of a quantitative
cellular mechanistic assay. Therefore, ectopic SMYD2 overexpression was intended to in-
crease the signal. Interestingly however, ectopic SMYD2 did not increase detectable p53
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methylation but revealed additional protein methylation. A reason for the still low levels
of p53 methylation, despite high total p53 protein levels, could be that ectopic SMYD2
did not increase the number of physical contacts to p53 protein due to different local-
izations within the cell and that only a small subset of total p53 was actually in close
proximity to SMYD2. Indeed, subcellular fractionation revealed nuclear and cytoplasmic
distribution of p53 whereas SMYD2 was mainly cytoplasmic (Fig. S7.52). Nonetheless,
the strong reactivity of SY46 antibody upon ectopic SMYD2 overexpression pointed to-
wards additional SMYD2 substrates with epitopes similar to p53 at K370 site. In fact,
other groups have reported on additional substrates besides p53 and histones like RB1105,
HSP9030, PARP198, PTEN91, and ERα141. However, none of the reported substrates were
able to explain the observed methylation pattern at high molecular weight in KYSE150,
MDA-MB231 and HeLa cells upon SMYD2 overexpression. Although the substrate(s) be-
hind the observed methylation signal initially remained elusive, it served as a convenient
opportunity to develop a robust quantitative assay to evaluate the cellular potency of syn-
thezised small molecular SMYD2 inhibitors. This, among other project activities, led to
the selection of the very potent and selective SMYD2 inhibitor probe BAY-598, which is
now available to the research community via the Structural Genomics Consortium (SGC,
www.thesgc.org/chemical-probes/BAY-598) and will hopefully allow scientists to en-
hance our understanding of the mysterious biological function of SMYD2.
In addition to successfully having supported the development of a SMYD2 probe inhibitor,
I aimed at identifying novel SMYD2 substrates by measuring proteome wide lysine methy-
lation in MDA-MB231 cells ectopically overexpressing SMYD2 with the hypothesis that
ectopic SMYD2 would have a significant impact on the overall lysine methylation. In total
188 and 695 sites of lysine mono-methylation were detected with SY46 and a pan-Kme1
antibody, respectively. This demonstrated the general feasibility of this approach to iden-
tify novel cellular lysine methylation and clearly shows how less lysine methylation outside
of histones is recognized and understood. Surprisingly, from all previous reported SMYD2
substrates only HSP90 K615 methylation was detected. This could have several reasons:
First, some of the described substrates were probably not sufficiently expressed at the pro-
tein level in the MDA-MB231 cell line model. Indeed, the described substrate estrogen
receptor alpha (ERα)60;141 is not expressed in the ER negative MDA-MB231 cell line63
and would therefore not be expected to be detected. Another reason could be that the
antibody was not able to capture some of the previous described methylation site due to
different physicochemical properties. For instance, the amino acid composition around the
described methylation site of PTEN at K313 significantly differs from that of p53 at K370.
Third, a neighboring modification like acetylation or phosphorylation could have prevented
detection of the methylation site by the antibody. For example, it was observed that phos-
phorylation at serine residue S28 can prevent detection of trimethylation at K27 by an
H3 K27me3 specific antibody using histone peptide arrays with combinations of different
modifications (inhouse observations). Last but not least, certain methylation sites may
be specifically regulated and did not occur under the tested conditions although protein
abundance of both enzyme and target protein were high. For instance, gene expression
data suggested high PARP1 abundance in MDA-MB231 cells. However, no methylation
was detected, perhaps, because PARP1 is involved in DNA single-stranded breaks repair68
and only under those conditions methylation might be relevant.
Nonetheless, with the help of stringent selection criteria, I was able to identify and validate
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AHNAK as a novel SMYD2 substrate that had the most dominant impact on the observed
methylation signals detected by SY46 antibody. AHNAK methylation was most clearly
detected upon ectopic SMYD2 overexpression but was also measurable at endogenous lev-
els of SMYD2 both in human cancer cell lines as well as in mouse cell lines and muscle
tissue from mice. This suggests that AHNAK methylation is conserved in different species.
Moreover, AHNAK methylation provides an unprecedented example of multi-methylation
due to its repetitive domain structure. In the present proteome study using MDA-MB231
breast cancer cells ectopically overexpressing SMYD2, 79 unique mono-methyl lysine sites
were detected with SY46 and a pan-Kme1 antibody together. It is unclear though, if all
methylation sites detected within AHNAK can be assigned to SMYD2 activity, but a se-
quence motif derived from all AHNAK methylation sites showed a clear enrichment for a
LKGPK motif. This suggests that at least lysines within the LKGPK or a similar motif
are likely target sites for SMYD2 methylation. The typical validation procedure, in which
single lysine residues are mutated to arginine to precisely map the methylation sites, was
unfeasible in this case given the high number of potential target sites and the large size
of the protein. However, in a biochemical methylation assay using recombinant AHNAK-
CRUs and recombinant SMYD2 enzyme it could be demonstrated that SMYD2 can di-
rectly methylate recombinant AHNAK protein fragments. Subsequent mass spectrometry
analyses from AHNAK-CRUs excised from protein gels detected peptides comprising the
methylated LK(me1)GPK motif and to a lesser extend LKGPK(me1) only in the samples
that had been incubated with SMYD2. This not only demonstrated that SMYD2 is able
to directly methylate AHNAK-CRUs but also further supported the idea that LKGPK is a
preferred motif for SMYD2 methylation. Surprisingly though, a biochemical SPA methyla-
tion assay using a peptide derived from AHNAK that comprised the LKGPK motif failed to
reveal measurable methylation in contrast to p53 peptide, which was efficiently methylated
under these conditions. One reason for such a negative result could be the differences in the
biotinylation sites of the peptides, as AHNAK derived peptide was biotinylated at the C-
terminus whereas p53 peptide was tagged with Biotin at the N-terminus. Interestingly, Wu
et al. compared the methyltransferase activity of SMYD2 in biochemical assays using full-
length p53, histones and peptides thereof137. They found that actually full-length histone
H2B and histone H4 were better substrates than p53 protein, which itself was a better
substrate than histone H3. However, when comparing peptides derived from these pro-
teins, p53 peptide comprising K370 showed significant better methylation rates than any
other peptides from histones. Using multistate computational protein design algorithms,
Lanouette et al. tried to predict novel SMYD2 substrates using the previously described
p53 peptide as starting point for their model74. They complemented this approach with
a biochemical methylation screen using permutated peptide substrates and measured the
methylation efficiency. With both approaches they hypothesized a recognition motif for
SMYD2 methylation of [LFM]-K(me1)-[AFYMSHRK]-[LYK]. Although there are similar-
ities between the recognition motifs from AHNAK methylation and from Lanouette et al.,
especially at the -1 position, glycine and proline at +1 and +2 position, respectively were
excluded by Lanouette et al. but were the dominant amino acids in the sequence motif of
AHNAK methylation. This shows that there is obviously a discrepancy in the methylation
preferences between unstructured oligopeptides and structured polypeptides or proteins.
On one hand, it means that the potential spectrum of SMYD2 substrate methylation sites
might be broader than originally predicted, on the other hand the presence of certain
recognition motifs and the ability for in vitro methylation of peptides does not allow a
1:1 inference to in vivo methylation. To be mentioned, none of the predicted substrates
from Lanouette et al. were either detected in the present proteome study or in the study
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from Olsen et al.96 (discussed below). Reasons are diverse and can be due to technical
limitations as already discussed above, but will also be due to the cellular context and
spatial proximity of enzyme and substrate within the cell.
5.5 Potential implications of AHNAK methylation
Having identified AHNAK as a substrate of SMYD2 that can be multi-methylated on
many lysine residues with LKGPK as the preferred methylation motif, the perhaps most
interesting question remains: What is the biological relevance of AHNAK methylation?
AHNAK, which means giant in Hebrew, is indeed a "giant" protein of about 630 kDa
(UniProt ID Q09666). It consists of an N-terminal PDZ domain, a large central domain
of 4300 aa, which itself is made of approximately 38 central repeated units of 68-128 aa
in length, and a C-terminal domain with potential nuclear localization motifs. The PDZ
domain is a protein-protein binding module implicated in binding C-terminal regions of
membrane receptor proteins (e.g. G protein coupled receptors (GPCRs)) and connecting
these to the cytoskeleton76.
AHNAK lacks enzymatic activity and its concrete function remains elusive. It most likely
acts as a scaffold protein to form multi-protein complexes. Most reports implicated reg-
ulation in cell signaling and calcium channels24, however, more recent publications have
suggested also implications in epithelial to mesenchymal transition (EMT) and tumor
metastasis114;125. It was first described by Shtivelmann et al. to be an unusually large
protein with a polyionic rod like shape of 1.2 µm and to be differentially expressed in neu-
roblastomas compared to healthy nerve tissue119. At about the same time, Hashimoto et al.
discovered a large protein of desmosomal plaques, which was therefore named Desmoyokin,
and turned out to be identical to AHNAK50. Similar to SMYD2, AHNAK knockout mice
are viable, fertile and show no obvious phenotype71. Later, Haase et al. found a large
phosphoprotein, called phosphoprotein 700 (pp700), that was associated with the beta 2
subunit of cardiac L-type calcium channels in porcine and rat cardiomyocytes, to be the
ortholog to human AHNAK43. Phosphorylation of AHNAK occurred in a cAMP depen-
dent manner by protein kinase A (PKA) after beta-adrenergic receptor stimulation. It
was suggested that under basal conditions AHNAK inhibits calcium channel activation,
but phosphorylation of AHNAK releases the beta-2 subunit of the calcium channel, which
allowed calcium influx and contraction. PKA is a serine/threonine kinase. In fact, many
serine residues lie within the CRUs of AHNAK in the vicinity of detected methylated lysine
residues. Therefore, one might speculate that these serine residues might be phosphory-
lated by PKA, depending on the presence or absence of nearby lysine methylation, or, like
in the case of MAP3K2 methylation by SMYD386, that phosphorylation is maintained by
nearby methylation through a mechanism that prevents phosphatase recruitment.
AHNAK was also found to bind and activate phospholipase C (PLC) in the presence of
arachidonic acid111 as well as protein kinase C (PKC)77;78. Interestingly, binding and ac-
tivation of both PLC and PKC was mediated by the central repeated units of AHNAK.
Activation of PLC was also connected to breast cancer metastasis108. If methylation of
AHNAK influences PLC or PKC binding or activation might be worth investigating.
Immunofluorescence images of ectopic SMYD2 and SY46 detected methylation in KYSE150
cells revealed mainly cytoplasmic staining in interphase cells. However, both SMYD2 as
well as methylation signals revealed strong staining of the spindle machinery in mitotic
cells. Localization of SMYD2 to spindle fibers has not yet been described. Interestingly,
mitotic spindle localization was detected by several monoclonal antibodies against the
PEVK region of titin (the largest protein of the human genome and specific to muscle
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cells) in non-muscle derived cells135. In the same study, the authors demonstrated that
these antibodies cross-reacted with AHNAK protein, suggesting that SMYD2 together with
methylated AHNAK are localized to and might also regulate mitotic spindles. Definitively,
more work is needed to reveal a clear function of SMYD2 and AHNAK methylation.
However, answering this question in the future will be challenging as knockout mice of both
SMYD2 and AHNAK did not show obvious phenotypes27;72;103. If a protein as a whole
is dispensable for normal development a phenotype of a posttranslational modification on
that protein might be even more subtle. It also raises the question, why are both SMYD2
enzyme as well as methylation motifs on AHNAK conserved among species, if they are
dispensable et least under laboratory conditions? One explanation could be that there is
functional redundancy which is able to compensate loss of function of both proteins. How-
ever, redundancy is unlikely to be accomplished by paralogs as there was no indication
for upregulation of other SMYD family members upon SMYD2 inhibition and AHNAK
and AHNAK2 seemed to be reversely regulated at least during C2C12 differentiation. My
personal view on that question is that both may be relevant under certain stress conditions
so far not tested or would give an evolutionary advantage in the long run in a real world
environment. More work is definitively needed to uncover this mystery.
5.6 Comparison with another proteome study of SMYD2 in KYSE150
Given the high number of detected methylation sites in the current proteome study and the
obviously brougth substrate specificity of SMYD2, it is very likely that SMYD2 activity
was responsible for additional methylation sites of other proteins, although this might have
been overshadowed by AHNAK methylation. However, to clearly identify those, more com-
prehensive quantitative methods would have been required. Interestingly, very recently,
Olsen et al. have reported on results of another proteome study in the KYSE150 cell line
model96. In that study, they indeed used a quantitative SILAC (stable isotope labeling
of amino acids97) based proteomic approach and compared global lysine methylation of
SMYD2 knockdown cells with the corresponding parental cell line and in addition, they
also compared global lysine methylation in ectopic SMYD2 overexpressing KYSE150 cells
before and after treatment with the SMYD2 inhibitor probe LLY-50793. By that, they
were able to quantitatively measure relative changes in protein methylation between treat-
ment groups. They identified 35 methylation sites that were significantly reduced upon
SMYD2 depletion/inhibition. Strikingly, very similar to my own results, their list of 35
regulated methylation sites included HSP90 methylation at K615, but none of the other
reported SMYD2 substrates. What is more, out of the 35 methylation sites identified by
Olsen et al. 17 sites were also detected in the present proteome study (for details see
supplement). Most importantly, among them also several sites of AHNAK and AHNAK2.
This really indicates that SMYD2 contains a larger set of substrates that are common to
cells of different tissue origin and that AHNAK and AHNAK2 are among these commonly
chaired substrates.
It is now tempting to speculate if there is a functional connection between the different
substrates. The 17 sites are within proteins like MAP2K480, a family member of the mi-
togen activated kinases that is able to activate the stress activated JNK1, JNK2, and p38
kinases.
FIGNL1, a gene associated with DNA damage response where it plays a role in DNA
double-strand break repair via homologous recombination140.
HN1 also contained a methylation site that was detected in MDA-MB231 and for which
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downregulation of HN1 methylation was reported in KYSE150 cells upon SMYD2 inhi-
bition. This protein has been implicated in regulation of regeneration and differentiation
and was connected to the p38 kinase pathway.
Another protein PHACTR2 has been described to regulate the activity of protein phos-
phatase 1 (PP1) and actin4. PP1 is a ubiquitously expressed protein phosphatase that is
modulated in its dephosphorylation activity towards specific substrates by association with
different regulatory subunits like PHACTR2. Methylation of PHACTR2 could potentially
influence its association with PP1. However, this would need further investigation.
Another potential SMYD2 target detected in both cell lines is PRKDC. This gene encodes
the catalytic subunit of the DNA-dependent protein kinase and is also involved in DNA
double strand break repair and recombination.
Another prominent member of methylated proteins that was detected in KYSE150 and
MDA-MB231, and which is presumably a substrate for SMYD2 methylation, is RICTOR,
a subunit of the mTORC2 complex that is involved in phosphorylation of AKT at S473
and in cytoskeleton regulation through its stimulation of F-actin stress fibers57;112. These
studies have suggested that mTORC2 controls the actin cytoskeleton by promoting protein
kinase C alpha (PKCα) phosphorylation, phosphorylation of paxillin and its relocalization
to focal adhesions, and the GTP loading of RhoA and Rac1. The molecular mechanism
by which mTORC2 regulates these processes has not been determined, but interestingly,
as mentioned earlier, AHNAK was suggested to activate PKC. To mention in this context,
AHNAK was described to be localized to costameres in muscle cells85, which can be viewed
as specialized focal adhesions and share many common proteins.
5.7 Potential functions of SMYD2 mediated lysine methylation
Several functions have been assigned to lysine methylation mostly driven by observations
on histone methylation, but these may also be transferred to non-histone methylation.
The fact, that in endogenous systems only small fractions of total substrates seem to be
methylated, suggests that protein methylation similar to histone methylation allows for
differentiated functions of sub-pools of proteins.
Lysine residues are targets of a number of posttranslational modifications besides methyla-
tion such as acetylation, ubiquitination or sumoylation among others82. Importantly, these
different modifications are mutually exclusive and possess different properties. That means
different modifications may be competing against each other on certain lysine residues and
promote different outcomes. For example, lysine methylation may prevent polyubiquitina-
tion, which otherwise would lead to protein degradation through the ubiquitin-proteasome
pathway. However, there was no evidence so far that this could be the case for AHNAK,
because no other lysine modifications for this protein have been reported to date and pro-
tein stability seemed not to be influenced in the present experiments after changes of lysine
methylation.
Another function of lysine methylation is the modulation of protein-protein interactions.
Lysine methylation does not change the charge of the protein in contrast to phosphory-
lation or acetylation and leads only to a small change in size (14 Da). However, it alters
the hydration energies and hydrogen bonding potential of the lysine side chains25. There
are a number of so called "reader" domains that have been identified, which allow the
recruitment of the corresponding proteins to the site of lysine methylation and thereby
enabling the assembly of functional protein complexes. Domains with reported methyl
binding properties are TUDOR84, PHD14, MBT11, CHROMO33, PWWP100 and WD40
repeat126 domains. Therefore, one could envision that, in analogy to chromatin, AHNAK
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serves as a scaffold for the recruitment and assembly of specific signalosomes, which are
regulated by diverse combinations of posttranslational modifications on the protein, among
them SMYD2 mediated lysine methylation. It is unclear though, if the above mentioned
domains for lysine methylation recognition are also relevant in the cytoplasm or if other
domains may be able to do so.
In addition, another possibility is that lysine methylation prevents protein interaction.
For instance MAP3K2 protein kinase has been reported to be methylated by SMYD3, a
close homolog of SMYD2. This methylation prevented interaction with the phosphatase
PP2A and thereby maintaining MAP3K2 phosphorylation and activation86. AHNAK has
been described to be a phospho-protein118 and several serine residues lie in the vicinity to
the methylated lysine residues. Therefore, one could imagine that there exists a cross talk
between both modifications. Unfortunately, I was not able to detect AHNAK phosphoryla-
tion with a pan-Ser/Thr antibody (data not shown) and therefore could not pursue on that
hypothesis. Another way to determine if AHNAK methylation influences protein-protein
interactions would be a GST-pulldown with recombinant AHNAK or subunits thereof, that
are either methylated or unmethylated and test, whether certain proteins are differentially
bound to both forms of AHNAK. This approach proved to be successful for identifying
the relevance of MAP3K2 methylation. However, such approach would require quantita-
tive SILAC based mass spectrometry analyses and efficient methylation of recombinant
AHNAK-CRUs in order to obtain a clear differentiation.
5.8 Functional characterization of SMYD2 inhibition
In the last part of my thesis I functionally characterized the effects of SMYD2 inhibition
or depletion in selected cell models. The first model system was chosen to reveal the rele-
vance of SMYD2 inhibition in normal physiology. For this, the C2C12 cell line model was
selected because of the observation of high SMYD2 protein expression in skeletal muscle
tissue. C2C12 are mouse myoblasts that can be easily differentiated into myotubes and
form muscle fiber like structures that even start to contract after several days of differ-
entiation. Analysis of gene expression revealed a successive downregulation of SMYD2
during differentiation. This was unexpected, as high levels of SMYD2 in muscle tissue of
adult mice suggested also high expression in differentiated C2C12 myotubes. However, it
is difficult to compare both systems and perhaps SMYD2 expression in muscle precursors
during development or undifferentiated satellite cells within adult muscle tissue is even
higher than in differentiated muscle fibers. Despite significant expression of SMYD2, per-
manent inhibition of SMYD2 activity with BAY-598 treatment had no measurable impact
on myoblasts and differentiation. This is actually in line with the fact that SMYD2 knock-
out mice are viable and show no developmental defects even in tissues of high SMYD2
expression like heart and skeletal muscle. The lack of phenotype may be explained by
compensatory mechanisms or redundancy. However, analyses of transcript and protein
expression of the other SMYD family members gave no hint that compensation might be
achieved by close paralogs. Also literature does not point sofar to overlapping substrates of
different SMYD proteins, although a systematic approach for identifying substrates for the
other SMYD family members are still missing and therefore shared substrates cannot be
ruled out. Stable knockdown of SMYD2 in MDA-MB231 cells did also not reveal consistent
upregulation of other genes in different knockdown cell lines in a global gene expression
study.
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5.8.1 SMYD2 activity does not impact H-Ras transformation of NIH3T3
cells
The second model system was intended to reveal more insights about SMYD2 function
during tumorigenesis based on a report that observed SMYD2 upregulation in a mouse
model of oncogenic RAS driven ductal adenocarcinoma formation in pancreas103. Strik-
ingly, conditional knockout of SMYD2 in pancreas had no impact on normal pancreas
physiology but significantly compromised oncogenic RAS driven tumor formation in this
organ. This suggested that SMYD2 might be an important downstream effector of onco-
genic RAS signaling. To recapitulate this idea in a simple cellular in vitro system, NIH3T3
mouse fibroblasts were employed that are highly succeptable for oncogene transformation,
especially oncogenic RAS. For that purpose I not only generated NIH3T3 SMYD2-KO
cells, in analogy above mentioned publication but also tested in parallel the clinically more
relevant inhibition of SMYD2 via BAY-598. However, in both cases permanent inhibition
of SMYD2 actitiy with BAY-598 or via CrispR/Cas9 knockout of SMYD2 did not compro-
mise H-RAS G12V transformation of NIH3T3. Also parental NIH3T3 cells did not reveal
protein upregulation of SMYD2 after RAS transformation. This indicated that SMYD2 is
probably not a direct downstream effector of RAS signaling. The observed effects in pan-
creas in vivo points towards more complex regulation that cannot be easily reconstructed in
2D cell culture. Therefore, I suspect that upregulation of SMYD2 in pancreatic lesions was
not a direct effect of RAS signaling but rather an indirect consequence of dramatic changes
in the microenvironment of cancerous lesions, like inflammation, immune cell infiltration,
hypoxia and other stresses. The authors also noted decreased inflammatory response in
SMYD2-KO mice during tumor formation, especially lower serum levels of IL-6, a proin-
flammatory cytokine. Therefore, it might be interesting to further investigate on the role
of SMYD2 during inflammation, a process that is not activated in normal development,
which might explain a lack of phenotype.
5.9 Conclusion
The current work constitutes a significant contribution to the development of the specific
small molecule SMYD2 inhibitor probe BAY-598 by establishing a quantitative mechanistic
assay that was able to measure the methyltransferase activity of this enzyme in cells.
Furthermore, I was able to identify and validate AHNAK as a novel SMYD2 substrate,
which showed unprecedented multi-methylation along the protein. Although the biological
relevance of SMYD2 and AHNAK methylation or other SMYD2 substrate methylation is
still mysterious, initial tests of SMYD2 inhibition in two cell culture models showed the
feasibility of inhibitor probes to test functional hypotheses. Therefore, with the help of
BAY-598 it will be easy and convenient to test more sophisticated model systems, which
are obviously needed to uncover SMYD2 function. Coming back to the initial idea that
SMYD2 might be a promising target in cancer therapy, when looking at the present data in
conjunction with findings from Eggert et al.32 it appears rather unlikely to employ SMYD2
inhibition in a mono-therapy strategy in cancer patients. However, future research may
identify rational combination therapies.
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7 Supplement
7.1 Translated protein sequences of expression constructs
1CRU-N-term. GST-fusion (red) protein incl. eTEV cleavage site (yellow)
(388 aa, theor. MW: 44.2 kDa, pI 6,04)
Represents aa 3987-4129 of human full-length AHNAK (Uniprot ID Q09666)
1 MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
61 GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV
121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK
181 KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD PITSLYKKAG Fdydiptten
241 lyfqgPKFKM PEMNIKAPKI SMPDFDLHLK GPKVKGDVDV SLPKMEGDLK APEVDIKGPK
301 VDIDAPDVDV HGPDWHLKMP KVKMPKFSMP GFKGEGPEVD VNLPKADIDV SGPKVDIDTP
361 DIDIHGPEGK LKGPKFKMPD LHLKAPKI
3sCRU-N-term. GST-fusion (red) protein incl. eTEV cleavage site (yellow)
(453 aa, theor. MW: 51.0 kDa, pI 6.01)
Represents aa 4384-4591 of human full-length AHNAK (Uniprot ID Q09666)
1 MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
61 GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV
121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK
181 KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD PITSLYKKAG Fdydiptten
241 lyfqgKISMP DIDFNLKGPK VKGDVDVSLP KVEGDLKGPE IDIKGPSLDI DTPDVNIEGP
301 EGKLKGPKFK MPEMNIKAPK ISMPDFDLHL KGPKVKGDVD VSLPKVESDL KGPEVDIEGP
361 EGKLKGPKFK MPDVHFKSPQ ISMSDIDLNL KGPKIKGDMD ISVPKLEGDL KGPKVDVKGP
421 KVGIDTPDID IHGPEGKLKG PKFKMPDLHL KAP
3lCRU-N-term. GST-fusion (red) protein incl. eTEV cleavage site (yellow)
(629 aa, theor. MW: 70.3 kDa, pI 5.54)
Represents aa 1066-1449 of human full-length AHNAK (Uniprot ID Q09666)
1 MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
61 GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV
121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK
181 KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD PITSLYKKAG Fdydiptten
241 lyfqgKMSLP DVDLDLKGPK MKGNVDISAP KIEGEMQVPD VDIRGPKVDI KAPDVEGQGL
301 DWSLKIPKMK MPKFSMPSLK GEGPEVDVNL PKADVVVSGP KVDIEAPDVS LEGPEGKLKG
361 PKFKMPEMHF KTPKISMPDV DLHLKGPKVK GDVDVSVPKV EGEMKVPDVE IKGPKMDIDA
421 PDVEVQGPDW HLKMPKMKMP KFSMPGFKGE GREVDVNLPK ADIDVSGPKV DVEVPDVSLE
481 GPEGKLKGPK FKMPEMHFKA PKISMPDVDL NLKGPKLKGD VDVSLPEVEG EMKVPDVDIK
541 GPKVDISAPD VDVHGPDWHL KMPKVKMPKF SMPGFKGEGP EVDVKLPKAD VDVSGPKMDA
601 EVPDVNIEGP DAKLKGPKFK MPEMSIKPQ
– –
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Human SMYD2 with N-terminal 2x-c-myc tag (yellow)
(454 aa , theor. MW: 52.0 kDa, pI 5.80)
Histidine marked in red corresponds to endogenous SMYD2 (NP_064582) position H207
and was replaced in the enzymatic inactive mutant (H207A) by alanine.
1 MEQKLISEED LEQKLISEED LRAEGLGGLE RFCSPGKGRG LRALQPFQVG DLLFSCPAYA
61 YVLTVNERGN HCEYCFTRKE GLSKCGRCKQ AFYCNVECQK EDWPMHKLEC SPMVVFGENW
121 NPSETVRLTA RILAKQKIHP ERTPSEKLLA VKEFESHLDK LDNEKKDLIQ SDIAALHHFY
181 SKHLGFPDND SLVVLFAQVN CNGFTIEDEE LSHLGSAIFP DVALMNHSCC PNVIVTYKGT
241 LAEVRAVQEI KPGEEVFTSY IDLLYPTEDR NDRLRDSYFF TCECQECTTK DKDKAKVEIR
301 KLSDPPKAEA IRDMVRYARN VIEEFRRAKH YKSPSELLEI CELSQEKMSS VFEDSNVYML
361 HMMYQAMGVC LYMQDWEGAL QYGQKIIKPY SKHYPLYSLN VASMWLKLGR LYMGLEHKAA
421 GEKALKKAIA IMEVAHGKDH PYISEIKQEI ESH
Human SMYD3 isoform 1 with N-terminal 2x-FLAG tag (yellow)
(444 aa , theor. MW: 51.0 kDa, pI 5.96)
Asparagine marked in red corresponds to endogenous SMYD3 (NP_001161212) position
N205 and was replaced in the enzymatic inactive mutant (N205A) by alanine.
1 MDYKDDDDKD YKDDDDKEPL KVEKFATAKR GNGLRAVTPL RPGELLFRSD PLAYTVCKGS
61 RGVVCDRCLL GKEKLMRCSQ CRVAKYCSAK CQKKAWPDHK RECKCLKSCK PRYPPDSVRL
121 LGRVVFKLMD GAPSESEKLY SFYDLESNIN KLTEDKKEGL RQLVMTFQHF MREEIQDASQ
181 LPPAFDLFEA FAKVICNSFT ICNAEMQEVG VGLYPSISLL NHSCDPNCSI VFNGPHLLLR
241 AVRDIEVGEE LTICYLDMLM TSEERRKQLR DQYCFECDCF RCQTQDKDAD MLTGDEQVWK
301 EVQESLKKIE ELKAHWKWEQ VLAMCQAIIS SNSERLPDIN IYQLKVLDCA MDACINLGLL
361 EEALFYGTRT MEPYRIFFPG SHPVRGVQVM KVGKLQLHQG MFPQAMKNLR LAFDIMRVTH
421 GREHSLIEDL ILLLEECDAN IRAS
eGFP
(240 aa , theor. MW: 26.9 kDa, pI 5.58)
1 MVSKGEELFT GVVPILVELD GDVNGHKFSV SGEGEGDATY GKLTLKFICT TGKLPVPWPT
61 LVTTLTYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL
121 VNRIELKGID FKEDGNILGH KLEYNYNSHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA
181 DHYQQNTPIG DGPVLLPDNH YLSTQSALSK DPNEKRDHMV LLEFVTAAGI TLGMDELYK
– –
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7.2 List of mono-methylated peptides detected in proteom study
Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 DST 861 Q03001 K590 [PLLK(me1)SSL]
pan-Kme1 DST 861 Q03001 K6757 [LGAK(me1)HSV]
pan-Kme1 MACF1 838 Q9UPN3 K6604 [LGGK(me1)QPV]
both SYNE2 796 Q8WXH0-9 K265 [EAYK(me1)NF_]
both AHNAK 629 Q09666 K1012 [PSLK(me1)GEG]
both AHNAK 629 Q09666 K1024 [NLSK(me1)ANV]
pan-Kme1 AHNAK 629 Q09666 K1077 [LDLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K1080 [KGPK(me1)MKG]
pan-Kme1 AHNAK 629 Q09666 K1082 [PKMK(me1)GNV]
SY46 AHNAK 629 Q09666 K1184 [PKFK(me1)MPE]
both AHNAK 629 Q09666 K1191 [MHFK(me1)TPK]
both AHNAK 629 Q09666 K1205 [LHLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K1208 [KGPK(me1)VKG]
pan-Kme1 AHNAK 629 Q09666 K1268 [PGFK(me1)GEG]
both AHNAK 629 Q09666 K1319 [MHFK(me1)APK]
both AHNAK 629 Q09666 K1333 [LNLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K1336 [KGPK(me1)LKG]
pan-Kme1 AHNAK 629 Q09666 K1396 [PGFK(me1)GEG]
both AHNAK 629 Q09666 K1461 [LHLK(me1)GPK]
both AHNAK 629 Q09666 K1464 [KGPK(me1)MKG]
pan-Kme1 AHNAK 629 Q09666 K1524 [PGFK(me1)GEG]
pan-Kme1 AHNAK 629 Q09666 K1589 [LNLK(me1)APK]
pan-Kme1 AHNAK 629 Q09666 K1594 [PKLK(me1)TDV]
pan-Kme1 AHNAK 629 Q09666 K1791 [LNLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K1911 [PKFK(me1)MPD]
pan-Kme1 AHNAK 629 Q09666 K1918 [MHFK(me1)APK]
both AHNAK 629 Q09666 K2194 [LNLK(me1)GPK]
both AHNAK 629 Q09666 K2197 [KGPK(me1)VKG]
pan-Kme1 AHNAK 629 Q09666 K2257 [PGFK(me1)GEG]
both AHNAK 629 Q09666 K2322 [FNLK(me1)GPK]
both AHNAK 629 Q09666 K2396 [LHLK(me1)SPK]
pan-Kme1 AHNAK 629 Q09666 K243 [GHSK(me1)LQV]
pan-Kme1 AHNAK 629 Q09666 K2449 [MHFK(me1)APN]
pan-Kme1 AHNAK 629 Q09666 K2463 [LNLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K2466 [KGPK(me1)IKG]
both AHNAK 629 Q09666 K2589 [LHLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K2652 [PGFK(me1)GEG]
pan-Kme1 AHNAK 629 Q09666 K2973 [LHLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K3164 [PGFK(me1)GEG]
both AHNAK 629 Q09666 K3229 [LNLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K3249 [GDLK(me1)GPA]
pan-Kme1 AHNAK 629 Q09666 K3306 [KGSK(me1)LKG]
pan-Kme1 AHNAK 629 Q09666 K3404 [SKFK(me1)MPF]
pan-Kme1 AHNAK 629 Q09666 K3425 [LNLK(me1)SPK]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 AHNAK 629 Q09666 K3527 [GGLK(me1)GPK]
both AHNAK 629 Q09666 K3681 [LNLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K3684 [KGPK(me1)MKG]
pan-Kme1 AHNAK 629 Q09666 K3686 [PKMK(me1)GDV]
pan-Kme1 AHNAK 629 Q09666 K371 [GKLK(me1)GPQ]
both AHNAK 629 Q09666 K3741 [MHLK(me1)APK]
both AHNAK 629 Q09666 K4125 [LHLK(me1)APK]
pan-Kme1 AHNAK 629 Q09666 K4139 [LNLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K4142 [KGPK(me1)MKG]
pan-Kme1 AHNAK 629 Q09666 K4330 [PGFK(me1)GEG]
both AHNAK 629 Q09666 K4395 [FNLK(me1)GPK]
both AHNAK 629 Q09666 K4515 [VHFK(me1)SPQ]
both AHNAK 629 Q09666 K4529 [LNLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K4532 [KGPK(me1)IKG]
pan-Kme1 AHNAK 629 Q09666 K4794 [PGFK(me1)GEG]
both AHNAK 629 Q09666 K4859 [LDLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K4862 [KGPK(me1)VKG]
both AHNAK 629 Q09666 K4879 [GTLK(me1)GPE]
both AHNAK 629 Q09666 K4886 [VDLK(me1)GPR]
pan-Kme1 AHNAK 629 Q09666 K4905 [PSLK(me1)MPS]
pan-Kme1 AHNAK 629 Q09666 K4926 [LHLK(me1)APK]
both AHNAK 629 Q09666 K4945 [VDLK(me1)GPK]
pan-Kme1 AHNAK 629 Q09666 K4985 [FGAK(me1)SPK]
pan-Kme1 AHNAK 629 Q09666 K5204 [VNLK(me1)GPK]
both AHNAK 629 Q09666 K5281 [VSLK(me1)GPG]
both AHNAK 629 Q09666 K5307 [LNLK(me1)GPS]
both AHNAK 629 Q09666 K5312 [PSLK(me1)GDL]
SY46 AHNAK 629 Q09666 K5323 [PSMK(me1)VHA]
pan-Kme1 AHNAK 629 Q09666 K537 [VALK(me1)GSR]
both AHNAK 629 Q09666 K5434 [GELK(me1)GPG]
both AHNAK 629 Q09666 K5443 [VNLK(me1)GPR]
pan-Kme1 AHNAK 629 Q09666 K5528 [GGLK(me1)GSE]
both AHNAK 629 Q09666 K5725 [PKGK(me1)GGV]
pan-Kme1 AHNAK 629 Q09666 K584 [PKVK(me1)GGV]
both AHNAK 629 Q09666 K828 [LHLK(me1)GPN]
pan-Kme1 AHNAK 629 Q09666 K855 [VELK(me1)SAK]
pan-Kme1 AHNAK 629 Q09666 K891 [PGFK(me1)AEG]
pan-Kme1 AHNAK 629 Q09666 K942 [MNIK(me1)APK]
pan-Kme1 AHNAK 629 Q09666 K956 [LHMK(me1)GPK]
both AHNAK2 617 Q8IVF2 K1097 [VALK(me1)GPQ]
both AHNAK2 617 Q8IVF2 K1104 [VDVK(me1)GPK]
both AHNAK2 617 Q8IVF2 K1427 [VDLK(me1)GPE]
both AHNAK2 617 Q8IVF2 K1757 [VALK(me1)GPQ]
both AHNAK2 617 Q8IVF2 K1764 [MDVK(me1)GPK]
pan-Kme1 AHNAK2 617 Q8IVF2 K2094 [VDIK(me1)GPK]
pan-Kme1 AHNAK2 617 Q8IVF2 K2582 [MDLK(me1)GPQ]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 AHNAK2 617 Q8IVF2 K2589 [LDVK(me1)GPK]
pan-Kme1 AHNAK2 617 Q8IVF2 K3249 [IDIK(me1)GPK]
both AHNAK2 617 Q8IVF2 K3407 [VDLK(me1)SPQ]
pan-Kme1 AHNAK2 617 Q8IVF2 K3414 [VDIK(me1)GPK]
pan-Kme1 AHNAK2 617 Q8IVF2 K3417 [KGPK(me1)LDL]
pan-Kme1 AHNAK2 617 Q8IVF2 K4397 [VDLK(me1)GPQ]
both AHNAK2 617 Q8IVF2 K4562 [VDLK(me1)GPQ]
both AHNAK2 617 Q8IVF2 K4569 [VDVK(me1)GPK]
pan-Kme1 AHNAK2 617 Q8IVF2 K839 [PKFK(me1)MPS]
both AHNAK2 617 Q8IVF2 K932 [VDLK(me1)GPQ]
both AHNAK2 617 Q8IVF2 K939 [IDVK(me1)GPK]
pan-Kme1 AHNAK2 617 Q8IVF2 K942 [KGPK(me1)LDL]
pan-Kme1 EPPK1 556 P58107 K680 [VFAK(me1)LLS]
pan-Kme1 DYNC1H1 532 Q14204 K3480 [ALLK(me1)SLS]
pan-Kme1 DYNC1H1 532 Q14204 K4154 [PGVK(me1)ANM]
pan-Kme1 PLEC 532 Q15149 K915 [NEYK(me1)GHL]
pan-Kme1 DYNC2H1 493 Q8NCM8 K2455 [KNLK(me1)NHS]
pan-Kme1 PRKDC 469 P78527 K2694 [APLK(me1)SVG]
pan-Kme1 VPS13B 449 Q7Z7G8 K2052 [KPLK(me1)ANL]
pan-Kme1 KMT2A 432 Q03164 K3804 [VQLK(me1)SAR]
SY46 USP34 404 Q70CQ2 K1201 [SHLK(me1)ALS]
pan-Kme1 SPEN 402 Q96T58 K2680 [TTLK(me1)SLV]
pan-Kme1 VPS13A 360 Q96RL7 K1454 [FSLK(me1)NCI]
pan-Kme1 HTT 348 P42858 K9 [KLMK(me1)AFE]
pan-Kme1 EP400 343 Q96L91 K3018 [PALK(me1)TQF]
pan-Kme1 BPTF 338 Q12830 K791 [SQLK(me1)SQQ]
pan-Kme1 BPTF 338 Q12830 K833 [VIMK(me1)GNI]
pan-Kme1 CRYBG3 331 Q68DQ2 K1193 [LDLK(me1)SSL]
pan-Kme1 CRYBG3 331 Q68DQ2 K293 [SSMK(me1)GNL]
pan-Kme1 BOD1L1 330 Q8NFC6 K123 [QVLK(me1)SGM]
pan-Kme1 LRBA 319 P50851-2 K212 [FPGK(me1)SAA]
both PRRC2C 317 Q9Y520-7 K27 [NTYK(me1)GKS]
both PRRC2C 317 Q9Y520-7 K29 [YKGK(me1)SLE]
pan-Kme1 PRRC2C 317 Q9Y520-7 K35 [ETQK(me1)TTV]
pan-Kme1 PRRC2C 317 Q9Y520-7 K437 [FPSK(me1)QQV]
pan-Kme1 ITPR1 314 Q14643 K1574 [LFLK(me1)SHS]
pan-Kme1 USP24 294 Q9UPU5 K620 [DGFK(me1)SSQ]
both GCN1L1 293 Q92616 K1663 [PGLK(me1)ASL]
pan-Kme1 GCN1L1 293 Q92616 K802 [YSFK(me1)EQI]
pan-Kme1 FLNC 291 Q14315 K1073 [PGLK(me1)GGL]
pan-Kme1 MTOR 289 P42345 K2496 [LNKK(me1)AIQ]
both MAST4 284 O15021 K1868 [SSLK(me1)MNK]
both MAST4 284 O15021 K1871 [KMNK(me1)SYL]
SY46 SPTA1 280 P02549 K1486 [KALK(me1)AQL]
pan-Kme1 SPG11 279 Q96JI7 K2200 [GTLK(me1)TAL]
pan-Kme1 SPG11 279 Q96JI7 K2374 [RLLK(me1)SSI]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 FLNB 278 O75369 K1339 [PGLK(me1)EAF]
both FLNB 278 O75369-8 K1477 [SPLK(me1)ALS]
SY46 DOPEY1 277 Q5JWR5 K1273 [FSFK(me1)EKL]
SY46 DOPEY1 277 Q5JWR5 K1275 [FKEK(me1)LSE]
SY46 DOPEY1 277 Q5JWR5 K414 [ENKK(me1)TAE]
pan-Kme1 BAHCC1 277 Q9P281 K659 [GGLK(me1)ASC]
pan-Kme1 BAHCC1 277 Q9P281 K713 [ARQK(me1)DTV]
SY46 SPTBN1 275 Q01082 K1156 [ELHK(me1)MWE]
pan-Kme1 ANKRD17 274 O75179 K879 [LQLK(me1)TQQ]
pan-Kme1 PRPF8 274 Q6P2Q9 K1443 [TDFK(me1)QYQ]
pan-Kme1 TLN1 270 Q9Y490 K1332 [PNLK(me1)SQL]
pan-Kme1 TLN1 270 Q9Y490 K2266 [PELK(me1)QQL]
pan-Kme1 NAV2 268 Q8IVL1 K59 [IPLK(me1)SQV]
pan-Kme1 CASC5 265 Q8NG31 K846 [GVLK(me1)SNC]
pan-Kme1 AHCTF1 252 Q8WYP5 K969 [PALK(me1)LNQ]
pan-Kme1 ASCC3 251 Q8N3C0 K1382 [APLK(me1)ALV]
pan-Kme1 ASCC3 251 Q8N3C0 K938 [ISHK(me1)AYQ]
pan-Kme1 RTTN 249 Q86VV8 K1882 [HALK(me1)ANL]
pan-Kme1 SVIL 248 O95425 K927 [SILK(me1)SQA]
pan-Kme1 CABIN1 246 Q9Y6J0 K2173 [QKLK(me1)SAI]
pan-Kme1 CAD 243 P27708 K1301 [AYLK(me1)AML]
pan-Kme1 CAD 243 P27708 K186 [CGLK(me1)YNQ]
pan-Kme1 CAD 243 P27708 K1963 [LKGK(me1)VMA]
pan-Kme1 MYOF 235 Q9NZM1 K1416 [PQLK(me1)ASL]
pan-Kme1 FANCM 232 Q8IYD8 K1343 [PLSK(me1)SNT]
pan-Kme1 RALGAPA1 230 Q6GYQ0 K1133 [WLFK(me1)ATM]
pan-Kme1 MYH9 227 P35579 K1918 [SSLK(me1)NKL]
pan-Kme1 MYH9 227 P35579 K1920 [LKNK(me1)LRR]
pan-Kme1 DOCK4 225 Q8N1I0 K1818 [SPLK(me1)GSV]
pan-Kme1 MICAL3 224 Q7RTP6 K1364 [VSLK(me1)SYS]
pan-Kme1 HEATR5A 222 Q86XA9 K2036 [IQLK(me1)TSF]
pan-Kme1 TANC2 220 Q9HCD6 K7 [NSLK(me1)MLL]
pan-Kme1 ARHGAP21 217 Q5T5U3 K346 [ILLK(me1)SGN]
pan-Kme1 ARHGAP21 217 Q5T5U3 K590 [PDLK(me1)TLQ]
pan-Kme1 ARHGAP21 217 Q5T5U3 K897 [LSFK(me1)HVS]
pan-Kme1 POLR2A 217 P24928 K767 [NNFK(me1)SMV]
SY46 ALG9 215 Q9H6U8 K11 [QRLK(me1)GSG]
pan-Kme1 DOCK5 215 Q9H7D0 K1765 [QRPK(me1)SLQ]
pan-Kme1 KIAA1217 214 Q5T5P2 K1872 [HTGK(me1)GHH]
pan-Kme1 NUP214 214 P35658 K1037 [PFAK(me1)SHL]
pan-Kme1 NUP214 214 P35658 K640 [VPLK(me1)SSV]
pan-Kme1 MYLK 211 Q15746 K1101 [PAFK(me1)QKL]
pan-Kme1 MYLK 211 Q15746 K1103 [FKQK(me1)LQD]
SY46 TNRC6A 210 Q8NDV7-3 K5 [LQDK(me1)RME]
pan-Kme1 PDCD11 209 Q14690 K219 [PLLK(me1)AQE]
pan-Kme1 MLLT4 207 P55196-1 K1699 [SYLK(me1)TQV]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 ECM29 204 Q5VYK3 K1099 [NSRK(me1)GAA]
pan-Kme1 ARFGEF2 202 Q9Y6D5 K1026 [GSLK(me1)GHT]
pan-Kme1 RBBP6 202 Q7Z6E9 K208 [PNMK(me1)GAM]
pan-Kme1 SIPA1L1 200 O43166 K776 [TFPK(me1)SNV]
pan-Kme1 CARD11 197 Q9BXL7 K1050 [AKNK(me1)HCL]
pan-Kme1 POLR1A 195 O95602 K1049 [VIMK(me1)SQH]
pan-Kme1 ITSN2 193 Q9NZM3 K902 [ENLK(me1)AQA]
pan-Kme1 ARAP2 193 Q8WZ64 K439 [RTQK(me1)ALI]
pan-Kme1 LMO7 193 Q8WWI1-3 K1241 [GSVK(me1)TST]
SY46 RICTOR 192 Q6R327 K1304 [QSLK(me1)APS]
pan-Kme1 ARHGEF28 192 Q8N1W1 K545 [LQSK(me1)ESL]
pan-Kme1 PIK3C2A 191 O00443 K326 [VNGK(me1)SLS]
pan-Kme1 TIAM2 190 Q8IVF5 K69 [SHFK(me1)SNQ]
pan-Kme1 IQGAP1 189 P46940 K942 [KKNK(me1)EQL]
pan-Kme1 FAM208A 189 Q9UK61 K360 [TLWK(me1)GQL]
pan-Kme1 AIM1 189 Q9Y4K1 K988 [GLFK(me1)SSR]
SY46 ADCY10 187 Q96PN6-3 K4 [MLFK(me1)AYM]
pan-Kme1 EIF2AK4 187 Q9P2K8 K535 [QLLK(me1)HSF]
pan-Kme1 KIF14 186 Q15058 K41 [LHLK(me1)SDM]
pan-Kme1 IQGAP3 185 Q86VI3 K1152 [KVLK(me1)ATL]
pan-Kme1 MADD 183 Q8WXG6-3 K884 [PSLK(me1)GNR]
pan-Kme1 TOP2B 183 Q02880 K412 [FGSK(me1)CQL]
pan-Kme1 TOP2B 183 Q02880 K957 [QVYK(me1)EQV]
pan-Kme1 DNMT1 183 P26358 K142 [RRSK(me1)SDG]
both TNKS1BP1 182 Q9C0C2 K1641 [LGTK(me1)GLK]
both TNKS1BP1 182 Q9C0C2 K1644 [KGLK(me1)VNL]
both API5 182 Q9BZZ5-2 K487 [PSGK(me1)YSS]
pan-Kme1 TNKS1BP1 182 Q9C0C2 K80 [SARK(me1)MNM]
pan-Kme1 NHS 179 Q6T4R5 K1591 [FSSK(me1)SFA]
pan-Kme1 CDC42EP4 179 Q9H3Q1 K5 [PILK(me1)QLV]
pan-Kme1 CAMSAP1 178 Q5T5Y3 K211 [VKLK(me1)QQL]
pan-Kme1 CAMSAP1 178 Q5T5Y3 K912 [KLGK(me1)AAF]
SY46 DNMBP 177 Q6XZF7 K1009 [SHLK(me1)HLT]
pan-Kme1 EIF4G3 177 O43432 K1077 [SWGK(me1)GSS]
pan-Kme1 TOP2A 174 P11388 K936 [QTYK(me1)EQV]
SY46 BAI1 174 O14514 K1126 [ITDK(me1)KLK]
pan-Kme1 EPRS 171 P07814 K861 [LSLK(me1)AQY]
pan-Kme1 TULP4 169 Q9NRJ4 K1014 [PLAK(me1)SKG]
pan-Kme1 TULP4 169 Q9NRJ4 K997 [ATLK(me1)MAQ]
pan-Kme1 ERCC6 168 Q03468 K729 [TAYK(me1)CAC]
pan-Kme1 CAMSAP2 168 Q08AD1 K368 [NAAK(me1)RNV]
both GLI2 168 P10070 K738 [EKLK(me1)SLK]
both GLI2 168 P10070 K741 [KSLK(me1)DSC]
pan-Kme1 CLIP1 162 P30622 K509 [VSEK(me1)SRI]
pan-Kme1 CLIP1 162 P30622 K517 [ELEK(me1)DLA]
pan-Kme1 ROCK2 161 O75116 K1368 [TSMK(me1)IQQ]
– –
PhD Thesis Supplement
Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 FGD6 161 Q6ZV73 K175 [VVLK(me1)ASV]
pan-Kme1 FGD6 161 Q6ZV73 K650 [FWSK(me1)SSQ]
pan-Kme1 DAPK1 160 P53355 K700 [GSGK(me1)TTL]
pan-Kme1 DAPK1 160 P53355 K708 [ESLK(me1)CGL]
pan-Kme1 BLM 159 P54132 K195 [NFFK(me1)AQL]
pan-Kme1 ERBB2IP 158 Q96RT1 K869 [SVVK(me1)SHS]
pan-Kme1 ERBB2IP 158 Q96RT1 K914 [VRSK(me1)SAT]
pan-Kme1 BCL9L 157 Q86UU0 K83 [HGAK(me1)ANQ]
pan-Kme1 INSR 156 P06213 K1352 [LGFK(me1)RSY]
pan-Kme1 TAOK3 156 Q9H2K8 K738 [KALK(me1)NHQ]
pan-Kme1 ANKRD50 156 Q9ULJ7 K1185 [NSLK(me1)SSK]
pan-Kme1 POGZ 155 Q7Z3K3 K480 [DGGK(me1)VAQ]
pan-Kme1 NUP153 154 P49790 K250 [SILK(me1)TSQ]
pan-Kme1 NUP153 154 P49790 K292 [RQMK(me1)AKQ]
pan-Kme1 NUP153 154 P49790 K294 [MKAK(me1)QLS]
pan-Kme1 RAD50 154 Q92878 K458 [NELK(me1)NVK]
pan-Kme1 TECPR2 154 O15040 K1101 [HVAK(me1)GSL]
pan-Kme1 MSH6 153 P52701 K1092 [LELK(me1)GSR]
both WHSC1 152 O96028 K582 [SSLK(me1)SQA]
SY46 WHSC1 152 O96028 K588 [AATK(me1)NLS]
pan-Kme1 ACIN1 152 Q9UKV3 K81 [TDLK(me1)AAL]
pan-Kme1 PARD3 151 Q8TEW0 K1018 [GMLK(me1)GLG]
pan-Kme1 PARD3 151 Q8TEW0-10 K984 [GMLK(me1)GLG]
pan-Kme1 KIF7 151 Q2M1P5 K869 [LELK(me1)HEQ]
pan-Kme1 PLCG1 149 P19174 K178 [KDLK(me1)NML]
SY46 RNF123 149 Q5XPI4 K991 [HLLK(me1)TKL]
SY46 RNF123 149 Q5XPI4 K993 [LKTK(me1)LED]
pan-Kme1 CLUH 147 O75153 K384 [AIFK(me1)VHS]
SY46 SPAG9 146 O60271 K577 [VNLK(me1)YNA]
pan-Kme1 VPS33B 143 Q9H267 K419 [RSLK(me1)TQY]
pan-Kme1 TRAPPC10 142 P48553 K507 [GALK(me1)NYL]
SY46 PHLDB2 142 Q86SQ0 K50 [LRFK(me1)ANG]
pan-Kme1 DHX9 141 Q08211 K1024 [LIHK(me1)SSV]
pan-Kme1 MTR 141 Q99707 K461 [AGLK(me1)CCQ]
pan-Kme1 EIF5B 139 O60841 K424 [ATLK(me1)LLQ]
pan-Kme1 TIMELESS 139 Q9UNS1 K288 [QGLK(me1)SIG]
pan-Kme1 EDRF1 139 Q3B7T1 K140 [PYSK(me1)SHV]
pan-Kme1 SSFA2 138 P28290 K701 [AQMK(me1)VCS]
pan-Kme1 TPP2 138 P29144 K1187 [FAYK(me1)HAL]
pan-Kme1 TPP2 138 P29144 K467 [SGLK(me1)ANN]
pan-Kme1 SKIV2L 138 Q15477 K837 [NGLK(me1)SLS]
SY46 RAB11FIP1 137 Q6WKZ4 K284 [TDLK(me1)QLN]
both RAPH1 135 Q70E73 K129 [HTLK(me1)HGT]
both RAPH1 135 Q70E73 K134 [GTLK(me1)GLS]
pan-Kme1 VCPIP1 134 Q96JH7 K1028 [FQGK(me1)GHS]
pan-Kme1 POLR2B 134 P30876 K445 [DGLK(me1)YSL]
– –
PhD Thesis Supplement
Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 RTEL1 134 Q9NZ71 K216 [RNLK(me1)QQA]
SY46 NAA15 133 Q9BXJ9 K756 [TFLK(me1)RNS]
pan-Kme1 RECQL4 133 O94761 K110 [QRLK(me1)ANL]
pan-Kme1 RECQL4 133 O94761 K114 [ANLK(me1)GTL]
both FNDC3B 133 Q53EP0 K215 [SIYK(me1)SSC]
SY46 FNDC3B 133 Q53EP0 K227 [GYGK(me1)GHS]
pan-Kme1 REXO1 132 Q8N1G1 K921 [EDLK(me1)GAA]
pan-Kme1 ARHGEF18 131 Q6ZSZ5 K1080 [FDLK(me1)QQL]
pan-Kme1 BMP2K 129 Q9NSY1-2 K656 [GHLK(me1)AYF]
pan-Kme1 ENAM 129 Q9NRM1 K21 [LVPK(me1)GKM]
pan-Kme1 ENAM 129 Q9NRM1 K23 [PKGK(me1)MKI]
SY46 TBC1D8B 129 Q0IIM8 K453 [KMLK(me1)EKM]
pan-Kme1 RBM6 129 P78332 K36 [PPLK(me1)SHA]
SY46 RASAL2 129 Q9UJF2 K662 [HKLK(me1)SPS]
pan-Kme1 INPP5F 128 Q9Y2H2 K774 [AQGK(me1)NFL]
pan-Kme1 RFC1 128 P35251 K645 [SSFK(me1)AAL]
both MICAL2 127 O94851-4 K646 [SLAK(me1)SSI]
pan-Kme1 RGSL1 126 A5PLK6 K616 [EIIK(me1)ETK]
pan-Kme1 TEX2 125 Q8IWB9 K383 [IELK(me1)SSQ]
pan-Kme1 POLD1 124 P28340 K414 [QTLK(me1)VQT]
pan-Kme1 RAB3GAP2 124 Q9H2M9 K913 [QTSK(me1)VSS]
pan-Kme1 NEMF 123 O60524 K311 [IDLK(me1)ALQ]
pan-Kme1 AASDH 123 Q4L235 K720 [QNLK(me1)GLN]
pan-Kme1 USP28 122 Q96RU2 K402 [YRSK(me1)ELI]
both LIMCH1 122 Q9UPQ0 K588 [SLTK(me1)SQM]
pan-Kme1 SECISBP2L 122 Q93073 K176 [VVPK(me1)QQL]
both RABGAP1 122 Q9Y3P9 K445 [PFSK(me1)RST]
pan-Kme1 MAP4 121 P27816 K933 [PDLK(me1)NVR]
pan-Kme1 USP53 121 Q70EK8 K536 [SSSK(me1)SQI]
SY46 FAM120C 121 Q9NX05 K674 [TQRK(me1)MER]
pan-Kme1 AP3B2 119 Q13367 K120 [RGLK(me1)DPN]
pan-Kme1 U2SURP 118 O15042 K392 [ERLK(me1)NPN]
pan-Kme1 U2SURP 118 O15042 K82 [NKLK(me1)AFS]
pan-Kme1 PHF8 118 Q9UPP1 K486 [NVGK(me1)TSN]
pan-Kme1 UBA1 118 P22314 K304 [ISFK(me1)SLV]
pan-Kme1 ANKRD27 117 Q96NW4 K603 [TPLK(me1)CAL]
pan-Kme1 MPRIP 117 Q6WCQ1 K200 [PTTK(me1)STL]
pan-Kme1 PSD3 116 Q9NYI0 K124 [SHLK(me1)EQS]
pan-Kme1 BMPR2 115 Q13873 K219 [AVYK(me1)GSL]
pan-Kme1 ANKRD52 115 Q8NB46 K1036 [SLLK(me1)NCS]
pan-Kme1 NNT 114 Q13423 K6 [NLLK(me1)TVV]
SY46 NEFH 112 P12036 K663 [SPEK(me1)EEA]
pan-Kme1 USP15 112 Q9Y4E8 K259 [RNVK(me1)NSN]
pan-Kme1 ZC3H7B 112 Q9UGR2 K689 [HAGK(me1)ASS]
pan-Kme1 ARHGEF2 112 Q92974 K100 [ALLK(me1)NNT]
pan-Kme1 SEC23IP 111 Q9Y6Y8 K871 [SDLK(me1)QGF]
– –
PhD Thesis Supplement
Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 DENND1A 111 Q8TEH3 K314 [AFLK(me1)AQA]
pan-Kme1 ZBED6 110 P86452 K250 [FLIK(me1)SNI]
pan-Kme1 INPP4A 110 Q96PE3 K321 [PSFK(me1)ASS]
pan-Kme1 SMG8 110 Q8ND04 K242 [PLLK(me1)TAI]
pan-Kme1 DIS3 109 Q9Y2L1 K331 [RMLK(me1)TAV]
pan-Kme1 DIS3 109 Q9Y2L1 K585 [INSK(me1)ASL]
pan-Kme1 COG1 109 Q8WTW3 K506 [LSMK(me1)AQA]
both THRAP3 109 Q9Y2W1 K252 [PALK(me1)SPL]
pan-Kme1 RBM15 107 Q96T37 K420 [GFLK(me1)FEN]
pan-Kme1 ZC3H18 106 Q86VM9 K229 [FFMK(me1)GNC]
pan-Kme1 SLK 105 Q9H2G2 K379 [LNSK(me1)ILN]
pan-Kme1 BBX 105 Q8WY36 K518 [SSGK(me1)GSI]
pan-Kme1 CASK 105 O14936 K305 [RKLK(me1)GAV]
pan-Kme1 CASK 105 O14936 K703 [WFGK(me1)KKK]
pan-Kme1 ZNF618 105 Q5T7W0 K950 [MFLK(me1)SNM]
pan-Kme1 PACS1 105 Q6VY07 K903 [VDSK(me1)SQV]
pan-Kme1 ZFPM1 105 Q8IX07 K168 [IHRK(me1)DDA]
pan-Kme1 CUL4B 104 Q13620-1 K142 [LKNK(me1)SIL]
pan-Kme1 GPATCH1 103 Q9BRR8 K456 [TDLK(me1)AAQ]
pan-Kme1 TUBGCP2 103 Q9BSJ2 K714 [KNLK(me1)SAS]
both EIF4G2 102 P78344 K431 [KFMK(me1)SQG]
pan-Kme1 EIF4G2 102 P78344 K464 [FSKK(me1)GQL]
pan-Kme1 KIF18A 102 Q8NI77 K360 [SSLK(me1)SNV]
pan-Kme1 TRAK2 101 O60296 K831 [GQLK(me1)MNL]
SY46 WDR44 101 Q5JSH3 K486 [VKFK(me1)AAH]
SY46 WDR44 101 Q5JSH3 K492 [HGFK(me1)GPY]
pan-Kme1 KIFC1 101 Q9BW19 K308 [QELK(me1)GNI]
pan-Kme1 ADNP 101 Q9H2P0 K408 [GQLK(me1)SPS]
pan-Kme1 GTF3C2 101 Q8WUA4 K148 [RKSK(me1)AEL]
pan-Kme1 CORO7 101 P57737 K491 [TNLK(me1)GLN]
pan-Kme1 DDHD1 100 Q8NEL9 K744 [NIGK(me1)ASI]
SY46 SYNPO 99 Q8N3V7 K599 [SHLK(me1)GQA]
SY46 SYNPO 99 Q8N3V7 K607 [PASK(me1)TGI]
pan-Kme1 SMTN 99 P53814 K751 [ELMK(me1)AQS]
pan-Kme1 PPP1R10 99 Q96QC0 K918 [FMMK(me1)GNC]
pan-Kme1 LRRC8D 98 Q7L1W4 K806 [LELK(me1)GNC]
pan-Kme1 DNM2 98 P50570 K44 [SAGK(me1)SSV]
pan-Kme1 COPG1 98 Q9Y678 K145 [RYMK(me1)QAI]
pan-Kme1 COPG2 98 Q9UBF2 K145 [RYMK(me1)QAI]
pan-Kme1 SMEK2 97 Q5MIZ7 K753 [ETKK(me1)AKE]
pan-Kme1 SMEK2 97 Q5MIZ7 K755 [KKAK(me1)ESE]
SY46 AKAP1 97 Q92667 K440 [SCLK(me1)SLL]
pan-Kme1 RHBDF2 97 Q6PJF5 K87 [AYLK(me1)SVS]
pan-Kme1 EXD3 97 Q8N9H8 K702 [CSLK(me1)AQQ]
pan-Kme1 PRICKLE2 96 Q7Z3G6 K820 [GLPK(me1)SST]
pan-Kme1 PAN3 96 Q58A45 K496 [RIQK(me1)SSN]
– –
PhD Thesis Supplement
Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 SMEK1 95 Q6IN85 K733 [VLLK(me1)TNL]
both ILF3 95 Q12906 K613 [GGPK(me1)FAA]
pan-Kme1 HSPA4L 95 O95757 K53 [NAAK(me1)SQI]
pan-Kme1 HSPA4 94 P34932 K53 [AAAK(me1)SQV]
pan-Kme1 CC2D1B 94 Q5T0F9 K785 [IFHK(me1)GSF]
pan-Kme1 CCSER2 94 Q9H7U1 K115 [GGLK(me1)SVS]
pan-Kme1 DOCK5 94 Q9H7D0 K1741 [SLSK(me1)SQV]
SY46 CALD1 93 Q05682 K504 [HKLK(me1)HTE]
both BCAR3 93 O75815 K334 [LSLK(me1)AHQ]
pan-Kme1 HSP90B1 92 P14625 K663 [RIMK(me1)AQA]
pan-Kme1 RBM5 92 P52756 K780 [VRLK(me1)GAG]
pan-Kme1 RBM5 92 P52756 K787 [LGAK(me1)GSA]
pan-Kme1 ANAPC4 92 Q9UJX5 K718 [ESMK(me1)AQY]
pan-Kme1 AFAP1L2 91 Q8N4X5 K332 [AGLK(me1)LSN]
SY46 BANK1 89 Q8NDB2 K79 [TSYK(me1)CKL]
pan-Kme1 PPP1R13L 89 Q8WUF5 K28 [MDLK(me1)QME]
SY46 PPP1R13L 89 Q8WUF5 K522 [RPLK(me1)RRG]
pan-Kme1 VEZT 89 Q9HBM0 K593 [LGFK(me1)ASE]
pan-Kme1 AFG3L2 89 Q9Y4W6 K618 [LYTK(me1)EQL]
pan-Kme1 MAPK7 88 Q13164 K480 [AALK(me1)AAL]
both IFI16 88 Q16666 K186 [ENPK(me1)TVA]
pan-Kme1 AARSD1 88 Q9BTE6-2 K378 [ALLK(me1)CGA]
pan-Kme1 DIEXF 87 Q68CQ4 K245 [IDLK(me1)SLH]
pan-Kme1 ERCC2 87 P18074 K133 [VDGK(me1)CHS]
pan-Kme1 TLK1 87 Q9UKI8-3 K3 [_MLK(me1)LAA]
pan-Kme1 AFAP1L1 86 Q8TED9 K383 [AELK(me1)GSM]
both TBC1D12 86 O60347 K335 [KELK(me1)SVV]
both TBC1D12 86 O60347 K345 [PGWK(me1)LFG]
SY46 ACO2 85 Q99798 K409 [HGLK(me1)CKS]
pan-Kme1 EZH2 85 Q15910 K735 [DALK(me1)YVG]
pan-Kme1 LIMA1 85 Q9UHB6 K292 [NELK(me1)ASG]
SY46 LIMA1 85 Q9UHB6 K447 [QLFK(me1)SKG]
SY46 LIMA1 85 Q9UHB6 K603 [TSVK(me1)SPK]
pan-Kme1 KIF3B 85 O15066 K583 [LKLK(me1)HLI]
pan-Kme1 TATDN2 85 Q93075 K189 [IYLK(me1)AIQ]
both HSP90AA1 85 P07900 K615 [RIMK(me1)AQA]
pan-Kme1 FAM129B 84 Q96TA1 K401 [HPLK(me1)MQS]
SY46 MAP7 84 Q14244 K136 [EEDK(me1)ERH]
pan-Kme1 GYS1 84 P13807 K381 [ETLK(me1)GQA]
pan-Kme1 BOP1 84 Q14137 K711 [KVLK(me1)GHV]
both HSP90AB1 83 P08238 K607 [RIMK(me1)AQA]
pan-Kme1 THNSL1 83 Q8IYQ7 K568 [DILK(me1)SSN]
pan-Kme1 GOLGA5 83 Q8TBA6 K74 [RNQK(me1)ATI]
pan-Kme1 OAS2 82 P29728 K419 [NSLK(me1)SYT]
pan-Kme1 MCM5 82 P33992 K141 [RSLK(me1)SDM]
pan-Kme1 C1orf168 82 Q5VWT5 K604 [DKLK(me1)MWK]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 EPB41L5 82 Q9HCM4 K563 [PDFK(me1)SNI]
pan-Kme1 EPB41L5 82 Q9HCM4 K568 [NILK(me1)AQV]
SY46 SLC26A2 82 P50443 K503 [DLPK(me1)MWS]
pan-Kme1 KIF2C 81 Q99661 K354 [GSGK(me1)THT]
pan-Kme1 KIF2C 81 Q99661 K365 [LSGK(me1)AQN]
pan-Kme1 DDHD2 81 O94830 K587 [MDLK(me1)NNL]
pan-Kme1 AKAP17A 81 Q02040 K56 [ERLK(me1)GMV]
pan-Kme1 RTF1 80 Q92541 K587 [HNMK(me1)NQQ]
pan-Kme1 DTL 79 Q9NZJ0 K537 [VSQK(me1)SSQ]
pan-Kme1 BBS12 79 Q6ZW61 K217 [RTLK(me1)NSL]
pan-Kme1 MPHOSPH10 79 O00566 K641 [KALK(me1)SSQ]
pan-Kme1 UVRAG 78 Q9P2Y5 K455 [PNLK(me1)NFM]
pan-Kme1 PRPF3 78 O43395 K282 [PTLK(me1)ANI]
both CAST 77 P20810-9 K303 [EVLK(me1)AQS]
pan-Kme1 NUFIP2 76 Q7Z417 K136 [TSLK(me1)QTV]
pan-Kme1 TMPO 75 P42166 K674 [TPFK(me1)GGT]
pan-Kme1 ZNF800 75 Q2TB10 K58 [KQLK(me1)HIL]
both GAS2L3 75 Q86XJ1 K360 [SSLK(me1)GGN]
pan-Kme1 FIGNL1 74 Q6PIW4 K126 [KKFK(me1)DSL]
pan-Kme1 FIGNL1 74 Q6PIW4 K296 [PTFK(me1)TAK]
pan-Kme1 FIGNL1 74 Q6PIW4 K299 [KTAK(me1)EQL]
pan-Kme1 PATZ1 74 Q9HBE1 K272 [RPRK(me1)ANL]
pan-Kme1 SARG 74 Q9BW04 K511 [SLGK(me1)GSF]
pan-Kme1 SLC24A2 74 Q9UI40 K288 [QVEK(me1)WVK]
pan-Kme1 SLC24A2 74 Q9UI40 K291 [KWVK(me1)QMI]
pan-Kme1 DDX3X 73 O00571 K81 [SRGK(me1)SSF]
pan-Kme1 AGPS 73 O00116 K628 [QWLK(me1)ESI]
pan-Kme1 TNK1 72 Q13470 K475 [DRKK(me1)ANL]
both HSPA5 72 P11021 K585 [LGGK(me1)LSS]
SY46 SAMHD1 72 Q9Y3Z3 K312 [DVDK(me1)WDY]
pan-Kme1 THEMIS2 72 Q5TEJ8 K573 [GGVK(me1)SSQ]
pan-Kme1 MTMR6 72 Q9Y217 K565 [PNLK(me1)TSL]
pan-Kme1 CD2AP 71 Q9Y5K6 K397 [PPTK(me1)ASN]
both CD2AP 71 Q9Y5K6 K557 [SASK(me1)ANT]
pan-Kme1 TRIM25 71 Q14258 K416 [VDLK(me1)QAG]
SY46 SCG2 71 P13521 K274 [NIEK(me1)NEQ]
SY46 SCG2 71 P13521 K283 [DEMK(me1)RSG]
both TXNRD1 71 Q16881 K138 [PTLK(me1)AYQ]
SY46 HSPA8 71 P11142 K251 [KHKK(me1)DIS]
pan-Kme1 HSPA8 71 P11142 K3 [_MSK(me1)GPA]
pan-Kme1 PABPC4 71 Q13310 K375 [EERK(me1)AHL]
pan-Kme1 LBR 71 Q14739 K147 [APHK(me1)NTQ]
pan-Kme1 WNT5B 71 Q9H1J7 K327 [NQFK(me1)SVQ]
pan-Kme1 VPS33B 71 Q9H267 K59 [SILK(me1)QHE]
pan-Kme1 HSPA1A 70 P0DMV8 K3 [_MAK(me1)AAA]
pan-Kme1 PHACTR2 70 O75167 K29 [PPFK(me1)RKG]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
both DENND6A 70 Q8IWF6 K510 [HFLK(me1)SPN]
pan-Kme1 TRIM47 70 Q96LD4 K361 [SFTK(me1)SSQ]
pan-Kme1 BTBD9 69 Q96Q07-2 K344 [PELK(me1)QSS]
pan-Kme1 DDX5 69 P17844 K197 [CRLK(me1)STC]
pan-Kme1 FAM107B 69 Q9H098 K25 [NPVK(me1)TSR]
pan-Kme1 ARHGAP40 69 Q5TG30 K145 [SGMK(me1)GAQ]
pan-Kme1 ZNF143 69 P52747 K285 [YGLK(me1)SHV]
SY46 SNX18 69 Q96RF0 K290 [TKFK(me1)GMK]
both SNX18 69 Q96RF0 K293 [KGMK(me1)SYI]
pan-Kme1 GNL1 69 P36915 K373 [NVGK(me1)SSL]
SY46 EPN2 68 O95208 K423 [SAGK(me1)RAS]
pan-Kme1 PPP1R18 68 Q6NYC8 K8 [PDWK(me1)LQL]
pan-Kme1 ZNF668 68 Q96K58 K337 [RPFK(me1)CLQ]
pan-Kme1 MSN 68 P26038 K143 [EVHK(me1)SGY]
pan-Kme1 STXBP3 68 O00186 K11 [RGLK(me1)SVV]
pan-Kme1 ARAF 68 P10398 K431 [RDLK(me1)SNN]
pan-Kme1 WDR1 66 O75083 K334 [NGGK(me1)SYI]
pan-Kme1 NOP56 66 O00567 K375 [LANK(me1)CSI]
pan-Kme1 KLC1 65 Q07866-6 K548 [GSLK(me1)RSG]
pan-Kme1 CDKAL1 65 Q5VV42 K150 [DYLK(me1)GLS]
pan-Kme1 FRMD5 65 Q7Z6J6 K313 [LFFK(me1)GSR]
pan-Kme1 CHMP4B 65 Q9H444 K107 [EVLK(me1)NMG]
pan-Kme1 BIN1 65 O00499 K7 [MGSK(me1)GVT]
pan-Kme1 C3orf17 65 Q6NW34 K332 [FDFK(me1)CSQ]
pan-Kme1 ASNS 64 P08243 K467 [WRPK(me1)EAF]
pan-Kme1 ASNS 64 P08243 K556 [THYK(me1)SAV]
pan-Kme1 SARG 64 Q9BW04 K480 [MNFK(me1)SNT]
pan-Kme1 RIOK2 64 Q9BVS4 K531 [IFTK(me1)QRR]
pan-Kme1 PDLIM5 64 Q96HC4 K116 [AVSK(me1)VTS]
pan-Kme1 RAVER1 64 Q8IY67 K587 [PAQK(me1)AAM]
pan-Kme1 RAVER1 64 Q8IY67-2 K657 [AGLK(me1)QSH]
pan-Kme1 ZFP91 63 Q96JP5 K174 [SRSK(me1)TGS]
pan-Kme1 UTP14A 63 Q9BVJ6 K136 [AFNK(me1)TAQ]
pan-Kme1 RIOK2 63 Q9BVS4 K541 [QNIK(me1)SSL]
pan-Kme1 CPNE8 63 Q86YQ8 K405 [RSLK(me1)SVQ]
pan-Kme1 NARS 63 O43776 K31 [TGLK(me1)ALM]
pan-Kme1 WDR20 63 Q8TBZ3 K446 [AGSK(me1)SSV]
pan-Kme1 SLC22A5 63 O76082 K553 [TILK(me1)STA]
both PIP5K1A 63 Q99755 K86 [SALK(me1)GAI]
both CAMK2G 63 Q13555 K301 [RKLK(me1)GAI]
pan-Kme1 GMEB1 63 Q9Y692 K359 [HRLK(me1)SQT]
pan-Kme1 SLAIN2 63 Q9P270 K182 [SALK(me1)RQN]
pan-Kme1 SLAIN2 63 Q9P270 K429 [DSVK(me1)SSR]
pan-Kme1 GLUD1 61 P00367 K171 [MTYK(me1)CAV]
pan-Kme1 FAM114A1 61 Q8IWE2 K135 [SWGK(me1)SLL]
pan-Kme1 PAF1 60 Q8N7H5 K62 [VQYK(me1)ATS]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 CCT7 59 Q99832 K430 [IPGK(me1)QQL]
pan-Kme1 OASL 59 Q15646 K331 [QCLK(me1)QDC]
both ATE1 59 O95260 K285 [SQFK(me1)ATL]
pan-Kme1 KIAA1671 59 Q9BY89 K853 [RAIK(me1)AAI]
pan-Kme1 SPATA2 58 Q9UM82 K510 [LNYK(me1)STQ]
pan-Kme1 CCT4 58 P50991 K65 [QDGK(me1)GDV]
both ZNF513 58 Q8N8E2 K166 [SHLK(me1)RHM]
pan-Kme1 DKC1 58 O60832 K394 [LMIK(me1)QGL]
pan-Kme1 ARFGAP2 57 Q8N6H7 K209 [LELK(me1)SSI]
pan-Kme1 DYNC1LI1 57 Q9Y6G9 K435 [PNMK(me1)AGA]
SY46 CAMK2D 56 Q13557 301 [RKLK(me1)GAI]
pan-Kme1 CAMK2D 56 Q13557 K301 [RKLK(me1)GAI]
pan-Kme1 LAP3 56 P28838-2 K3 [_MTK(me1)GLV]
pan-Kme1 CBX2 56 Q14781 K277 [LALK(me1)AQA]
pan-Kme1 SHMT2 56 P34897 K469 [QDFK(me1)SFL]
pan-Kme1 IMPDH2 56 P12268 K195 [ITLK(me1)EAN]
pan-Kme1 SRP54 56 P61011 K496 [GNMK(me1)GMM]
pan-Kme1 PRPF31 55 Q8WWY3 K438 [YGGK(me1)STI]
pan-Kme1 RTCB 55 Q9Y3I0 K308 [DYLK(me1)GMA]
pan-Kme1 PRPF19 55 Q9UMS4 K428 [KNFK(me1)TLQ]
pan-Kme1 ZMPSTE24 55 O75844 K437 [ALIK(me1)LNK]
pan-Kme1 ICA1 55 Q05084 K118 [ATGK(me1)ALC]
pan-Kme1 YAP1 54 P46937 K321 [LRLK(me1)QQE]
SY46 WASF2 54 Q9Y6W5 K109 [QDQK(me1)LFD]
pan-Kme1 NONO 54 Q15233 K5 [QSNK(me1)TFN]
pan-Kme1 DLD 54 P09622 K66 [LGFK(me1)TVC]
pan-Kme1 FBXW9 54 Q5XUX1-3 K301 [ALLK(me1)HQQ]
pan-Kme1 ZBTB45 54 Q96K62 K448 [YLLK(me1)HMV]
pan-Kme1 ZNF518B 54 Q9C0D4 K482 [VALK(me1)GHS]
pan-Kme1 ETV4 54 P43268 K6 [RRMK(me1)AGY]
pan-Kme1 TRIM38 53 O00635 K222 [LGLK(me1)SNE]
pan-Kme1 ACOT2 53 P49753 K39 [WSLK(me1)SSA]
pan-Kme1 EPHX1 53 P07099 K117 [PHFK(me1)TKI]
pan-Kme1 EPHX1 53 P07099 K119 [FKTK(me1)IEG]
pan-Kme1 MINA 53 Q8IUF8 K87 [TDLK(me1)SLC]
pan-Kme1 PPHLN1 53 Q8NEY8-2 K206 [QSLK(me1)TSR]
pan-Kme1 SNX8 53 Q9Y5X2 K103 [QRFK(me1)SSV]
pan-Kme1 DGCR14 53 Q96DF8 K358 [LGLK(me1)MAN]
SY46 DGCR14 53 Q96DF8 K429 [THLK(me1)TPA]
both SAMM50 52 Q9Y512 K255 [HSLK(me1)SSL]
pan-Kme1 SNX4 52 O95219 K356 [FSLK(me1)GMT]
both CAP1 52 Q01518 K287 [PALK(me1)AQS]
pan-Kme1 NSUN6 52 Q8TEA1 K192 [PELK(me1)GMG]
pan-Kme1 POLD3 51 Q15054 K231 [APGK(me1)GNM]
pan-Kme1 ODR4 51 Q5SWX8 K282 [VNLK(me1)GAV]
SY46 TMPO 51 P42167 K303 [GNFK(me1)HAS]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 ERRFI1 51 Q9UJM3 K16 [VPLK(me1)TGF]
pan-Kme1 ERRFI1 51 Q9UJM3 K41 [SEFK(me1)NNF]
pan-Kme1 EEF1A2 50 Q05639 K165 [YSEK(me1)RYD]
pan-Kme1 EEF1A2 50 Q05639 K318 [VSVK(me1)DIR]
both EEF1A2 50 Q05639 K79 [SLWK(me1)FET]
both EEF1A2 50 Q05639 K84 [ETTK(me1)YYI]
SY46 SH3BP5 50 O60239 K217 [LKAK(me1)YYV]
both EEF1A1 50 P68104 K165 [YSQK(me1)RYE]
both EEF1A1 50 P68104 K172 [EIVK(me1)EVS]
pan-Kme1 EEF1A1 50 P68104 K318 [VSVK(me1)DVR]
both EEF1A1 50 P68104 K55 [GSFK(me1)YAW]
pan-Kme1 TUBAL3 50 A6NHL2 K361 [LDHK(me1)FDL]
pan-Kme1 TBL2 50 Q9Y4P3 K276 [FELK(me1)GHS]
pan-Kme1 SDE2 50 Q6IQ49 K173 [SVLK(me1)GMQ]
pan-Kme1 HNRNPH1 49 P31943 K185 [EIFK(me1)SSR]
pan-Kme1 ARMCX1 49 Q9P291 K116 [NTLK(me1)EQA]
pan-Kme1 VPS4A 49 Q9UN37 K23 [DKAK(me1)NYE]
pan-Kme1 ACP6 49 Q9NPH0 K116 [TTLK(me1)GGM]
pan-Kme1 LRRC42 49 Q9Y546 K349 [APLK(me1)CPL]
pan-Kme1 KHDRBS1 48 Q07666 K432 [RPVK(me1)GAY]
both DBNL 48 Q9UJU6 K164 [VYQK(me1)TNA]
pan-Kme1 PIP4K2C 47 Q8TBX8 K220 [YDLK(me1)GSL]
pan-Kme1 ENO1 47 P06733 K343 [LLLK(me1)VNQ]
pan-Kme1 ENO1 47 P06733 K406 [RLAK(me1)YNQ]
SY46 SENP3 47 Q9H4L4 K43 [PRLK(me1)SGG]
pan-Kme1 PLIN3 47 O60664 K166 [DKTK(me1)SVV]
pan-Kme1 EIF4A3 47 P38919 K198 [KGFK(me1)EQI]
SY46 NSUN5 47 Q96P11-2 K144 [NTLK(me1)TCS]
pan-Kme1 TBC1D13 47 Q9NVG8 K168 [TTLK(me1)SQT]
pan-Kme1 LUC7L2 47 Q9Y383 K37 [RVCK(me1)SHL]
pan-Kme1 SUCLG2 47 Q96I99 K218 [GPLK(me1)SQA]
pan-Kme1 SUCLG2 47 Q96I99 K83 [IVLK(me1)AQI]
pan-Kme1 ARRB2 46 P32121 K397 [LRLK(me1)GMK]
pan-Kme1 TSEN34 45 Q9BSV6 K87 [TSFK(me1)RQQ]
both HSDL2 45 Q6YN16 K163 [VWFK(me1)QHC]
both KIN 45 O60870 K221 [TSSK(me1)SST]
SY46 KIN 45 O60870 K231 [SALK(me1)TIG]
pan-Kme1 CCDC85C 45 A6NKD9 K416 [NQFK(me1)GPL]
pan-Kme1 TSPYL5 45 Q86VY4 K108 [GPGK(me1)AAS]
pan-Kme1 RBM17 45 Q96I25 K24 [KNFK(me1)LLQ]
pan-Kme1 RBM17 45 Q96I25 K383 [RVVK(me1)ACF]
pan-Kme1 OLA1 45 Q9NTK5 K24 [TSLK(me1)IGI]
pan-Kme1 YY1 45 P25490 K401 [TNLK(me1)SHI]
pan-Kme1 PGK1 45 P00558-2 K2 [__MK(me1)NNQ]
pan-Kme1 PGK1 45 P00558 K30 [VPMK(me1)NNQ]
both MAP2K4 44 P45985 K45 [KALK(me1)LNF]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
both MAP2K4 44 P45985 K54 [PPFK(me1)STA]
SY46 RRAGC 44 Q9HB90 K387 [SSLK(me1)ALT]
pan-Kme1 PA2G4 44 Q9UQ80 K191 [HQLK(me1)QHV]
pan-Kme1 MAT2A 44 P31153 K367 [LDLK(me1)KPI]
pan-Kme1 PTRF 43 Q6NZI2 K152 [RNFK(me1)VMI]
pan-Kme1 PELO 43 Q9BRX2 K254 [YSLK(me1)EAL]
pan-Kme1 PDHA1 43 P08559 K77 [MELK(me1)ADQ]
pan-Kme1 METAP1 43 P53582 K278 [IIQK(me1)HAQ]
pan-Kme1 GTPBP10 43 A4D1E9 K161 [NAGK(me1)SSL]
pan-Kme1 UBE2Q2 43 Q8WVN8-3 K10 [TEEK(me1)LEC]
pan-Kme1 IDH3G 43 P51553 K115 [VALK(me1)GNI]
pan-Kme1 LDB2 43 O43679-2 K232 [DCLK(me1)TCL]
SY46 LDB2 43 O43679-2 K37 [EMNK(me1)RLQ]
pan-Kme1 SERPINB1 43 P30740 K213 [EDLK(me1)CRV]
SY46 DEK 43 P35659 K84 [AQGK(me1)GQK]
SY46 SAPCD2 43 Q86UD0 K233 [KQMK(me1)ELE]
pan-Kme1 KCTD9 43 Q7L273 K241 [INFK(me1)MAN]
pan-Kme1 RAD9A 43 Q99638 K2 [__MK(me1)CLV]
both WDR74 42 Q6RFH5 K311 [VYLK(me1)SQL]
pan-Kme1 MTHFSD 42 Q2M296 K41 [PNFK(me1)GSY]
pan-Kme1 VAT1 42 Q99536 K372 [DAMK(me1)QMQ]
pan-Kme1 MBNL1 42 Q9NR56 K41 [HPSK(me1)SCQ]
pan-Kme1 AS3MT 42 Q9HBK9 K22 [QVLK(me1)RSA]
pan-Kme1 SH3GL1 41 Q99961 K12 [QFYK(me1)ASQ]
pan-Kme1 SH3GL1 41 Q99961 K67 [SRAK(me1)LTM]
pan-Kme1 SURF6 41 O75683 K7 [LLAK(me1)DAY]
pan-Kme1 AMZ2 41 Q86W34 K12 [QTLK(me1)TAL]
pan-Kme1 PEX14 41 O75381 K220 [NSLK(me1)GLL]
pan-Kme1 PSAT1 40 Q9Y617 K333 [LSLK(me1)GHR]
pan-Kme1 NUCKS1 40 Q9H1E3 K175 [PRLK(me1)ATV]
pan-Kme1 FAM50A 40 Q14320 K5 [AQYK(me1)GAA]
pan-Kme1 FAM50A 40 Q14320 K61 [AELK(me1)SST]
pan-Kme1 FAM50A 40 Q14320 K74 [NDMK(me1)AKQ]
pan-Kme1 SLC25A3 40 Q00325-2 K111 [VTLK(me1)EDG]
pan-Kme1 SLC25A3 40 Q00325-2 K233 [TMMK(me1)FAC]
pan-Kme1 DCDC1 40 P59894 K287 [IRMK(me1)KLT]
pan-Kme1 DCDC1 40 P59894 K288 [RMKK(me1)LTE]
pan-Kme1 MCUR1 40 Q96AQ8 K257 [HQLK(me1)QQV]
both RFC4 40 P35249 K6 [AFLK(me1)GTS]
both ALDOA 39 P04075 K322 [ENLK(me1)AAQ]
pan-Kme1 TNIP3 39 Q96KP6 K247 [SQIK(me1)ACQ]
pan-Kme1 TNIP3 39 Q96KP6 K253 [QMEK(me1)EKL]
pan-Kme1 CDC37L1 39 Q7L3B6 K62 [EFVK(me1)SSV]
pan-Kme1 AVEN 39 Q9NQS1 K230 [MQLK(me1)GPL]
pan-Kme1 AVEN 39 Q9NQS1 K245 [FELK(me1)SVA]
pan-Kme1 GPALPP1 38 Q8IXQ4 K335 [SHGK(me1)GNM]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 L3HYPDH 38 Q96EM0 K299 [RAFK(me1)SSA]
pan-Kme1 TMEM245 38 Q9H330-2 K875 [EDLK(me1)SSV]
pan-Kme1 SCAMP1 38 O15126 K334 [NAFK(me1)GNQ]
SY46 PRKAG1 38 P54619 K34 [SFMK(me1)SHR]
both CNN3 36 Q15417 K158 [GKLK(me1)AGQ]
both CNN3 36 Q15417 K172 [GTNK(me1)CAS]
pan-Kme1 CNN3 36 Q15417 K256 [ASQK(me1)GMS]
pan-Kme1 JUN 36 P05412 K35 [KILK(me1)QSM]
pan-Kme1 SEC13 36 P55735 K203 [GQWK(me1)EEQ]
pan-Kme1 SEC13 36 P55735 K207 [EEQK(me1)LEA]
pan-Kme1 MTX3 35 Q5HYI7 K38 [APLK(me1)VNV]
pan-Kme1 GNB2L1 35 P63244 K12 [GTLK(me1)GHN]
pan-Kme1 TOMM34 35 Q15785 K241 [LVLK(me1)QYT]
pan-Kme1 NT5C3B 34 Q969T7 K10 [TLMK(me1)ATV]
pan-Kme1 NT5C3B 34 Q969T7-2 K2 [__MK(me1)ATV]
both RPL5 34 P46777 K164 [GALK(me1)GAV]
pan-Kme1 CDK1 34 P06493 K266 [LLSK(me1)MLI]
both CNN2 34 Q99439 K160 [ATMK(me1)AGQ]
both CNN2 34 Q99439 K174 [GTNK(me1)CAS]
both CFDP1 34 Q9UEE9 K219 [SGLK(me1)RSS]
both BLVRA 33 P53004 K234 [FHFK(me1)SGS]
pan-Kme1 DTWD2 33 Q8NBA8 K271 [HLLK(me1)NGL]
pan-Kme1 ALKBH3 33 Q96Q83 K19 [APVK(me1)SQA]
pan-Kme1 CDK5 33 Q00535 K20 [TVFK(me1)AKN]
pan-Kme1 CDK5 33 Q00535 K22 [FKAK(me1)NRE]
pan-Kme1 PURB 33 Q96QR8 K136 [LDLK(me1)ENQ]
pan-Kme1 SLC25A4 33 P12235 K43 [HASK(me1)QIS]
pan-Kme1 RPSA 33 P08865 K89 [AVLK(me1)FAA]
pan-Kme1 SLC25A5 33 P05141 K166 [KIYK(me1)SDG]
pan-Kme1 SLC25A5 33 P05141 K52 [KQYK(me1)GII]
pan-Kme1 HAUS1 32 Q96CS2 K186 [DFLK(me1)AKS]
pan-Kme1 HAUS1 32 Q96CS2 K188 [LKAK(me1)SEE]
pan-Kme1 GEMIN2 32 O14893 K125 [SHWK(me1)SQQ]
pan-Kme1 CAPZB 31 P47756-2 K267 [EALK(me1)RKQ]
both TPI1 31 P60174 K231 [GWLK(me1)SNV]
pan-Kme1 FAM122A 31 Q96E09 K203 [GPLK(me1)RKC]
pan-Kme1 CPSF4 30 O95639 K46 [FFLK(me1)AAC]
pan-Kme1 CPSF4 30 O95639 K51 [ACGK(me1)GGM]
pan-Kme1 TIGAR 30 Q9NQ88 K37 [TGFK(me1)QAA]
pan-Kme1 DNAJC9 30 Q8WXX5 K217 [DSLK(me1)AAI]
pan-Kme1 NECAP1 30 Q8NC96 K154 [LGFK(me1)EGQ]
both LASP1 30 Q14847 K75 [LRLK(me1)QQS]
pan-Kme1 PSMA1 30 P25786 K50 [VALK(me1)RAQ]
pan-Kme1 USE1 29 Q9NZ43 K184 [RSLK(me1)TNT]
pan-Kme1 RPL7 29 P18124 K148 [PNLK(me1)SVN]
pan-Kme1 MVB12A 29 Q96EY5 K179 [QPSK(me1)GGL]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
SY46 RPS6 29 P62753 K2 [__MK(me1)LNI]
pan-Kme1 NIPSNAP3A 28 Q9UFN0 K166 [DAFK(me1)RAV]
SY46 NECAP2 28 Q9NVZ3 K58 [AYIK(me1)LED]
SY46 VAPA 28 Q9P0L0 K26 [LKFK(me1)GPF]
pan-Kme1 PSMA7 28 O14818 K157 [HAWK(me1)ANA]
both U2AF1 28 Q01081 K39 [LHNK(me1)PTF]
pan-Kme1 ETFB 28 P38117 K200 [NIMK(me1)AKK]
pan-Kme1 ETFB 28 P38117 K202 [MKAK(me1)KKK]
both C12orf60 28 Q5U649 K201 [EDSK(me1)NPT]
both C12orf60 28 Q5U649 K205 [NPTK(me1)SAA]
SY46 KLC2 27 Q9H0B6 K439 [SWYK(me1)ACK]
pan-Kme1 EFHD2 27 Q96C19 K233 [AAFK(me1)ELQ]
pan-Kme1 RABL3 26 Q5HYI8 K231 [GTLK(me1)SLH]
SY46 CHTOP 26 Q9Y3Y2 K28 [NMLK(me1)NKQ]
pan-Kme1 CHCHD3 26 Q9NX63 K203 [QTLK(me1)CSA]
pan-Kme1 QDPR 26 P09417 K109 [LMWK(me1)QSI]
both CXorf56 26 Q9H5V9 K213 [AKMK(me1)GTL]
pan-Kme1 ALG2 26 Q9H553 K383 [PSLK(me1)ATM]
pan-Kme1 POP4 25 O95707 K2 [__MK(me1)SVI]
pan-Kme1 PSPH 25 P78330 K59 [VPFK(me1)AAL]
pan-Kme1 PTPN23 25 Q9H3S7 K1602 [RMSK(me1)HNF]
both C18orf21 25 Q32NC0 K215 [SSLK(me1)GGL]
pan-Kme1 RAB11B 24 Q15907 K24 [GVGK(me1)SNL]
SY46 TTC9 24 Q92623 K61 [HEFK(me1)SQG]
pan-Kme1 TPD52 24 P55327 K149 [AGQK(me1)ASA]
pan-Kme1 RPL13 24 P26373 K177 [KNFK(me1)AFA]
pan-Kme1 CHMP2B 24 Q9UQN3 K6 [SLFK(me1)KKT]
pan-Kme1 CHMP2B 24 Q9UQN3 K7 [LFKK(me1)KTV]
pan-Kme1 RPL14 23 P50914 K53 [MPFK(me1)CMQ]
pan-Kme1 GSTP1 23 P09211 K45 [GSLK(me1)ASC]
pan-Kme1 TPD52L2 22 O43399 K90 [GELK(me1)QNL]
both BTF3 22 P20290-2 K2 [__MK(me1)ETI]
pan-Kme1 BTF3 22 P20290 K46 [PQMK(me1)ETI]
pan-Kme1 BTF3 22 P20290 K57 [KLAK(me1)LQA]
pan-Kme1 COMMD3 22 Q9UBI1 K137 [YQIK(me1)TNQ]
pan-Kme1 HIST1H1C 21 P16403 K46 [LITK(me1)AVA]
both COMMD1 21 Q8N668 K54 [FLAK(me1)MRG]
pan-Kme1 UBE2M 21 P61081 K3 [_MIK(me1)LFS]
pan-Kme1 TRAPPC5 21 Q8IUR0 K9 [TRGK(me1)SAL]
both PDAP1 21 Q13442 K126 [RYMK(me1)MHL]
both TDRP 20 Q86YL5 K145 [GSTK(me1)YTS]
pan-Kme1 COPZ1 20 P61923 K172 [EQIK(me1)WSL]
both HN1L 20 Q9H910 K184 [PGGK(me1)SSI]
pan-Kme1 HN1L 20 Q9H910 K67 [PGGK(me1)GSG]
pan-Kme1 HN1L 20 Q9H910 K90 [PGGK(me1)TSD]
pan-Kme1 ARPC4 20 P59998 K44 [RSSK(me1)ELL]
– –
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Tab. 7.10: Detected lysine mono-methylation sites
Antibody Gene Mass, kDa Uniprot ID Kme1 site
pan-Kme1 CNBP 19 P62633 K8 [ECFK(me1)CGR]
pan-Kme1 PCNP 19 Q8WW12 K81 [QTTK(me1)KAS]
pan-Kme1 PCNP 19 Q8WW12 K82 [TTKK(me1)ASA]
SY46 MRPL30 19 Q8TCC3 K140 [TCLK(me1)STG]
pan-Kme1 RPS11 18 P62280 K38 [RYYK(me1)NIG]
pan-Kme1 C19orf43 18 Q9BQ61 K128 [LALK(me1)TGI]
pan-Kme1 PPIA 18 P62937 K49 [FGYK(me1)GSC]
SY46 PPIA 18 P62937 K91 [FILK(me1)HTG]
both NCBP2 18 P52298 K7 [GLLK(me1)ALR]
pan-Kme1 C5orf49 17 A4QMS7 K61 [CIFK(me1)RRL]
SY46 CALML3 17 P27482 K78 [RKMK(me1)DTD]
pan-Kme1 EDF1 16 O60869 K25 [AKSK(me1)QAI]
pan-Kme1 C1D 16 Q13901 K119 [RFVK(me1)NAL]
pan-Kme1 HN1 16 Q9UK76 K148 [PGGK(me1)SSL]
pan-Kme1 HN1 16 Q9UK76 K8 [TTFK(me1)GVD]
pan-Kme1 SOD1 16 P00441 K10 [CVLK(me1)GDG]
pan-Kme1 POLR1E 16 Q9GZS1-2 K80 [GALK(me1)CNT]
both HIST1H3A 15 P68431 K80 [QDFK(me1)TDL]
SY46 MPC1L 15 P0DKB6 K10 [LWRK(me1)MRD]
SY46 MPC1L 15 P0DKB6 K18 [FQSK(me1)EFR]
pan-Kme1 SRP14 15 P37108 K107 [KKTK(me1)AAA]
pan-Kme1 PPP1R11 14 O60927 K59 [RSSK(me1)CCC]
pan-Kme1 SNRPD3 14 P62318 K104 [AILK(me1)AQV]
pan-Kme1 TSTD1 13 Q8NFU3 K83 [QMGK(me1)RGL]
both RPL36A 12 P83881 K53 [GQTK(me1)PIF]
both HIST1H4A 11 P62805 K21 [RHRK(me1)VLR]
SY46 HIST1H4A 11 P62805 K92 [YALK(me1)RQG]
pan-Kme1 CSTB 11 P04080 K44 [VSFK(me1)SQV]
pan-Kme1 RPS21 9 P63220 K51 [GQFK(me1)TYA]
pan-Kme1 GNG12 8 Q9UBI6 K4 [MSSK(me1)TAS]
pan-Kme1 TMA7 7 Q9Y2S6 K50 [AAGK(me1)GPL]
– –
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7.3 Gene ontology analyses of genes corresponding to methylated
peptides detected in proteom study
Tab. 7.11: Gene ontology analysis of genes corresponding to methylated peptides in proteom study using
AmiGO web service.
GO biological process complete Fold Enrichment P value
retrograde vesicle-mediated transport, Golgi to ER 5.48 2.56E-02
regulation of viral genome replication 5.41 2.91E-02
DNA duplex unwinding 5.35 3.31E-02
telomere organization 5.21 4.25E-02
positive regulation of viral life cycle 5.08 2.28E-02
protein localization to endoplasmic reticulum 4.22 3.73E-02
Golgi vesicle transport 3.8 6.55E-07
microtubule-based movement 3.69 2.37E-03
DNA replication 3.42 1.40E-02
DNA conformation change 3.36 3.48E-03
ribosome biogenesis 3.29 2.09E-04
rRNA processing 3.27 5.60E-03
RNA splicing, via transesterification reactions 3.22 4.36E-03
rRNA metabolic process 3.2 8.31E-03
mRNA splicing, via spliceosome 3.14 1.14E-02
establishment of protein localization to membrane 3.12 1.30E-02
ribonucleoprotein complex biogenesis 2.99 2.28E-05
microtubule cytoskeleton organization 2.78 1.57E-02
– –
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Tab. 7.12: Gene ontology analysis of genes corresponding to methylated peptides in proteom study using
AmiGO web service.
GO molecular function complete Fold Enrichment P value
ATP-dependent DNA helicase activity 7.41 4.48E-02
cadherin binding involved in cell-cell adhesion 6.48 7.77E-22
DNA helicase activity 6.28 1.70E-02
protein binding involved in cell-cell adhesion 6.27 3.15E-21
protein binding involved in cell adhesion 6.17 6.70E-21
microtubule motor activity 5.28 1.21E-02
ribonucleoprotein complex binding 4.62 2.01E-02
actin filament binding 4.36 3.84E-03
cell adhesion molecule binding 4.22 5.59E-15
microtubule binding 3.85 1.89E-04
poly(A) RNA binding 3.78 2.47E-34
tubulin binding 3.56 2.20E-05
actin binding 3.48 5.77E-08
GTPase binding 3.27 2.15E-04
RNA binding 3.17 1.73E-32
cytoskeletal protein binding 3.11 3.80E-14
Tab. 7.13: Gene ontology analysis of genes corresponding to methylated peptides in proteom study using
AmiGO web service.
GO cellular component complete Fold Enrichment P value
cell-cell adherens junction 5.63 1.70E-19
nucleolar part 5.59 2.23E-02
microtubule associated complex 3.99 2.91E-03
ruffle 3.79 5.73E-03
adherens junction 3.78 9.36E-19
anchoring junction 3.73 9.68E-19
cell-cell junction 3.6 2.05E-15
spliceosomal complex 3.6 6.02E-03
coated vesicle 3.53 2.28E-04
postsynaptic specialization 3.5 4.88E-03
nuclear speck 3.39 7.52E-03
excitatory synapse 3.29 1.14E-02
cell-substrate junction 3.18 3.01E-06
focal adhesion 3.15 6.51E-06
cell-substrate adherens junction 3.13 7.87E-06
nucleolus 3 1.39E-13
cell leading edge 2.87 8.52E-04
actin cytoskeleton 2.87 2.62E-05
microtubule 2.86 1.63E-04
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7.4 Exemplary MS/MS spectra of methylated peptides of
AHNAK-CRUs after biochemical methylation with SMYD2
Fig. 7.49: SMYD2 in vitro methylates AHNAK-CRUs at LK*GP motifs.
Exemplary MS/MS spectrum of peptide from AHNAK-3sCRU after in vitro methylation with
SMYD2. Monomethylation was detected at lysine within the LK*GP motif. For detection,
protein bands from the gel shown in Fig. 4.36 were cut off and processed for mass spectrometry
analysis.
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Fig. 7.50: SMYD2 in vitro methylates AHNAK-CRUs at LK*GP motifs.
Exemplary MS/MS spectrum of peptide from AHNAK-3lCRU after in vitro methylation with
SMYD2. Monomethylation was detected at lysine within the LK*GP motif. For detection,
protein bands from the gel shown in Fig. 4.36 were cut off and processed for mass spectrometry
analysis.
– –
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Fig. 7.51: SMYD2 in vitro methylates AHNAK-CRUs at LK*GP motifs.
Exemplary MS/MS spectrum of peptide from AHNAK-3lCRU after in vitro methylation with
SMYD2. Monomethylation was detected at lysine within the LK*GP motif. For detection,
protein bands from the gel shown in Fig. 4.36 were cut off and processed for mass spectrometry
analysis.
– –
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7.5 Localization of SMYD2 after cellular fractionation
GAPDH 
SMYD2 
p53 
HSP90 
Fig. 7.52: SMYD2 is localized to the cytoplasm.
Parental KYSE150 cells were lysed and fractionated into cytoplasmic and nuclear fractions
using a cytoplasmic/nuclear extraction kit (Thermo Fisher Scientific, #78833) according to
the manufactures protocol. Samples were analyzed by western blot and probed for SMYD2,
p53, GAPDH and HSP90.
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